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“Nature’s destruction of fetal structures that are superfluous in the adult seems to 
me something much greater than her original creation of those structures” wrote 
Galen when he recognized the fetal structures of the ductus arteriosus (DA) and 
the foramen ovale in the second century AD.1 In countries under German influence 
the first description of the ductus arteriosus is erroneously attributed to the late-
renaissance Italian surgeon Leonardo Botallo. Working in France he gave his 
name to the foramen ovale “le trou de Botal”.2 Due to a mistake in the German 
edition of Botallo’s work his name became associated with the DA.  The 
understanding of the functional role of the fetal arterial connection between 
pulmonary artery and aorta was possible after the discovery of the blood circulation 
by William Harvey, who in 1628 described ductus arteriosus and foramen ovale in 
“unripe births of mankind” in Exercitatio Anatomica De Motu Cordis et Sanguinis in 
Animalibus.3 But still it took many years until the transitional circulatory changes at 
birth were described and graphically demonstrated in vivo by Barclay et al 4 and 
the disturbances of this physiological process noted by Lind.5 Virchow is credited 
with being the first to note the histological differences between DA and the 














Figure 1.1  The ductus arteriosus as depicted in „de formatu fetu“ Tab VI, Fig XV, Hieronymus Fabricius 
ab Aquapendente (1537-1619). Source: Venice edition 1600, Bibliotheca Universitaria, Bologna: Aula-A 
VIII HH I 5 Legends: A: descending aorta, B: heart, C: left lung, D: ascending aorta, E: ductus arteriosus 
originally described as „ propago magnae arteriae in venam arterialem, que in foetibus ampla apparet: 
in natis ut funiculus fit“ F: pulmonary trunk, G: left pulmonary artery, H: aortic arch branches. 
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In the second half of the last century physiological studies of fetal cardiovascular 
development and the transition to postnatal life by Rudolph7 together with 
biochemical studies,8,9 and histological studies10,11 enormously increased our 
knowledge of this unique process. From the appreciation of the two main regulators 
of DA dilatation and constriction (i.e. prostaglandin and oxygen) it was a small step 
to use synthetic prostaglandins and prostaglandin-synthesis inhibitors for the 
medical treatment of DA related pathology in neonates.12 
The DA and the development of pediatric cardiac surgery and 
pediatric cardiology  
In view of the development of pediatric cardiac surgery and pediatric cardiology the 
persistent DA (PDA) was ascribed the role of a pathfinder by RM Marquis.13 The 
first successful pediatric cardiac surgical procedure was the ligation of a PDA 
performed on an eight year old girl at Children's Hospital Boston in 1938 by Robert 
E. Gross.14 In 1944 the concept of Helen Taussig to create an artificial DA hereby 
improving pulmonary perfusion in deeply cyanosed children with a tetralogy of 
Fallot opened a new era in pediatric cardiology and pediatric cardiac surgery.15 The 
introduction of synthetic prostaglandins in 1975 was the beginning of the next new 
era, which enabled pediatric cardiologists to keep neonates with complex cardiac 
defects alive and pediatric cardiac surgeons to treat them.12  With an open DA 
most critically ill ductus-dependent neonates can be stabilized before surgical 
treatment is offered. A better preoperative condition of the patients and the 
development of more sophisticated surgical techniques made that nowadays more 
than 15% of the cardiac defects are treated at neonatal age. Not only pediatric 
cardiac surgery but also pediatric cardiology was stimulated by new treatment 
options for the DA. In 1967 Porstmann demonstrated with the first closure of a PDA 
by catheter technique that congenital cardiac defects could be “corrected” in the 
catheterization lab.16 This took place just one year after pediatric interventional 
cardiology was founded by the first palliative procedure, the balloon atrial 
septostomy, reported by Rashkind and Miller.17 In 1979 Rashkind reported the first 
successful catheter interventional treatment of a PDA in an infant.18 Since then 
various devices have been invented for closure of small and larger PDA19-25 and 
catheter treatment has become the method of choice for treatment of PDA beyond 
neonatal age. Later catheter techniques have been developed to palliate neonates 
with complex DA-dependent anomalies by DA-stenting.26,27 The stented DA 
functions as a substitute for a (modified) Blalock-Taussig shunt or guarantees the 
Chapter 1 
12 
systemic circulation in infants palliated with the staged hybrid procedure for 
hypoplastic left heart syndrome or its variants.28-30 After stenting the combination of 
physiological and stent-related remodeling of the DA puts the patient at risk for 
occlusion of the DA.31 As procedural and long-term success of DA stenting 
techniques depend on reliable DA patency in the first months of life it is important 
to increase the knowledge of the underlying molecular mechanisms of 
physiological DA closure in the neonate.  
Patent or persistent DA – not only a matter of definition 
In clinical practice the expression “patent DA” is often used synonymously with 
persistent DA and both are abbreviated as PDA although they differ in 
morphology,10 causes and clinical implication. Definition, morphology and 
physiological changes during process of normal DA closure are extensively 
reviewed in chapter 2.  
As in our review we will use “patent DA” in this thesis as umbrella term for all 
situations in which the DA is open either physiologically or pathologically. The 
structurally normal DA in neonates is at risk to remain patent mostly due to 
immaturity32 and altered environmental conditions.  An open DA in children beyond 
the age of three months after full gestation is defined as “persistent DA”.33 The 
persistent DA is a structural anomaly, characterized by an abnormal amount of 
elastin in its wall and the presence of a subendothelial elastic lamina.10 In chapter 2 
various causes of structural anomalies of the DA are discussed such as perinatal 
viral infections (i.e. rubella) and diverse genetic syndromes (i.e. Char, CHARGE, 
Noonan, Cri-du-chat, Holt-Oram syndrome). A structurally abnormal DA is also 
found in association with other congenital heart diseases (CHD), heritable 
disorders of connective tissue and mutations in contractile proteins34,35 These 
associations, documented in families (chapter 6), indicate that under certain 
circumstances a PDA is part of a more complex cardiac or systemic vascular 
disorder. Recently the strict distinction between functional anomalies of the 
immature DA and structural anomalies of the DA has been challenged by studies 
on the genetic influence on patency of DA in premature babies.36-38 Genetic 
variations in the TFAP2B gene, also affected by a dominant-negative mutation in 
patients with Char-syndrome, were identified as genetic risk factors for patency of 
the DA in premature infants36,37suggesting a functional role for this transcription 
factor during normal DA closure in neonates. By comparing gene expression in the 
DA and aorta in fetal rats we identified the DA-dominant expression of the rat 
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analogue of TFAP2B in endothelial (EC) and smooth muscle cells SMC at the end 
of gestation (chapter 5). 
Remodeling of the DA and similar vascular remodeling processes  
In all air-breathing vertebrates the DA can be traced back to a specific segment of 
the 6th pharyngeal arch that matures and remodels different from all adjacent 
vascular structures.39  
As reviewed in chapter 2 the unique remodeling process of the DA starts already 
during the second trimester of pregnancy when intimal thickening regulated by 
prostaglandins develops.40,41 At birth contraction of SMC in response to rising 
oxygen partial pressure and prostaglandin withdrawal closes the DA and initiates 
its degeneration by apoptosis and cytolytic necrosis.10,32,40 Intimal thickening and 
loss of SMC are histological features that are comparable between DA remodeling, 
the arteries of children with Hutchinson-Gilford progeria syndrome (HGPS)42,43 and 
ageing individuals. This similarity and the knowledge that progerin, the truncated 
lamin A protein causing HGPS, is also expressed in genetically normal aged 
individuals, triggered us to study (chapter 4) lamin A/C and progerin expression in 
the neonatal DA. Because of the mutually exclusive spatiotemporal expression of 
lamin A/C and progerin in the neonatal DA we propose that activation of alternative 
splicing of the lamin A/C gene is involved in the circulatory system during neonatal 





Aim and chapter outline of the thesis 
In this thesis we have studied various aspects of physiological DA closure and PDA 
in animal models and humans. We were intrigued by the fact that the DA reacts 
completely different to the postnatal change in environmental conditions than the 
adjacent vessels. Therefore we aimed to identify genes and molecular 
mechanisms, which give the DA a specific genetic signature and might explain 
some of its characteristic morphological features. As all current therapeutic 
approaches to the DA have major side effects we hope that knowledge of genes 
that maintain fetal ductal patency and promote closure of the DA will help to 
develop new therapeutic strategies. These strategies might be tailored to individual 
genomes in order to improve the present approach targeting the prostaglandin 
pathway, using implantable intravascular devices or surgery. Furthermore we 
studied PDA-patients and their extended families with the aim to identify patients in 
whom the PDA is a heritable structural anomaly either of the DA or a more general 
vasculopathy.  
 
In chapter 2 we give insights into the pathogenesis and genetic background of 
patency of the DA. For this purpose normal DA closure, animal models of PDA and 
genetic syndromes with PDA are reviewed in this chapter. 
 
In chapter 3 we introduce a new model of a small laboratory animal with PDA. In 
the BN-inbred rat strain a small PDA and aortic fragility are associated and the 
implications of this association are discussed.  
 
In chapter 4 we studied progerin and lamin A/C expression in the neonatal human 
DA considering that activation of alternative splicing of the lamin A/C gene might be 
involved in human neonatal DA closure. 
 
In chapter 5 we analyzed DA- and aorta-specific transcriptional profiles selectively 
in ECs and SMCs harvested by laser-capture microdissection from the fetal DA 
and aorta of Wistar-rats. Using microarray and quantitative RT-PCR technique we 
identified genes that have not earlier been described in relation with DA-specific 
remodeling.  
 
In chapter 6 data of a retrospective patient-based study assessing the prevalence 
of PDA and other cardiovascular disease in families of PDA-patients are presented. 
These data provide evidence for a genetic association of PDA and aortic disease in 
these families.  
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Finally, chapter 7 presents concluding considerations of the topics covered by the 
chapters 2 to 6. It brings the data from basic research in the clinical context of all 
medical specialties that deal with problems related to the process of closure of the 
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The unique differentiation program of the ductus arteriosus (DA) is essential for its 
specific task during foetal life and for the adapting circulation after birth. Phenotypic 
changes occur in the DA during the normal maturation and definitive closure. 
Morphological abnormalities of the vessel wall characterise the persistent DA 
(PDA) in older children. Here, we give an overview of the animal models of DA 
regulation and remodelling. Genetic research has identified the cause of syndromic 
forms of PDA, such as the TFAP2B mutations in Char syndrome. Genes that 
interfere with the remodelling of vascular smooth muscle cells (SMCs) of the ductal 
media are affected in virtually all of these anomalies. Therefore, the pivotal 
regulatory role of SMCs is emphasised. A better understanding of the genetic 
background of this developmental process may help develop new strategies to 
manipulate the DA in premature infants, neonates with duct-dependent anomalies, 
and patients with syndromic and non-syndromic PDA.  
 Insights into the pathogenesis and genetic background of patency of the ductus arteriosus 
23 
Introduction 
Reflecting the increased survival of premature infants, the prevalence of patent 
ductus arteriosus (DA) has risen to 13.5% of all heart defects present at birth.1In 
clinical practice, the expression patent DA is often used synonymously with 
persistent DA. Both are abbreviated as “PDA”, although they differ in morphology2,3 
and therapeutic implications. In this review, we will use the abbreviation PDA to 
refer to persistent DA. 
The term “patent DA” is an umbrella term for all situations in which the DA is open 
either physiologically or pathologically. In healthy premature infants of 30-37 
gestational weeks, spontaneous closure of the DA is documented by 
echocardiography in 50-58% of infants on the second and 81-87% of infants on the 
third day of life.4 In 90% of healthy term babies, the DA is functionally closed by 
72 hours of life.5 Term infants with respiratory failure show a significant delay in 
ductal closure within the first 24 hours of life6 and sometimes suffer from a 
hemodynamically significant patent DA that requires treatment.7 Causes for the 
prolonged patency of the DA can be structural, as well as functional, immaturity 
and altered physiological conditions. Targeted deletions of genes that are essential 
in the physiological closing process have produced animal models of patent DA.  
 
PDA in older children (beyond three months after full gestation) is histologically 
characterised by an abnormal high amount of elastin and the presence of a 
subendothelial elastic lamina.2 Variants of PDA have also been documented in 
adult animals.8,9 PDA should be distinguished from the immature but normally 
developed patent DA in premature and young infants and must be considered as a 
primary congenital malformation of the vessel wall.2 Because it usually occurs 
sporadically, PDA has not been regarded as a typical genetic disorder. 
Nonetheless, PDA occurs in 5% of siblings of PDA cases10 suggesting a genetic 
component to the pathogenesis, which has typically been presumed to be 
multifactorial. Very recently, the contribution of genetic factors to the incidence of 
patent DA in premature infants has also been documented.11,12  
Heritable PDA has been described in various animal models.8,9 In humans, 8-11% 
of cases with PDA have a chromosomal abnormality.13,14 The search for a 
functional link between the genes affected in genetic syndromes associated with 
PDA may elucidate the complex interactions between mutations and modifier 
genes as well as between environmental factors and genetic polymorphisms 
related to PDA and patent DA in premature infants. Serious side effects and 
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therapeutic failure are associated with the present pharmacological approach to 
the DA targeting on the prostaglandin-pathway. Knowledge of which genes 
maintain the balance between patency and closure of the DA may help to develop 
pharmacogenetic strategies tailored to individual genomes in order to improve our 
therapeutic protocols. In the present paper, human and animal data on DA 
maturation and remodelling and the genetic background of DA closure and patency 
are reviewed. 
Animal models  
Physiological ductal closure in animals 
Physiological ductal closure has been studied in various vertebrate species.15 Most 
of the data are derived from mammals. Since 2006, there is growing amount of 
literature on birds.16-18 Birds and humans share basic mechanisms of vasoreactivity 
and response to oxygen at the end of the foetal period. The easy accessibility of 
the foetal circulation in a chicken egg makes it an attractive model for DA 
physiological studies.19  
The DA remodels and matures in diverse ways among the different vertebrates, but 
its origin can be traced back to a specific segment of the sixth pharyngeal arch in 
all of them. In all species, the foetal DA is a large muscular artery composed of 
layers of vascular smooth muscle cells (SMCs) separated by layers of elastin. 
Figure 2.1 presents a schematic overview of the morphological appearance of the 
human DA during maturation and the processes involved in its functional and 
permanent closure. The characteristic histological features of delayed ductal 
closure in the premature neonate and the PDA are included in this figure. In larger 
animals, such as dogs8, lambs20, and primates21, ductal closure is accompanied by 
intimal cushion formation, which starts during foetal life. Although there is some 
resemblance in the process of ductal closure between larger animals and humans, 
the relevance of intimal cushions seems to be different. Humans show the earliest 
onset of intimal thickening and, by far, the most extensive cushion formation.22 The 
DA of small animals, such as rats, rabbits, and mice, show less pronounced intimal 
thickening. These ducts close functionally within minutes after birth, predominantly 
by vasoconstriction.15 The same sequence of structural changes occurs in all 
species: (1) endothelial detachment from the internal elastic lamina (IEL); (2) 
subendothelial accumulation of the extracellular matrix; (3) migration of SMCs 
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through a fragmented IEL; (4) occlusion of the lumen by the thickened intima; and 
(5) degeneration of the DA into a fibrous remnant.15 In larger8 as well as smaller16 
animal models, the process proceeds from the pulmonary to the aortic end of the 
DA. Anatomic remodelling and permanent closure of the DA require the 
environmental and physiological changes related to birth and air breathing. For 
instance, intense hypoxia within the constricted vessel wall of the DA at birth is a 
trigger for SMCs to express vascular endothelial cell growth factor (VEGF).21,23  
VEGF stimulates neointima proliferation and vasa vasorum in-growth, thereby 
playing a role during permanent DA closure in lambs and baboons and probably 
also in humans.24 These interactions between functional and morphological 
changes in the DA inspired us to include all aspects of foetal regulation and of 
















Figure 2.1  Schematic overview of the processes related to functional and anatomical closure in the 
human ductus arteriosus. Normal: During intrauterine life, the ductus remains in a dilated state. 
Functional closure after birth is achieved by immediate contraction of the ductus. Postnatal occlusion of 
the lumen and anatomical closure is facilitated by the development of intimal cushions, completely 
obliterating the lumen in the mature ductus. The ductus finally degenerates into a fibrous remnant 
through apoptosis and necrosis. The histological maturity stages are derived from Gittenberger et al.22   
Premature: The delayed closure of the ductus arteriosus in premature neonates with poorly developed 
intimal cushions.  PDA>3 months: Schematic representation of the PDA of older children, which is 


























Figure 2.2  Diagram of the experimental data on intracellular and intercellular signalling related to 
ductus closure and remodelling that is presented in this review. Endothelial cells (ECs) are depicted in 
light blue. SMCs are indicated by the large pink rectangle. For the sake of clarity, not all downstream 
signalling steps are included. On the left side, the dominant signalling pathways in the foetus are shown. 
The middle section illustrates the changes related to the increase of oxygen saturation at birth. The 
section to the right of the vertical dotted line focuses on anatomical remodelling. Remodelling proceeds 
through a sequence of events including the differentiation of SMCs and ECs, extracellular matrix 
production, SMC migration, and finally apoptosis and necrosis.  
Receptors:     , cytokine/hormone:     , protein:          , ion-channels: 
Abbreviations: AA=arachidonic acid, ACE=angiotensin-converting enzyme, Ang II=angiotensin II with 
AT1 receptor, BK=bradykinin with receptors B1 and B2, Ca++=calcium ion and channels: CaSOC=store-
operated, L-Ca=voltage-dependent; CaM=calmodulin, cAMP=cyclic adenosine monophosphate, 
cGMP=cyclic guanosine monophosphate, CO=carbon monoxide, COX=cycloxygenase isoforms 1 and 
2, CREB=cAMP response element-binding protein, ECM=extracellular matrix, EDHF=endothelium 
hyperpolarising factor, EPAC=exchange proteins activated by cAMP, ET-1=endothelin-1 with ET-A and 
ET-B receptors, HAS-2=hyaluronansynthase-2, FnR=fibronectin receptor, HA hyaluronic acid receptors, 
CD 44 and CD168=receptors for hyaluronic acid mediated motility, HIF-2a=hypoxia-inducible factor 2 
alpha, HO=hemoxygenase, K+= potassium ion and channels: KATP=ATP-sensitive channel, Kv=voltage-
gated channel; LC3=microtubule-associated protein, LnR= laminin receptor, MLCK=myosin light-chain 
kinase, MLCP=myosin light chain phosphatase, NO=nitric oxide, NOS=nitric oxide synthase isoforms 
(endothelial) eNOS and (neuronal) nNOS, PGH2=prostaglandin H2, PG=prostaglandins, predominantly 
PGE2 acting via prostaglandin receptors (EP 2,3,4), PKA=protein kinase A, RAP1=small RAS-like 
GTPase acting downstream of EPAC, ROCK-1=Rho-associated, coiled-coil-containing protein kinase 1, 
ROS=reactive oxygen species, TFAP2b=transcription-factor-activating protein 2 beta, SOC=store-
operated channel,  VEGF=vascular endothelial growth factor. 
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Physiology and pharmacology of constriction and relaxation 
For decades, the constrictive effect of oxygen on the DA in the neonate25 as well as 
the relaxing effect of prostaglandin (PG) E2
26 have been shown. Studies in various 
animal species and in vitro models revealed additional mediators for DA regulation 
and remodelling. Species differences in the degree, timing, and type of reaction to 
the stimuli have been documented. Figure 2.2 shows a compilation of these 
experimental in vitro and in vivo data in order to illustrate parallel actions and 
potential interactions of the various signalling pathways.  
PGE2 plays a major role in maintaining ductal patency in utero in smaller and larger 
mammals including humans.27 The postnatal fall in blood levels of PGE2 is central 
to the closure of the ductus. The reduction of PGE2 is largely due to metabolism by 
PGDH.28 Both locally released and circulating vasodilatory PGs regulate ductal 
closure mediated via specific receptors.29 Among the four PGE2-receptor subtypes 
(EP1-4), the EP4 receptor is expressed predominantly on SMCs and is probably 
the most relevant mediator of prostaglandin-induced vasodilatation before birth in 
humans.30 EP3 receptors are also found on SMCs but are dominant on endothelial 
cells (ECs).29 They activate endothelial NO synthase (eNOS) via calcium increase 
and calcium/calmodulin-binding. The cyclooxygenases COX1 and COX2 catalyse 
PG synthesis from arachidonic acid. Although both isoforms are present in the 
human ductus, COX1 has a predominant role during gestation.30 Exposure in utero 
to COX-inhibitors, such as indomethacin, can result in premature closure of the 
DA.31 Conversely, an increase of the incidence of symptomatic patent DA in infants 
of mothers who received indomethacin tocolysis has also been observed.32 These 
contradictory observations suggest a more complex role for PGs in the 
developmentally regulated process of DA maturation and postnatal closure. 
Several agents sustaining ductal patency in concert with PGs in animal studies do 
not act in the same way in humans.33 Nitric oxide (NO) produced mainly via eNOS 
is a vasorelaxant in the DA.34 NO acts as an alternative for, and synergises with, 
PGE2.
35 The NO mechanism is relatively more important in the preterm than in the 
full term ductus36 and can compensate for prostaglandin-induced relaxation when 
PG biosynthesis is eliminated or inhibited by drugs.37,38 In their in vitro and in vivo 
studies using wild-type and gene-deleted mice, Baragatti et al.35 described NO and 
CO as being cooperative mediators of bradykinin-induced relaxation in the absence 
of PGE2. In the absence of all three agents (PGE2, NO and CO), bradykinin induces 
a relaxant substance that behaves like endothelium-derived hyperpolarizing factor. 
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Although there are interspecies differences in timing, the rise in blood oxygen 
tension with the start of respiration is critical for early (functional) closure of the 
ductus.25 The contraction in response to oxygen is intrinsic to SMCs of the ductus 
and is highly conserved. Ion channels and other vasoactive systems are involved in 
the acute ductal constriction immediately after birth. SMC contraction is regulated 
by phosphorylation/dephosphorylation of myosin light chains (MLCs). Inhibition of 
myosin light chain phosphatase (MLCP) and activation of the calcium/calmodulin-
dependent myosin light chain kinase (MLCK) both increase phosphorylation and 
thereby facilitate myosin/actin interaction and contraction. Kajimoto et al.39 recently 
determined that Rho-kinase (ROCK) activation by O2 in the DA (but not in other 
foetal arteries) involves a redox-dependent activation of ROCK-1. They concluded 
that the DA had a relatively unique ability of increasing endogenous H2O2 in 
response to increased PO2 and proposed a temporal sequence of O2 constriction 
in three phases: (1) an early electrical phase that involves Kv channel inhibition, 
membrane depolarisation, and activation of the L-type, voltage-gated calcium 
channel; (2) a mediator phase that involves increased endothelin (ET-1) synthesis; 
and (3) a calcium-sensitisation phase that involves the activation of ROCK. In the 
neonate, the increased arterial O2 concentration inhibits voltage-gated potassium 
channels (Kv) and promotes calcium entry via L-type calcium channels.40,41 Oxygen 
sensing takes place in the proximal electron transport chain in the mitochondrion 
and is mediated by ROS (H202).
33 The cytochrome P450 heme protein in the 
plasma membrane of the SMCs has been previously suggested as a receptor for 
oxygen-induced events.42  
The potent vasoconstrictor ET-1 is produced by ECs and SMCs in the DA42 and 
interacts with both endothelin receptors (ETA and ETB). In vitro, ET-1 is released 
in response to increased oxygen levels, which may be sensed by cytochrome 
P450.42,43 The role of ET-1 in vivo is less clear and probably varies between 
different species. An ETA receptor blockade in lambs does not impair ductal 
constriction.44 In foetal rats45 ET-receptor blockade prevents constriction of the DA 
by cyclooxygenaseinhibitors. The DA in ETA receptor-deleted mice closes 
postnatally, but the acute vasoconstrictor response to oxygen is attenuated.46 This 
may reflect the disruption of a normal reinforcing effect of ET-1 on voltage-gated 
potassium channels47 or the IP3-dependent release of intracellular calcium.39 
Calcium-sensitisation pathways have been documented in rabbits and humans.48 
Store-operated calcium channels act as additional components of normoxic 
contraction. Functional immaturity of calcium-dependent and calcium-sensitisation 
pathways during the hypoxic phase of remodelling might explain why the DA in 
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prematures tends not to stay tightly closed.48 Gene expression data show an up-
regulation of the angiotensin receptor gene (Agtr1) in neonatal rats.49 Therefore, 
angiotensin II has also been suggested to be a vasoconstrictive effector. 
PDA in animals 
PDA in dogs 
Most cardiac malformations known to man are also observed with a similar 
prevalence in dogs (5-8/1,000).50 In 1982, Helen Taussig described that several of 
these malformations are heritable in specific breeds of dogs (PDA, pulmonary 
stenosis, and subaortic stenosis), rabbits (vestigial pulmonary artery), and rats 
(ventricular septal defect). The fact that these malformations occur in various 
animals that cannot interbreed made her conclude that the deoxyribonucleic acid 
(DNA) that codes for these malformations must lie in a portion of DNA that is 
common to all mammals and, therefore, may be genetic variants of cardiac 
development.50  
PDA is the most common cardiac anomaly in dogs.51 An animal model of inherited 
PDA has been studied in dogs by Patterson and co-workers,52 and the 
pathomorphology has been described.8 Histological features of the normal DA and 
PDA in this strain of dogs resemble those of the normal DA and PDA in humans, 
suggesting a similar pathogenesis in both species. Immunohistochemical data from 
this dog model suggest a role for prostacyclin (PGI2) in the process of intimal 
thickening. The distribution of PGI2 synthase is identical in all permanently patent 
vessels.53 PDA, aorta, and pulmonary artery show high PGI2 synthase expression 
in the endothelium and low expression in SMCs. In the normal closing DA of these 
dogs, however, high amounts of PGI2 and no PGE2 or PGDH activity were found in 
the SMCs of the intimal cushions.53  
PDA in rats 
Brown-Norway rat 
In a morphological study,9 we previously described hereditary PDA in a specific rat 
inbred strain – the Brown-Norway (BN) rat. The PDA in BN rats shows abundant 
elastic lamellae in the intima, a subendothelial elastic lamina, and failure of intimal 
SMC proliferation. These histological features are also hallmarks of human and 
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canine PDA.2,8 In the media of the BN ductus, the elastic lamellae are virtually 
absent. The aortic media shows impaired elastic lamellae,54 with ruptures in the 
IEL.55 This phenotype has been related to the increased vascular fragility that is 
characteristic of the BN rat.55 In PDA, the subendothelial elastic lamina is thought 
to limit the access of the SMCs from the media to the intima. There is also strong 
evidence that intimal cells arise both during development and under pathologic 
conditions from delamination of ECs56 and their circulating precursors.57 
Endothelial-mesenchymal transformation has also been described during 
arteriogenesis in the embryo.58 Because ECs can also produce elastic laminae, the 
abundant elastic lamellae in the intima in the PDA support the idea that the intimal 
mesenchymal cells are also endothelially derived. 
Linkage studies revealed different loci for elastic lamellar anomalies and PDA in 
BN rats. In a backcross between BN and the Louvain (LOU) reference strain, the 
phenotype of a ruptured IEL in the abdominal aorta and the iliac artery showed a 
highly significant linkage to chromosome 5 and a suggestive linkage to 
chromosome 10 in BN rats.59 In the same population, Kota et al.59 linked PDA in 
BN rats to two different loci on chromosomes 8 and 9.  
 
Adult BN rats exhibit phenotypic variations in their DA morphology. Unlike other rat 
strains, a normal ductus ligament is only present in 14% of the rats59 (20% in our 
own observations, unpublished). In the remaining 86% of BN rats, variations 
between grossly visible ductus ligaments and a PDA are found. These variations 
point to a polygenic control of normal ductal closure. Our own crossing studies in 
BN/Wistar rats showed one PDA (2.4%) in the F2 generation and thick ligaments in 
41% and 43% of the rats in the F1 and F2 generations, respectively. In 59% of the 
rats in the F1 and 57% in the rats of the F2 generation, the ligament was thin, as 
seen in Wistar rats. These findings are comparable to the results of the crossing 
experiments reported by Kota59 in BN/LOU backcross rats, in which only 3.7% of 
rats had a macroscopically visible ductus with a widely patent aortic and stenosed 
pulmonary end.  
Gene-targeted mice  
Gene-targeted mice have been created in order to elucidate mechanisms by which 
known effectors affect ductus development, prenatal patency, and postnatal ductal 
closure. Mice carrying deletions of components of the prostaglandin pathway, the 
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ET-1 receptor, and other genes interfering with SMC differentiation will be 
discussed in the following section.  
Mouse models with deletions in the prostaglandin pathway 
Targeted deletions that reduce the PGE2 production or function paradoxically do 
not affect the prenatal ductal patency60,62 but instead may result in impaired DA 
closure after birth.61,62 Although the importance of PGE2 signalling for postnatal DA 
closure has been known from Ep4-deleted and Cox-deleted animals for a long 
time, the explanation for this paradoxical behaviour has only recently been 
elucidated by Yokoyama et al.63 In their study, they were able to document that 
PGE2 binding to the Ep4 receptor results in intimal cushion formation via the cAMP 
/protein kinase A (PkA) pathway. Pka mediates the direct vasodilating effect of 
PGE2 by inhibiting MLCK. Furthermore, Pka and exchange proteins activated by 
cAMP (EPAC1), a newly identified effector cAMP, promote hyaluronic acid 
production by hyaluronic acid synthase 2 (HAS2) activation. Subendothelial 
hyaluronic acid accumulation induces the formation of intimal cushions, which are 
required for DA closure (see Figure 2.2).  
As cyclooxygenase–peroxidases, COX1 and COX2 catalyse the synthesis of 
PGH2, which is the precursor of biologically active PGs. When looking at the Cox-
deleted mice in detail, Cox2 seems to be more important for DA closure than Cox1. 
Trivedi et al.64 were the first to emphasize that Cox2 has a vital role for ductal 
closure after term birth and is attenuated in preterm gestation. In addition to the 
Cox2 effect, a gene-dosage dependent effect of Cox1 has been documented.61,65 
Two groups61,66 have described contrasting results concerning the impact of 
individual Cox isoform ablation on the postnatal closure of the DA in mice. 
Baragatti et al.66 documented no genotype-related difference in postnatal closure of 
the DA in Cox-deleted mice born after vaginal delivery while Loftin et al.61 
described mortality due to patent DA in 35% of Cox2 (-/-) mice and 100% of mice 
deficient for both isoforms. The absence of the COX1 isoform did not affect DA 
closure in the experimental setting of Loftin et al.61 who studied the mice after a 
caesarean section at gestational day 19.5. The mortality (35%) and incidence of 
patent DA due to the absence of COX2 is, however, significantly increased (79%) 
when one copy of the gene encoding COX1 is also inactivated. When comparing 
the phenotypes of the COX2-deficient mice with a model of selective genetic COX2 
inhibition that leaves its peroxidase activity intact, Yu et al.65 surprisingly found no 
abnormalities in ductal remodelling after birth. These findings might imply that a 
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COX 1/2 heterodimer is involved in signalling in the ductus.67 Interestingly, there is 
also interplay between EP4 receptor activation and Cox-2 expression. The 
experiments of Trivedi et al.64 indicate that the genetic deficiency of EP4 results in 
attenuated Cox-2 expression.  
In the late nineties Ngyuen et al.62 and Segi et al.68 both generated Ep4 receptor 
knockout (KO) mice and described the same phenotype. They found that the loss 
of the Ep4 receptor is not lethal in utero but causes 95% mortality within 72 hours 
after delivery due to congestive heart failure. Histological examination confirmed 
ductal patency. In the remaining 5% of Ep4 (-/-) mice, the ductus was either closed 
or severely narrowed. The animals were fertile and survived for more than a year.68 
Ngyuen et al.62 were able to show that selective breeding of the survivors 
increased the survival rate among Ep4 (-/-) mice to 21%, suggesting that other 
alleles on other loci can provide an alternative to Ep4.   
Endothelin-1 receptor KO mice  
Mice lacking the ET-1 receptor ETA are described by Coceani et al.46 These mice 
showed a discrepant behaviour of the ductus in vivo and in vitro. Isolated DA from 
Eta -/- mice contracted marginally to oxygen and ET-1 but responded to a 
thromboxane analogue. In normoxic newborn mice, reduction in the ductus lumen 
was equally pronounced in -/- and +/+ littermates. Conversely, no such narrowing 
was seen in hyperoxic -/- foetuses, although it did occur in +/+ littermates. No 
genotype-related difference was noted in the morphology of the ductus. These data 
indicated that ET-1 mediates the ductus constriction in response to oxygen but is 
not critical for postnatal ductus closure.  
Smooth muscle myosin heavy chain (SM-Mhc) KO mice 
Proper regulation of SMC contraction in response to the postnatal rise of oxygen 
tension is necessary for functional ductal closure. The observation of delayed (6 to 
12 hours post partum) but not failed closure of the DA in SM-Mhc KO mice 
suggests that ductal SMC contractions can be generated partly (phase 2 or 
sustained state of contraction) by activation of the non-muscle myosin heavy chain 
(NM-MHC), as documented for intact bladder preparations from the same mice. 
The ability to recruit two distinct contractile systems, namely SM myosin for phasic 
contraction and non-muscle (NM) myosin during prolonged tonic contraction, can 
explain the unique properties of SMCs during prolonged activation.69  
 Insights into the pathogenesis and genetic background of patency of the ductus arteriosus 
33 
Transcription factor AP2 beta (Tfap2B) KO mice 
Targeted deletion of Tfap2B, a neural-crest-enriched transcription factor, causes 
apoptosis of renal epithelial cells and postnatal death, possibly related to polycystic 
kidney disease.70 Ivey et al.71 did not observe morphological differences between 
the Tfap2B -/- and wild-type mice that were studied beyond mid-gestation at 
embryonic days (EDs) 13.5, 15.5 and 18.5. Data on postnatal ductal behaviour and 
morphology in Tfap2B -/- mice are not included in their paper. Preferential calponin 
expression, which characterises the advanced maturation and differentiation of 
ductal SMCs in wild-type mice, was lost in Tfap2B -/- mice by ED 18.5. These data 
indicate that TfapB disruption affects the development of SMCs within the DA. 
Abnormal maturation of ductal SMCs may contribute to delayed ductal closure in 
Tfap2B -/- mice and PDA in humans with Char syndrome. 
Selective ablation of the myocardin gene in neural crest-derived SMCs  
Myocardin regulates the expression of genes required for the contractile phenotype 
of neural crest-derived SMCs. Mice generated after selective myocardin ablation of 
cardiac neural crest-derived SMCs were symptomatic for a patent DA and died at 
postnatal day 3. The vascular phenotype of the ductus exhibited ultrastructural and 
immunohistochemic features that are generally associated with a synthetic rather 
than a contractile SMC phenotype.72 In the mutant mice, the architecture of the 
intima and media was markedly disorganised, showing a dramatic increase of 
extracellular matrix and a relative loss of SMC volume. Relatively few myofibers 
and a marked increase in synthetic organelles were documented by electron 
microscopy. 
Gene transfer experiments 
In vitro gene transfer experiments were carried out in order to study the 
maturational increase of O2-sensitive, voltage-gated potassium (Kv) channels. 
Transmural Kv1.5 or Kv2.1 gene transfer “rescued" the developmental deficiency in 
Kv, conferring O2 responsiveness to preterm rabbits. Targeted SMC Kv1.5 gene 
transfer also enhanced O2 constriction in human DA.
73  
Gene transfer strategies were also evaluated as a potential substitute for systemic 
PG administration in neonates with ductus-dependent circulations. In lambs, gene 
transfer is feasible and can be used to bioengineer a patent ductus. Mason et al.74 
were able to restrain SMC migration and intima formation in the ductus by inhibiting 
fibronectin translation. More recently, Humpl et al.75 achieved prolonged postnatal 
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ductal patency by transfecting human PG synthase into the vessel wall of the 
ductus of newborn lambs.  
PDA as part of a clinical syndrome in humans 
PDA is described as part of the spectrum of cardiovascular anomalies in various 
genetic syndromes. Between 28-88% of PDA cases have other cardiac or non-
cardiac defects, and 8-11% of cases with PDA have chromosomal 
abnormalities.13,14 In the clinical paediatric literature, the association of isolated 
PDA with Down’s syndrome (4% of all associated congenital cardiac defects), 
CHARGE syndrome76, Cri-du-chat-syndrome77, Noonan syndrome (2.2% of all 
associated congenital cardiac defects)78, and Holt-Oram syndrome79 is well 
described. Insight into the cellular mechanisms underlying the phenotypes of these  
syndromic anomalies is increasing. Even now, a ductus-specific molecular 
mechanism cannot be derived from a particular syndrome. The most consistent 
association of PDA with mild dysmorphic features has been found in Char 
syndrome.  
Char syndrome is a more recently described genetic syndrome consisting of PDA 
in association with facial anomalies and minor skeletal anomalies and is caused by 
mutations in the transcription factor TFAP2B, which is expressed in neural crest 
cells.80 Multiple dominant negative mutations have been documented. Interestingly, 
genotype-phenotype correlations have been documented for mutations in the basic 
DNA binding domain and the transactivation domain of TFAP2B.81 A high 
prevalence of PDA with very mild facial anomalies and no apparent hand 
anomalies are found among the carriers of the mutation in the transactivation 
domain. The genotype-phenotype correlation in Char families with a distinct 
phenotype, combining PDA with only very mild facial and no hand anomalies, 
suggests the existence of TFAP2B coactivators as a cause for ductal tissue 
specifity.81  
 
Heritable disorders of connective tissue structures, such as Marfan, Loeys-Dietz, 
Larsen, and Ehlers-Danlos syndrome,82-85 and mutations in the SMC contractile 
proteins86,87 cause thoracic aortic aneurysms that lead to acute aortic dissections. 
Although some reports associate PDA or ductal aneurysm with these types of 
heritable aortic disorders, the present literature does not put particular emphasis on 
the DA.  
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Ductal aneurysm is not unanimously defined in the literature. Aneurysms of the DA 
are described to occur as a complication after surgical or catheter-interventional 
treatment of a PDA and also as an incidental finding at the aortic end of a 
spontaneously closed ductus in non-syndromic patients.88 Congenital ductal 
aneurysm may occur during the third trimester of pregnancy89-91 and is 
characterised by abnormal dilatation of the aortic end of the ductus with a 
significantly stenosed or completely occluded pulmonary end of the ductus.  
New insights in the molecular pathogenesis of Marfan syndrome (MFS) have 
challenged the definition of this syndrome as a structural connective tissue 
disorder.92 MFS is a developmental abnormality with broad and complex effects on 
the morphogenesis and function of multiple organ systems. Animal data derived 
from fibrillin-1-deficient mice have shown that increased TGF-beta signalling 
contributes to the process of aortic root dilatation in MFS and that TGF-beta 
antagonism (achieved by angiotensin II type 1 receptor blockade) may represent a 
productive treatment strategy. The up-regulation of TGF-beta may be a final 
common pathway for aortic aneurysms in many disease states, such as Loeys-
Dietz and non-syndromic thoracic aortic aneurysm/dissection.  
 
Loeys-Dietz syndrome is a combination of altered cardiovascular, craniofacial, 
neurocognitive, and skeletal development caused by mutations in TGF-beta 
receptors 1 and 2.83 The cardiovascular anomalies include aortic root aneurysm 
and aortic tortuosity in all patients. A PDA or ductal aneurysms were reported in 
54% of affected individuals. Considering that in vitro and in vivo data93-96 document 
an important role for TGF-beta during the physiological remodelling process of the 
DA, it is tempting to speculate that increased TGF-beta signalling might also be the 
final common pathway for ductal patency or ductus aneurysms in MFS and Loeys-
Dietz syndrome. The recent observation of the failure of ductal closure in mice after 
selective ablation of the myocardin gene in neural crest-derived SMCs72 also points 
to TGF-beta-signalling, because myocardin is able to participate in the TGF-beta 1 
pathway through direct interaction with Smad3 to activate SM22-alpha, SM-myosin 
heavy chain, and SM-alpha actin promoters.97  
 
Data from Zhu et al.86 and Guo et al.87 highlight the importance of contractile 
proteins for the structural integrity of the aorta. Both studies describe a high 
prevalence of PDA among families with mutations in SMC contractile proteins. In 
2005, Khau van Kien et al.98 documented the association of PDA and familial 
thoracic aortic aneurysm and dissection in a large French family. Linkage analysis 
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identified 16p12.2-p13.13 as the locus responsible for both TAAD and PDA in this 
family. Zhu et al.86 demonstrated that the disease is caused by mutations in the 
MYH11 gene, affecting the C-terminal coiled-coil region of the SM-MHC, a specific 
contractile protein of SMCs.  
 
Cyclic interaction between myosin encoded by MYH11 and alpha-actin encoded by 
ACTA2 are required for the contractile force of SMCs. Guo et al.87 have shown that 
missense mutations in the ACTA2 gene are responsible for 14% of the inherited 
thoracic aortic aneurysms and dissections. When reviewing the clinical 
characteristics and the familial segregation of ACTA2 mutations in fourteen 
families, six individuals from two families with a mutation altering Arg258 had PDA. 
The association of PDA and thoracic aortic aneurysms and dissections in families 
with mutations in two components of the SMC contractile proteins suggests that 
unimpaired SMC contractility is, in addition to its critical role in maintaining the 
structural integrity of the aorta, a prerequisite for ductal remodelling, which then 
leads to anatomical ductal closure. 
Non-syndromic PDA  
The contribution of a recessive locus to non-syndromic PDA in the Iranian 
population has been studied by Mani et al.99 The higher prevalence of PDA in Iran 
(15%) compared to that in the United States (2-7%), together with the increased 
rate of consanguinity (63%) among PDA cases compared to that in the general 
Iranian population (25%), facilitated their approach to the identification of a 
recessive locus. Using a genomewide linkage analysis in 21 unrelated, 
consanguineous PDA cases, they implicate a single locus on chromosome 12q24p. 
Based upon their data, they estimated that this locus contributes to the 
pathogenesis of one-third of the PDA cases in the Iranian population. Furthermore, 
they suggest a role for this locus in PDA worldwide.  
Genetic predisposition to patent ductus arteriosus in 
preterm infants 
Very recently, two studies11,12 dealing with the genetic contributions to ductal 
patency in premature babies have been published. In a quantitative heritability 
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study on premature twins, Bhandari et al.12 estimated that the genetic factors or the 
shared environment accounted for 76.1% of the variance in liability for patent DA. 
In a cohort of infants less than 32 weeks of gestation, Dagle et al.11 performed a 
single nucleotide polymorphism (SNP) analysis. Initially, they identified seven 
SNPs significantly associated with patent DA. A second analysis pinpointed an 
association between genetic variations in TFAP2B, tumor necrosis factor receptor-
associated factor 1, and prostacyclin synthase with ductal patency in premature 
babies.  
Conclusion  
The prenatal patency of the DA and its physiological closure are obtained by highly 
conserved and parallel acting mechanisms. Ductal remodelling requires a specific 
sequence of events, which includes the differentiation of SMCs and ECs, 
extracellular matrix production, SMC migration, and finally apoptosis and necrosis. 
Based upon data generated from human genetic syndromes and experimental 
animals, various genes that either directly or in combination with environmental 
factors predispose an individual to PDA have been identified. Because genes 
interfering with the recruitment of medial or with the proliferation, differentiation, 
migration, or apoptosis of SMCs are affected in virtually all of the syndromic 
anomalies associated with PDA, SMCs can be considered to be a pivotal cellular 
structure in the pathogenesis of PDA. Because the process of recruitment and 
differentiation of SMCs is dependent upon reciprocal signalling between ECs and 
mesenchymal cells,100 it is reasonable to infer that ECs in the ductus may also 
contain transcriptional targets or regulators necessary for the differentiation of the 
adjacent SMCs. Several “classical” angiogenic and vasculogenic signalling 
pathways are involved in ductus development and remodelling. VEGF regulates 
remodelling during permanent closure,23 PDGF-BB mediates SMC proliferation,101 
and the Agtr1 gene is up-regulated in the neonatal ductus. In addition, angiotensin 
has been suggested as a novel effector of ductus closure.49 A transcriptional 
network, including Tfap2B, endothelin-1, and hypoxia-inducible factor 1, has 
recently been suggested to act in ductal SMCs of developing mice.71 Our own 
microarray data in rats (chapter 5) show a significant up-regulation of Tfap2B gene-
expression in ductal SMCs compared to aortic cells. A PDA in combination with 
only very mild dysmorphic features in patients with Char syndrome underscores the 
tissue specifity of TFAP2B mutations. Furthermore, TFAP2B is one of the three 
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genes suggested in a recent study in preterm infants to be associated with 
persistent patency of the DA.11 In animal studies, TGF-beta signalling has also 
been linked to ductal remodelling.92-94 The role of TGF-beta signalling in the 
molecular regulation of the maturation and anatomical closure of the DA is not yet 
fully elucidated. The emerging knowledge of clinical syndromes associated with 
PDA or ductus aneurysms, which are related to mutations in the TGF-beta 
signalling cascade, draws further attention to this signalling pathway.  
 
Technological advances in high-throughput genetic screening will facilitate the 
identification of pathways and genes involved in ductus development and closure. 
A better understanding of the genetic background of this developmental process 
can help develop new strategies in order to manipulate the DA in premature 
infants, neonates with duct-dependent cardiac anomalies, and patients with 
syndromic and non-syndromic PDA.  
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Persistent ductus arteriosus (PDA) is a common cardiovascular anomaly in 
children caused by the pathologic persistence of the left sixth pharyngeal arch 
artery. The inbred Brown-Norway (BN) rat presents with increased vascular fragility 
due to an aortic elastin deficit resulting from decreased elastin synthesis. The 
strikingly high prevalence of PDA in BN rats in a pilot study led us to investigate 
this vascular anomaly in 12 adolescent BN rats. In all BN rats, a PDA was 
observed macroscopically, whereas a ligamentum arteriosum was found in adult 
controls. The macroscopic appearance of the PDA was tubular (n=2), stenotic 
(n=8), or diverticular (n=2). The PDA had the structure of a muscular artery with 
intimal thickening. In the normal closing ductus of the neonatal controls, the media 
consisted of layers of smooth muscle cells (SMCs) intermingled with layers of 
elastin. The intima was thin and poor in elastin. By contrast in the media of PDA in 
BN rats elastin lamellae were absent and the intima contained many elastic fibers. 
The abnormal distribution of elastin in the PDA of BN rats suggests that impaired 
elastin metabolism is related to the persistence of the ductus and implicates a 
genetically determined factor that may link the PDA with aortic fragility 
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Introduction 
Patent ductus arteriosus is frequently diagnosed in children. Reflecting the 
increased survival of premature infants the prevalence has risen to 13.5% of all 
heart defects at birth.1  
Patent ductus arteriosus in premature babies is a functional anomaly, which must 
be distinguished from the structural anomaly of the PDA in the spectrum of 
congenital heart disease. To separate those two entities clinically, a PDA is defined 
as a ductus that has failed to close after 3 mo of age.2 In the offspring of patients 
with PDA, the incidence of this cardiovascular anomaly is increased, suggesting a 
genetic background.1 Mutations in the transcription factor AP-2B (TFAP2B ) cause 
familial PDA in Char syndrome.3 Recently, a new aortic aneurysm syndrome has 
been described due to mutations in the genes encoding transforming growth factor 
(TGF-b) receptors 1 and 2 (TGF-b R1 and TGF-b R2) being associated with PDA 
and ductal aneurysm in 50% of the affected individuals.4 In human PDA, the 
ultrastructural changes associated with physiologic ductal closure do not occur. 
Intimal cushion formation is abnormal or absent and the endothelium remains 
attached to the internal elastic lamina or to an additional subendothelial elastic 
lamina; invagination of endothelium or migration of SMCs from the media are not 
observed.2,5 Until now, the only animal model of inherited PDA has been 
established in dogs by Patterson and coworkers.6,7 
The morphologic changes in canine PDA resemble those in humans. The process 
of physiologic ductal closure is well studied in various laboratory animals such as 
rats8,9, rabbits9, and lambs.10 The BN rat differs significantly from other strains of 
rats with respect to thoracic and abdominal aortic elastin content and internal 
elastic lamina rupture.11 This phenotype has been related to a genetically 
increased vascular fragility in the BN rat.12 The present study describes the 
morphologic details of a genetically determined PDA in an inbred strain of BN rats. 




Materials and methods 
Animals 
Twelve young adult female BN (BN/Rij) rats ranging in age between 9 and 11 wk 
(i.e. about 1–4 wk before fertility), supplied by Harlan Horst (The Netherlands) were 
studied. In addition to these 12 rats, 18 BN rats from the same age were studied 
macroscopically in our institution. Fourteen of these rats served as allogenic aortic 
valve donors in heterotopic aortic valve transplantation experiments published by 
Grauss et al.13 Twelve adult Wistar rats and 12 neonatal Wistar rats were used as 
normal controls. Animal care complied with the Guide for the Care and Use of 
Laboratory Animals published by the U.S. National Institutes of Health (National 
Institutes of Health Publication No. 85-23, revised 1996). Animal experiments were 
approved by the local committee of animal welfare of the Leiden University Medical 
Center (LUMC). 
Experimental protocol 
Rats were killed by CO2 inhalation followed by cervical dislocation. Neonatal rats 
were killed by decapitation. A median sternotomy was performed followed by en 
bloc removal of the lungs. The ductus arteriosus and the great vessels were 
inspected and documented photographically. After macroscopic examination, the 
great vessels and the ductus arteriosus were resected. The specimens were 
overnight fixed in 4% paraformaldehyde (PFA) dissolved in phosphate-buffered 
saline (PBS) or in 2% acetic acid in 100% ethanol overnight at 4°C. Fixed tissues 
were thoroughly rinsed in PBS and dehydrated in graded ethanol and xylene and 
embedded in paraffin. Sections of 5µm were cut and mounted onto several series 
of slides. Standard histologic stainings were performed with hematoxylin and eosin 
(HE) for a morphologic overview. Resorcin-fuchsin (RF) and sirius red (SR) were 
used to depict elastin and collagen, respectively. To detect SMCs, the mAb against 
smooth muscle -actin 1A4 (1:3000; DAKO A/S Glostrup, Denmark), horseradish 
peroxidase– conjugated rabbit anti–mouse antibody (1:250, DAKO) was used as 
second antibody. The staining procedure was performed as described by Grauss et 
al.13 Sections were briefly (5 s) counterstained with hematoxylin. 




Controls (Wistar rats) 
On analysis within 30 min after delivery, the ductus appeared as a small blood-
filled vessel. Twenty-four hours after delivery, the ductus arteriosus appeared 
as a whitish strand of vascular tissue. There were no indications of blood inside the 
ductus. Both the pulmonary and aortic end of the ductus were closed. In the adult 
Wistar rats, the ductus was a thin ligament hardly discernible from the surrounding 
tissue. 
BN rats 
In all adolescent BN rats, a macroscopically visible ductus arteriosus was found 
instead of the expected thin ligament. The persistent ductus in the 14 rats that were 
dissected in the course of heterotopic aortic valve transplantation experiments had 
to be ligated to avoid hemorrhage after transplantation. There were no signs of 
hemodynamic consequences of the PDA. In particular, cardiomegaly and 
pulmonary congestion were not found during dissection of the cardiovascular 
system. Female rats were able to survive pregnancy and delivery without clinical 
signs of heart failure. The morphologic characteristics of the ductus in the 12 
individual animals of the present study are summarized in Figure 3.1. The 
morphologic appearance varied between a longer, more tubular and a short conical 
structure. The largest ductus measured 25%–30% of the diameter of the ascending 
aorta. (Figure 3.2a). The aortic end of the ductus was open in all specimens and 
filled with blood at dissection. As to the morphology of the pulmonary end of the 
ductus arteriosus, three different types of ductus could be distinguished: 1) a 
tubular type with a widely patent pulmonary end in two rats (Figure 3.2a), 2) a 
stenotic type with a stenotic lumen at the pulmonary end filled with a small line of 
blood in eight rats (Figure 3.2b), and 3) a diverticular type with an occluded lumen 
at the pulmonary end in two rats (Figure 3.2c).Thus, the ductus was completely 





































Figure 3.2 Macroscopic image of the three morphologic types of PDA in adolescent BN-rats: tubular-
type PDA (a), stenosed-type PDA (b), diverticular-type PDA (c). ao, aorta ascendens; pa, pulmonary 
artery; the ductus arteriosus is marked by an arrow. The bar represents 2 mm. 
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Histology 
Controls (Wistar rats) 
Functional ductal closure in Wistar rats took place within the first hours after birth. 
The ductus of neonatal Wistar rats studied within 30 min after birth was still open. It 
appeared as an elastic artery with some intimal thickening inside the lumen (Figure 
3.3a and 3.3b). The media consisted of 10–12 elastin lamellae (Figure 3.3b) 
alternating with layers of SMCs confirmed by 1A4 staining (Figure 3.3c) and layers 
of collagen (Figure 3.3d). The inner elastic lamina forming the border between 
tunica media and intima was thicker than the other lamellae. The intima consisted 
of three to four layers of vertically oriented cells perpendicular to the circular layers 
expressing SMC actin. The elastin laminae were irregular and thin. The intima was 
devoid of collagen layers (Figure 3.3d). The outer part of the ductus was formed by 
four to five layers of loose adventitia tissue containing small amounts of elastin. In 
all animals studied at the age of 24 h postpartum, the ductal lumen was closed. In 
adult Wistar rats, the ductus arteriosus was degenerated into a ligament. A 
vascular structure of the ductus arteriosus was not detectable. The Wistar rats 
showed loosely arranged short elastic fibers accompanied by some SMCs seen at 
the site where the ductus ligament was connected to the pulmonary artery. 
BN rats 
The histologic findings confirmed the macroscopic diagnosis of the tubular, 
stenotic, and diverticular type of the PDA. The pulmonary end of the ductus was 
histologically patent in 10 of the 12 BN rats. Only in the two animals with the 
diverticular type PDA the pulmonary end of the ductus was closed. All three types 
of ductus arteriosus had the structure of a muscular artery with intimal thickening 
(Figure 3.4 and 3.5). Two types of intimal thickening were found. In the two 
specimens with tubular morphology of the ductus, the intima consisted of six to 
eight regularly organized elastin lamellae between single layers of SMCs (Figure 
3.4a and b). The first intimal elastin lamella was located subendothelially (Figure 
3.4a and b). In the remaining 10 ducti, belonging to the stenotic and diverticular 
groups (Figure. 3.4d–f and 3.5), the intimal thickening was less organized than in 
the tubular type. Areas with elastin lamellae were found neighboring areas of 
intimal thickening without elastin. In eight of the 10 ducti, small vessels indicating 
neovascularization of the intima were present (Figure 3.5a–d). These vessels 
consisted of endothelial cells (ECs), elastin lamellae, and SMCs (Figure 3.5a–d). 
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Combinations of both types of intimal thickening were also observed. The internal 
elastic lamina could be identified in all specimens as a boundary between intima 
and media. In the media, as confirmed by 1A4 staining (Figure 3.4f and 3.5c), 10 
layers of SMCs were found. 
Elastin lamellae, however, were absent in the media of BN ductus (Figure 3.4a, b, 
e and 3.5a) in contrast to the controls (Figure 3.3b). The four to five layers of 
adventitial tissue contained small amounts of elastin (Figure 3.4b, d and 3.5b). 
Collagen was predominantly present in the adventitia as in normal controls (Figure 
3.3d). Related to the internal elastic lamellae and in areas of intimal 

























Figure 3.3  Histology of a physiologically closing ductus arteriosus of a neonatal Wistar rat 30 min post 
partum. Stained with HE (a), RF (b), 1A4 (c), and SR (d). Note three to four layers of intimal thickening 
and the media consisting of 10–12 elastin lamellae interchanged with collagen layers and layers of 
SMCs. The internal elastic lamina is indicated by arrows. a, adventitia; m, media; i, intima; thr, 
thrombus. The bar represents 100 µm. 



































Figure 3.4  Histology of PDA of adolescent BN rats stained with RF (a, b, e), HE (c, d), and anti–smooth 
muscle actin 1A4 (f) (a–c) The tubular type ductus with subendothelial elastic laminae; (d–f) an example 
of a stenotic ductus. Here the intimal thickening consists of areas with subendothelial elastic laminae as 
well as areas with subendothelial accumulations of cells with less elastin. The media is devoid of elastin 
lamellae in both types of PDA. The internal elastic lamina is indicated by an arrow. a, adventitia; m, 




































Figure 3.5  Histology of the intimal neovascularization in PDA of adolescent BN rats stained with RF 
(a), HE (b), anti–smooth muscle actin 1A4 (c), and SR (d). The internal elastic lamina is indicated by an 
arrow. As in Figure 4, the media is devoid of elastin lamellae. m, media; i, intima; asterisk indicates 
microvessel. The bar represents 100 µm. 
 
Discussion 
We found a PDA in 9- to 11-week-old BN rats and failed to do so in control Wistar 
rats. The PDA in adolescent BN rats was histologically characterized by abundant 
elastin lamellae in the intima, a subendothelial elastic lamina, and the virtual 
absence of elastin in the media. By contrast, the normal closing ductus arteriosus 
in neonatal Wistar rats is an elastic vessel composed of an intima with a thin layer 
of endothelium and subendothelial connective tissue. The media consists of 
regularly organized elastin lamellae intermixed with layers of SMCs. To the best of 
our knowledge, this is the first report describing hereditary PDA in a specific rat 
 Persistent ductus arteriosus in the Brown-Norway inbred rat strain 
57 
strain. The morphologic characteristics of PDA in BN rats are comparable to the 
histologic findings both in human and canine PDA.6,7 The functional relevance of 
PDA in the adolescent BN rats is comparable to a small PDA, which is amenable to 
catheter interventional treatment in humans. Therefore, this rat strain may serve as 
a model for human PDA. BN rats differ from other rat strains with respect to the 
elastin content11and the rupture of the internal elastic lamina in the thoracic and 
abdominal aorta.12 This phenotype has been related to increased vascular fragility 
characteristic of the BN rat.12 Therefore, alterations in elastin regulation may link 
PDA and the aortic fragility characteristic of BN rats. By analogy, Khau van Kien et 
al.14described the association of PDA and familial thoracic aortic aneurysm and 
dissection (TAA/AD) in a large French family. Recently, mutations in the MHY11 
gene were identified as cause for both TAA/AD and PDA in this family.15 Elastin in 
the vascular wall is a polymer of the tropoelastin protein secreted by ECs, SMCs, 
and fibroblasts.16 Elastin is an autocrine regulator of SMC proliferation.17 In the 
normal closing ductus, impaired elastogenesis coincides with increased SMC 
migration and proliferation causing physiologic occlusion.18 By contrast, abundance 
of elastin lamellae in the intima, a subendothelial elastic lamina, and failure of 
intimal SMC proliferation are hallmarks of PDA in humans and canine pups.19-21 
PDA in BN rats is also characterized by elastin lamellae in the intima, a 
subendothelial elastic lamina, and the virtual absence of elastin in the media. The 
media of the normal closing ductus in rodents is built up by SMCs derived from the 
neural crest22 producing elastin lamellae. The absence of elastin in the media of a 
PDA in BN rats fits into a concept of an overall down-regulation of the aortic elastin 
production in this particular strain.11 In the normal closing ductus, SMCs from the 
media migrate through the fragmented internal elastic lamina into the intima and 
cause intimal proliferation leading to closure of the ductus.7 In PDA, the 
subendothelial elastic lamina is thought to limit the access of the SMCs from the 
media to the intima. There is also strong evidence that intima cells arise during 
development and under pathologic conditions from delamination of ECs23 and 
circulating precursors.24 The capability of endothelial-mesenchymal transformation 
has also been described during arteriogenesis in the embryo.25 As ECs can also 
produce elastic laminae, the elastic intima in the PDA supports the idea that the 
mesenchymal cells are derived from the endothelium. Hence, endothelium-derived 
SMCs in the intima exhibiting a predominantly secretory phenotype might lead to 
the excess local elastin production and inhibition of SMC proliferation and closure 
of the ductus observed in BN rats. The elastin poor media of PDA may be built up 
by SMCs of a different origin (probably neural crest cells) lacking secretory 
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properties. Genetic changes in the physiologic cell differentiation process of the 
ductus arteriosus might also contribute to the functional heterogeneity of SMCs. 
During the neonatal period, dedifferentiation of SMCs takes place in the inner 
intima of the ductus and has been related to intimal thickening and physiologic 
ductal closure in humans.26 Therefore, a spatiotemporal heterogeneity in 
differentiation with a lack of neonatal dedifferentiation in the intima of the PDA in 
BN rats might also be relevant for the development of the phenotypic 
characteristics of PDA. 
Elastin synthesis is modulated by various factors. In the rat aorta and in the caudal 
artery, it has been shown that TGF-beta1 increases elastin mRNA levels in SMCs 
and ECs.27 The role of TGF-beta during ductal closure was established in lambs 
years ago.28-30 In the present study TGF-beta signaling was not analyzed because 
of the fact that the PDA in the adolescent BN rat represents the endpoint of a 
defective developmental process. Several lines of evidence suggest a role of TGF- 
beta signaling in congenital cardiovascular anomalies. Recently, a syndrome of 
altered cardiovascular, craniofacial, neurocognitive, and skeletal development 
caused by mutations in TGF-beta receptors 1 and 2 has been described.4 The 
cardiovascular anomalies included aortic root aneurysm and aortic tortuosity in all 
patients. A PDA or ductal aneurysms were reported in 54% of the affected 
individuals. Histologically, the aortic anomaly was characterized by disorganization 
of the elastin matrix and loss of elastic fiber architecture. Studies on the expression 
of collagen, connective tissue growth factor, and Smad2 in the aortic media 
implicated perturbations in TGF-beta signaling as underlying pathogenetic 
mechanism. Recent data on Marfan syndrome also focus on mutations of the TGF- 
beta receptor. Marfan syndrome, an extracellular matrix disorder with the cardinal 
cardiovascular manifestations of aortic root dilatation and aneurysm formation, has 
been associated with defects in the gene encoding for fibrillin at 15q21.1.31A 
second type of Marfan syndrome (MFS II) has been related to locus 3p25-p24.2 
recently, which has been shown to be caused by heterozygous mutations in the 
TGFBR2 gene.32,33  
A diverticular phenotype of the ductus was observed in the present study in two of 
12 adolescent BN rats. Although strictly speaking, the diverticular ductus is not a 
patent ductus, it seemed justified to include the diverticular type ductus in the study 
group. The persistence of the aortic end of the ductus as a vascular structure has 
not been found in rats from other strains i.e. Wistar rats serving as controls. The 
diverticular type is considered as farthest end of a continuum of PDA. A similar 
phenotype has been described earlier in dogs with hereditary PDA7 and is referred 
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to as mixed-type ductus arteriosus. The mixed phenotype consists of stenosis and 
intimal thickening at the pulmonary end of the ductus and the lack of intimal 
thickening at the aortic end. In humans, a ductal aneurysm is known as a rare 
lesion developing in the third trimester of pregnancy.34 This anomaly is observed in 
connective tissue disorders such as Marfan and Ehlers-Danlos syndromes and 
other syndromal lesions in about 25% of the patients35 and is characterized by 
deficient or absent intima cushions and/or disorganized elastin lamellae in the 
ductal media.34 As intima cushion formation27-30 and elastic fiber organization are 
both regulated by TGF-beta signaling, the phenotype of congenital ductal 
aneurysm might be also the result of localized or generalized perturbations of TGF-
beta signaling. 
In eight of 12 BN rats, we observed neovascularization of the intima at the 
pulmonary end of the ductus. Similar findings have been described in dogs with a 
hereditary form of PDA. In these genetically defective dogs, the normal process of 
intimal thickening is impaired. Endothelial strands are observed in the 
subendothelial region suggestive of capillary formation.7 An important factor 
leading to abnormal intimal neovascularization is tissue hypoxia. In atherosclerotic 
systemic arteries, neovascularization develops in response to hypoxia in deep 
parts of atherosclerotic lesions.35 During physiologic ductal closure, tissue hypoxia 
appears to be responsible for anatomical closure36 and has been related to the 
death of SMCs in the inner media and consecutive vascular remodeling.26,36 The 
role of tissue hypoxia in ductal closure has extensively been studied in lambs.37,38 
In lambs, hypoxic cell death in the media has been attributed primarily to changes 
in vasa vasorum flow and medial thickness, which can occur before luminal blood 
flow had ceased.38 
In small animals such as rats, mice, and rabbits, intramural vasa vasorum are 
lacking.39 It has been suggested that, in this situation, the complete obliteration of 
the ductal lumen is necessary to initiate hypoxia-induced anatomic remodeling of 
the ductus. The exact mechanisms modulating functional and anatomic closure of 
the ductus are still not fully elucidated. In vitro data demonstrate a fundamental role 
for developmentally regulated O2-sensitive K-channels in ductal vascular SMCs 
during the initial postnatal vasoconstriction of the ductus arteriosus.40 Recent 
evidence suggests a role for endothelin as oxygen messenger in the ductus during 




The BN inbred rat strain has been characterized as a novel animal model of PDA. 
PDA in the BN rat may reflect the well-known elastin defect in this particular strain. 
The BN rat may serve as a model for defective vascular remodeling found in 
human PDA as well as in human thoracic aortic aneurysm and dissection. 
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Closure of the ductus arteriosus (DA) at birth is essential for the transition from 
fetal to postnatal life. Before birth the DA bypasses the uninflated lungs by shunting 
blood from the pulmonary trunk into the systemic circulation. The molecular 
mechanism underlying DA closure and degeneration has not been fully elucidated, 
but is associated with apoptosis and cytolytic necrosis in the inner media and 
intima. We detected features of histology during DA degeneration that are 
comparable to Hutchinson-Gilford Progeria syndrome and ageing. Immuno-
histochemistry on human fetal and neonatal DA, and aorta showed that lamin A/C 
was expressed in all layers of the vessel wall. As a novel finding we report that 
progerin, a splicing variant of lamin A/C was expressed almost selectively in the 
normal closing neonatal DA, from which we hypothesized that progerin is involved 
in DA closure. Progerin was detected in 16.2% ± 7.2 cells of the DA. Progerin-
expressing cells were predominantly located in intima and inner media where 
cytolytic necrosis accompanied by apoptosis will develop. Concomitantly we found 
loss of α-smooth muscle actin as well as reduced lamin A/C expression compared 
to the fetal and non-closing DA. In cells of the adjacent aorta, that remains patent, 
progerin expression was only sporadically detected in 2.5% ± 1.5 of the cells. Data 
were substantiated by the detection of mRNA of progerin in the neonatal DA but 
not in the aorta, by PCR and sequencing analysis. The fetal DA and the non-
closing persistent DA did not present with progerin expressing cells. Our analysis 
revealed that the spatiotemporal expression of lamin A/C and progerin in the 
neonatal DA was mutually exclusive. We suggest that activation of LMNA 
alternative splicing is involved in vascular remodeling in the circulatory system 
during normal neonatal DA closure. 
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Introduction 
The fetal ductus arteriosus (DA) is a muscular artery connecting the aortic arch and 
pulmonary trunk (Figure 4.1a). The DA shunts deoxygenated blood from the fetal 
right ventricle into the umbilico-placental circulation, where gaseous exchange 
takes place. Prenatally, the DA is indispensable. After birth, as blood becomes 
oxygenated in the lungs, the DA rapidly contracts followed by anatomical definitive 
closure (Figure 4.1a, b, f). The histological features of the normal closing muscular 
DA as well as the elastic structure of the aorta are depicted schematically (Figure 
4.1d, e). DA closure is incomplete in about 10% of neonates1causing a patent or 
persistent DA (PDA). This is the third most common congenital heart defect.2 
Normal closure of the DA, which can take place in both healthy neonates as well as 
in neonates with congenital heart malformations, is mediated by two processes, 
vascular smooth muscle cell (SMC) contraction, and anatomical closure on the 
basis of tissue degeneration.1,3-5 Contraction of SMCs in the DA results from the 
rapid rise in oxygen tension after delivery.6 Anatomical closure in humans starts 
already in the second trimester fetus by the initiation of intimal thickening which is 
regulated by the prostaglandin (PGE) receptor, EP47 via the protein kinase A and 
Epac regulatory pathways.8 After birth following contraction there are major 
changes in the inner media characterized by extracellular matrix deposition 
followed by apoptosis and cytolytic necrosis (CN) (Figure 4.1d). Eventually a DA 
ligament (Figure 4.1f) is formed.3,5-9 The molecular regulation of DA regression in 
the neonate is still incompletely understood.  
The anatomical process of postnatal DA closure and regression is common in 
mammals but the timing of the processes regulating DA closure varies between 
species. In humans DA maturation already starts in the prenatal period but without 
strict correlation between gestational age, postnatal age and the degree of 
maturation.1 For medical purposes, it is crucial to study the spatiotemporal 
regulation of DA regression in the prenatal and postnatal period.3-5In neonates with 
ductus-dependent heart anomalies, systemic administration of PGE can prevent 
constriction of the DA.10 Unrestricted flow via an open DA is essential for those 
neonates until they can undergo corrective surgery. Histological characteristics of 
the DA of healthy neonates and those with heart anomalies are identical3 and 
similarly influenced by PGE.11 This offers a unique opportunity to study DA 








































Figure 4.1 Schematic presentations of the great vessels.  
Anatomy of DA and the adjacent arteries. (a) A patent DA is found in the fetus before respiration starts. 
Oxygen-rich blood (in red) from the placenta passes though the aorta. Oxygen-poor blood from the fetus 
(in blue) passes the DA entering the descending aorta (in purple). (b) After the start of respiration the 
DA regresses into a ligamentum arteriosum. Aortic (red) and pulmonary (blue) circulations are 
disconnected. (c) In aortic coarctation, a left sided heart malformation, the DA is kept open by 
administration of PGE allowing blood to enter the systemic circulation. Dashed lines indicate the plane 
of tissue sections shown in d-h.  
Transverse sections of the muscular DA (d;1 in c), the elastic aorta (e;2 in a), and the ligamentum 
arteriosum (f;3 in b). Intimal thickening in the DA is indicated in yellow. Areas with CN are indicated in 
white and the wavy elastic lamellae with blue. Endothelial cells (red outlines) line the inside of the 
vessels. 
Longitudinal sections through the DA (4 in a, providing Fig. 1g, and 5 in c providing Fig 1h). (g) DA 
tissue and aorta tissue are merging and can be separately distinguished by their characteristic 
histology. (h) In coarctation, inner media and intimal thickening of the DA extend into the aorta 
sometimes almost encircling the lumen of the aortic arch at that site (as depicted). The aortic tissue will 
always be present in the roof of the coarctation. 
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Children with Hutchinson-Gilford Progeria Syndrome (HGPS) develop progressive 
arterial occlusive disease and will eventually die due to severe atherosclerosis, 
see12. HGPS is caused by a mutation in LMNA, which leads to accumulation of a 
truncated lamin A protein, progerin, at the nuclear lamina.13 Arteries of HGPS 
patients exhibit intimal thickening with dense fibrosis and thinning of the adjacent 
media.14 Relative to lesions in typical atherosclerosis, the atheromatous core tends 
to be smaller14 or even absent15 in HGPS arteries. Reduced numbers of SMCs in 
the aortic media was a prominent finding in a murine HGPS model.12 Marked 
adventitial fibrosis in arteries and veins has been added to the spectrum of 
vascular lesions in HGPS.14 The anatomical remodeling process that converts the 
muscular DA vessel of the fetus and neonate into the fibrous structure of the 
ligamentum arteriosum is characterized by intimal thickening without an 
atheromatous core. Furthermore, loss of SMC in the inner media and intima are 
due to CN.4,5,9 Although degeneration during closure of the DA and vascular 
pathology in HGPS is not identical, the similarities in intimal thickening and loss of 
VCMCs warrant the hypothesis that progerin may also play a role in the DA 
closure. Here, we show that progerin is specifically expressed during the closing 
process of the DA in areas with developing CN, while Lamin A/C is hardly 
expressed in these regions. The molecular and cellular implications of these novel 
findings are discussed. 
Materials and Methods 
Ethics statement  
The medical ethics committee of the Leiden University Medical Center exempted 
this study from review because tissues normally discarded were analyzed 
anonymously and waived the need for consent due to the fact that linkage of the 
samples received with individual patients was not possible.  
Tissue samples  
Postnatal human DA tissues were obtained during surgical correction of cardiac 
anomalies. The resection of the DA was part of the surgical strategy for aortic arch 
reconstruction in all cases (see Figure 4.1c,h, and dashed line 5 for site and 
orientation of the dissected biopsies). Fetal tissues were acquired from post-
mortem specimens after legal or spontaneous abortion after PGE induction. All 
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tissues were collected and stored at the department of Anatomy and Embryology of 
Leiden University. Tissue type, diagnosis and age were recorded for this study. 
 
Tissue samples were directly fixed in 4% phosphate-buffered formaldehyde or 2% 
acetic acid in absolute ethanol at room temperature. Fixed samples were 
embedded in paraffin and sectioned at 5 µm. For RNA extraction or cryostat 
sections, samples were placed in Tissue-tek, and were directly frozen in liquid 
nitrogen and stored at minimal -20°C. Fetal material was obtained from 2 cases (14 
and 18 weeks gestation) providing aorta and DA wall tissue. Neonatal tissue was 
studied in 16 DA biopsies and two descending aortas. The neonates (aged 3-21 
days, median 10 days) were born after 38 ± 2 weeks of gestation. All of them 
received a low dose of PGE (0,0125 µg/kg/min) because of left-sided cardiac 
defects with aortic arch anomalies (Figure 4.1c,h, dashed line 5). The biopsy of a 
PDA came from a 2-years-old child. A part of the descending aorta was collected 
from a 4-month-old infant during coarctation repair and served as a negative 
control (not shown).  
Immunohistochemistry microscopy and image quantification  
For a morphological overview sections were briefly (5 seconds) counterstained with 
haematoxylin eosin. Antibodies used in this study are: monoclonal lamin A/C 
(Chemicon International (Temecula, CA, USA); 1:50) 1:50, a monoclonal anti-lamin 
A G608 (progerin) antibody, kindly provided by K. Djabali (Dpt. of Dermatology, 
Columbia University, NY, USA) and mouse monoclonal antibody against smooth 
muscle alpha-actin 1A4 (1: 3000; DAKO A/S Glostrup, Denmark). Antibody 
incubation was performed in PBS containing 0.05% Tween 20 (PBS-T) and 1% 
bovine serum albumin overnight in a humidified chamber with the primary antibody 
at room temperature. The first antibody was detected with either HRP-conjugated 
secondary antibody (Vector Laboratories, Inc. Burlingame, CA, USA) or with a 
fluorescent- conjugated secondary antibody (Goat-anti-mouse/Alex 488, Invitrogen, 
Corp. Carlsbad, CA, USA, Donkey-anti-mouse/Cy3, Jackson ImmunoResearch 
Labaratories, West Grove, PA, USA). The fluorescent conjugated secondary were 
mounted in Citifluor (Agar Scientific) containing 400 µg/ml DAPI (Sigma-Aldrich) 
and examined with a confocal laser scanning microscopy (Leica SP5) or a 
Fluorescence microscope (Leica DM RXA), 63X and 100X lens NA 1.4 plan Apo 
objective. Apoptotic cells were determined using the in situ Cell Death Detection 
Fluorescein kit from Roche Diagnostics (Almere, Nederland) following the 
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manufacturer's instructions. Significance of statistical analysis was performed with 
the unpaired T-test with Welch’s correction.  
RNA isolation and RT-PCR reaction 
Total RNA was extracted from frozen biopsies using the RNA-Bee RNA extraction 
kit as per the manufacturer (AMS Biotechnology, Abingdon, U.K.). 1 µg of RNA 
from each sample was submitted to cDNA synthesis using the RevertAid™ First 
Strand cDNA Synthesis Kit (Fermantas, Ontario, Canada) or with the SuperScript® 
VILO™ cDNA Synthesis Kit (Invitrogen). 13.4 ng of cDNA was used for PCR using 
primers located in exon 9 and 12 of LMNA (forward: 
5′ ACCCCGCTGAGTACAACCT, and reverse: 5′ TGCAGTTCTGGGGGCTCT. The 
primers cover progerin cryptic site at position 2215 in LMNA mRNA, and are 2 bp 
longer than these that were previously described. Our set of primers gives less 
non-LMNA PCR products in DA and aorta as compared those reported in31. PCR 
conditions were 35 cycles, each cycle consisting of 30-sec denaturation at 94°C, 
30-sec annealing at 60°C, and 30-sec polymerization at 72°C. 15 µl of the reaction 
was analyzed on 2% agarose gel and stained with ethidium bromide. PCR 
products were eluted from gel and were sequenced at www.lgtc.nl. Primers for 
GUSB amplification are: forward- 5’CTCATTTGGAATTTTGCCGATT 3’; reverse- 
CCGAGTGAAGATCCCCTTTTTA. 
Results  
To determine whether progerin is expressed in neonatal DA, reverse transcriptase 
(RT) PCR was performed on fresh and frozen biopsies of DA that were collected 
during corrective cardiac surgery. The expression of progerin mRNA was analyzed 
in neonatal DA sections using primers that cover the progerin cryptic site.16 The full 
length mRNA PCR product is 270 bp (Figure 4.2A). In addition a 185 bp product 
representing the delta10 isoform was amplified in the DA and aorta tissues. 
Importantly, in the neonatal DA but not in aorta tissue a 120 bp PCR product was 
found (Figure 4.2A). These PCR products were evaluated by sequencing analysis 
which confirmed that the 120 bp fragment corresponds to progerin whereas the 
270 bp fragment is of LMNA full length mRNA (Figure 4.2B). It is relevant to note 
that in the analyzed biopsies this primer set led to unspecific PCR products (i.e. a 
100 bp fragment; Figure 4.2A). Therefore, it was essential to confirm LMNA gene 
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products by sequencing of the PCR products. The housekeeping beta-
glucuronidase (GUSB) gene was used as a control17 and PCR product was found 
in all tissues. In total, progerin PCR product was found in all 6 DA samples 
analyzed, but was not detected in the two aorta samples. Aorta and DA are 
physically connected, while remodeling in neonates is limited to the DA, suggesting 













Figure 4.2 RT-PCR reveals expression of progerin mRNA in DA. 
A. RT-PCR analysis of LMNA and progerin mRNA in neonatal aorta and DA was performed with 
primers that amplify 270 and 185 bp of LMNA, and 120 bp of progerin. GUSB PCR product was used as 
a control. Aorta tissue was obtained from a 4-month patient and DA tissues from 6 neonates 8 days 
after birth.  
B. Direct sequencing of PCR fragments 270, 185 and 120 bp. Shown are the sequence histograms from 
position 2212 bp.    
 
 
The low level of progerin mRNA in DA indicates that the protein would be 
expressed at very low levels or in only part of the cells. Progerin and lamin A/C 
protein expression was analyzed with immunohistochemistry using antibodies that 
specifically recognize progerin or lamin A/C.16 Due to irreversible farnesylation at 
the C-terminus, progerin accumulates at the nuclear lamina.18 In contrast, lamin 
A/C is also found in the nucleoplasm.18 Indeed, confocal microscopy revealed 
progerin expression (Figure 4.3A,c), at the nuclear lamina, while lamin A/C 
exhibited an additional nucleoplasm distribution (Figure 4.3A,b). This confirms that 
the two antibodies recognize different proteins. 
Progerin expression in neonatal DA was found in a large number of cells, while in 
the aorta its expression was less prominent (Figure 4.3B b,e). We determined that 
the mean fraction of progerin expressing cells in the DA was 16.2% ± 7.2 while in 
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the aorta it was only 2.5% ± 1.5 (Figure 4.3C,a) indicative for a tissue-specific 
expression of progerin. Since the major histological difference between the DA and 
aorta in neonates is degeneration of the inner media and the intima, we determined 
progerin expression across the DA layers. A higher fraction of progerin positive 
cells was found in the intima and inner media (25% ± 15.0), compared to the outer 
media (11% ± 11.2) (Figure 4.3C,b). This difference in the spatial distribution of 
progerin was statistically significant. TUNEL staining of the neonatal DA, indicative 
of apoptosis, was predominantly found in the inner media bordering the intima 
(Figure 4.4a-d). As cytolytic necrosis will initially develop in cells of the intima and 
inner media, the high expression of progerin in these layers supports a functional 
relationship with cell death. The spatial overlap in the DA between progerin 
expression and TUNEL, suggests a causal relation between progerin expression 
and apoptosis in the development of CN.  
Progerin expression was analyzed in 16 neonatal DA biopsies (including 2 with 
adjacent aortic tissue) with various degrees of CN development. Furthermore, 
specimens from a 14- and an 18-week-old fetus and a PDA from a 2-year-old child 
were studied. In the fetal DA CN is not developed, and, as expected, uniform SM-
actin staining was found across the DA layers (Figure 4.5A). Regression of the 
normal neonatal closing DA is characterized by a reduced expression of contractile 
proteins, such as alpha-SM-actin in the inner media.5,9 In the DA from neonate I 
(Figure 4.5B) SM-actin expression in the inner media was less intense compared to 
the adjacent wall layers. In the same area from the 10-day-old infant II (Figure 
4.5C), however, prominent CN in the inner media was present showing a zone 
without cells and complete absence of alpha-SM-actin expression (Figure 4.5C). 
These represent two subsequent stages in the degeneration of the neonatal DA. 
Spatially unchanged SM-actin staining was exhibited in the PDA (Figure 4.5D) 
similar to the fetal DA. In both the fetal and PDA without CN, progerin expression 
was not detected (Figure 4.5A,D). In contrast, in the DA of both neonates progerin 
expression was found in the intima and inner media but not in the outer media 
(Figure 4.5B,C), where SMCs remain present throughout ligament formation.  
Since progerin is a splicing variant of the lamin A gene, we investigated the 
expression pattern of lamin A/C in the DA. Lamin A/C expression was found in all 
nuclei in the fetal DA (Figure 4.5A), but in neonatal DA the expression was 
markedly less in areas of developing CN (Figure 4.5B,C). Lamin A/C was found in 
all layers in the PDA (Figure 4.5D) indicating a spatiotemporal association between 

































Figure 4.3 Spatial changes of progerin expression in a neonatal DA. 
A. (b) Confocal images of immunofluorescence show even nuclear distribution of lamin A/C (red) and 
(c) nuclear envelope localization of progerin (green)  in the media of DA. (a) Nuclei are counterstained 
with DAPI. (d) Merging of the staining patterns. Scale bars: 5 µm.  
B. Microscopic image of immunofluorescence in DA and aorta (Ao) show (a,d) the tissue specific 
expression of lamin A/C and (b,e) progerin. (c,f) in the media. Nuclei expressing both proteins as shown 
in the merged images.  Scale bars: 20 µm.  
C. (a) Box-plot shows the percentage of progerin positive cells in DA and aorta.  Statistical analysis 
represents 1302 nuclei in DA and 302 nuclei in aortas from 5 individuals. P-value indicates significant 
difference in progerin expression between DA and aorta. (b) Histograms show the average ratio of 
progerin positive cells in intima and inner media versus the outer media. Statistical analysis represents 
4 samples from each of the 5 individuals. P-value indicates that intima and inner media contain 
significantly more progerin expressing cells than the outer media.  





































Figure 4.4 Spatial distribution of TUNEL staining in the DA 
(a) A sister section of the neonatal DA from figure 3A that was stained with TUNEL (green). Details of 
the staining are shown in magnifications of the boxed areas b-d. TUNEL staining is predominantly found 
in the inner media (c) and the bordering intima (b). TUNEL positive nuclei were not found in the outer 




























Figure 4.5 Spatial and temporal expression of progerin is associated with development of CN in the DA  
A. Overview of the wall of the DA of an 18-week-old fetus depicting α-smooth muscle actin (αSM actin) 
staining of the vascular smooth muscle cells. Details of intima (i) and outer media (om) show the 
absence of progerin and the overall expression of lamin A/C in the cells. B. Overview of the DA of a 10-
day-old neonate with onset of degeneration of the inner media (im). In this layer there is loss of α-SM 
actin staining. Details of intima and inner media show progerin expressing nuclei (arrowheads) and 
reduction of lamin A/C expressing cells compared to the fetal DA in A. C. Overview of the DA of a 10-
day-old neonate with marked cytolytic necrosis (CN) in the inner media with loss of cells. Smooth 
muscle cells are still detectable in the intima and outer media. Detail of the intima shows some progerin 
expressing nuclei (arrowheads) and absence of these nuclei in the outer media. Lamin A/C expression 
is found in the inner and outer media. D. Overview of a non-closing persistent DA (PDA) of a 2-year-old 
infant. In all layers there is abundant α-SM actin expression. Details of the intima and outer media show 
absence of progerin and presence of lamin A/C expressing cells. Scale bars: overviews A-D 200 µm, 
details 50 µm. 
 
Discussion 
The molecular mechanisms that are involved in DA closure are poorly understood. 
Here we report, for the first time, progerin expression in the neonatal DA. We 
demonstrated expression of progerin predominantly in the neonatal but not in the 
fetal DA, and in a higher number of cells in intima and inner media, compared to 
the outer media and to the aorta. This spatial and temporal progerin expression 
pattern highly correlates with CN development in the degenerating neonatal DA 
implying a functional role for progerin in CN development. Abnormal DA closure 
was not reported so far in HGPS patients or in the HGPS mouse models. To 
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confirm a role for progerin in DA closure detailed studies in neonatal HGPS models 
and patients are relevant. 
Cell death in the DA is accompanied by activation of apoptosis.9,19 We show a 
spatial correlation between progerin expression and frequency of apoptosis. We 
postulate that progerin plays a role in cell death of smooth muscle cells in the DA. 
Reduction of alpha-SM-actin was found in arteries of HGPS patients in cells 
expressing progerin13 indicating that spatial and temporal expression of progerin 
correlates with development of apoptosis. Apoptosis frequency is increased in 
fibroblasts from HGPS20 and elevated apoptosis in the mouse model for progeria is 
reported.12 The role of progerin in initiating apoptosis of cells in the inner media 
and intima of the DA should be further investigated. 
Elevated progerin expression was spatially associated with reduced lamin A/C 
expression in the DA. These spatial changes between lamin A/C and progerin 
expression in the inner media and intima suggest an association with alternative 
splicing of LMNA gene products during DA remodeling. Activation of LMNA 
alternative splicing was found during cell differentiation and cell cycle 
progression.21 During postnatal cardiac development splicing variants of ASF/SF2 
and SERCA2 are activated22,23 to change cellular function. Lamin A/C was recently 
shown to play a role in cardiac disease. In heterozygous LMNA+/- knockout mice, 
a 50% reduction in lamin A/C protein levels cause myocardial apoptosis and 
cardiac abnormalities.24 Deregulation of lamin A/C processing correlates with 
atherosclerotic lesions from aged individuals. Pre-lamin A accumulates in medial 
SMC from aged individuals and in atherosclerotic lesions correlating with the down-
regulation of lamin A/C processing enzymes.25 Based on these studies we 
hypothesize that changes in lamin A/C expression and activation of splicing 
variants are an alternative mechanism to regulate cardiovascular development. 
Alternative splicing is affected by oxidative stress.26 Whether oxygen levels alter 
LMNA splicing during DA closure is yet to be determined Anatomical definitive 
sealing of the DA is preceded by contraction of SMCs in which many molecular 
pathways are involved1e.g. activated by reactive oxygen species. Accumulation of 
reactive oxygen species has been described in both the onset of DA closure27  as 
well as in vascular ageing.28 Progerin expression in coronary arteries of non-HGPS 
individuals, which significantly increases throughout life has been associated with 
vascular ageing.14 Farnesyltransferase inhibitors (FTIs) can in part correct cellular 
defects caused by progerin.29,30 FTIs reverse the permanent farnesylation of 
progerin or pre-lamin A and, thus repair structural and functional nuclear defects. 
Given our finding that progerin is expressed in the neonatal DA, it will be relevant 
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to study whether FTIs can interfere with local vascular remodeling and prevent 
anatomical DA closure.  
Our study indicates a novel role for progerin in a programmed cellular process 
although a relation between DA closure and the process of ageing needs further 
clarification. 
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Rationale: Closure of the ductus arteriosus (DA) is a crucial step in the transition 
from the fetal to the postnatal circulation. Patent DA is one of the most common 
cardiovascular anomalies in children causing morbidity especially in premature 
infants. Little is known about the molecular mechanisms regulating DA maturation 
and closure.  
 
Objective: We aimed to identify genes that specify the DA in the fetus and 
differentiate it from the non-closing aorta.  
 
Methods and results: Comparative microarray analysis of laser-captured 
microdissected endothelial (ECs) and vascular smooth muscle cells (SMCs) from 
the DA and aorta of fetal rats identified vessel-specific transcriptional profiles. The 
linear model of microarray analysis (LIMMA) revealed a strong age-dependency of 
gene expression in the samples from embryonic day 18 and 21. Among the DA-
dominant genes the regulator of the G-protein coupled receptor 5 (Rgs5) and the 
homeobox transcription factor Dlx1 exhibited the highest and most significant level 
of differential expression. The aorta showed a significant preferential expression of 
the Purkinje cell protein 4 (Pcp4) gene. The results of the microarray analysis were 
validated by real-time quantitative PCR. Finally, immunohistochemistry at day 21 
documented differential expression of the proteins encoded by the three newly 
identified genes in DA and aorta.   
 
Conclusion: Our study confirms a DA and aorta-specific transcriptional profile in 
ECs and SMCs. For the first time we recognized the preferential expression of 
Rgs5 and Dlx1 in the fetal DA. These genes represent novel molecular targets for 
the regulation of fetal DA maturation and postnatal DA closure. 
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Introduction 
The ductus arteriosus (DA) is a highly specialized fetal blood vessel that connects 
the pulmonary trunk with the descending aorta. In the fetal circulation the DA 
bypasses the fluid-filled lungs by shunting blood from the pulmonary trunk into the 
systemic circulation. At birth, with the transition from placental oxygen supply to air 
breathing, this connection becomes unnecessary and closes. DA closure is a 
crucial step in the transitional circulation as it ensures the efficient delivery of 
oxygenated blood from the lungs to all organs.    
Although sharing the same embryologic origin and environment the DA shows a 
deviant development and differentiation compared with other pharyngeal arch 
artery derivatives.1,2 Early in fetal development the DA acquires its typical muscular 
morphology while the adjoining aorta differentiates into an elastic vessel by elastin 
deposition and concomitant loss of actin expression in the media.2 Already at this 
early stage the DA media is composed of highly differentiated vascular smooth 
muscle cells (SMCs)3 compared to the aorta. From the second trimester of 
pregnancy onwards endothelial cells (ECs) and SMCs in the inner part of the DA 
undergo a ductus-specific remodeling process.4 As a result of this process the 
mature DA exhibits intimal thickening, which facilitates sealing of the constricting 
vessel immediately after birth. Early (functional) closure of the DA is triggered by 
the postnatal increase of oxygen partial pressure and prostaglandin withdrawal.5 
The contraction in response to oxygen is intrinsic to the SMCs of the DA and highly 
conserved among different species. Oxygen-induced inhibition of Kv channels, 
activation of L-type voltage-gated Ca-channels, increased endothelin synthesis and 
redox-dependent activation of ROCK6 and other calcium sensitization pathways7 
have been documented in the DA of humans and rabbits. After the functional 
closure the definitive anatomical closure of the DA is initiated. In the subsequent 
postnatal period the DA degenerates due to cytolytic necrosis and apoptosis from 
the muscular artery into a fibrous remnant,8 while the adjoining elastic vessels 
remain open.  
Although various anatomical, physiological and biochemical aspects of DA closure 
have been studied during the last decennia reviewed in Bökenkamp et al.5 little is 
known about the molecular mechanisms controlling the unique remodeling process 
of the DA. A recent study documented the expression of the truncated lamin A 
protein “progerin”, the underlying cause of Hutchinson-Gilford Progeria syndrome, 
related to the cytolytic necrosis process in the DA. This finding suggests 
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involvement of alternative splicing of lamin A (LMNA) in the vascular remodeling of 
the normal neonatal DA.9 
Human disease states offer insights into the transcriptional regulation of certain 
physiological processes. Regarding DA closure Char syndrome and patent DA in 
preterm infants are instructive. The patent DA and mild facial and hand anomalies 
in Char syndrome are caused by mutations in the neural crest-related transcription 
factor AP2B gene (TFAP2B).10 Sequence polymorphisms in the same gene are 
associated with isolated non-syndromic patent DA in preterm infants11-13 and 
consequently suggest a role for TFAP2B in the transcriptional control of normal DA 
closure. Targeted deletions of Tfap2B in mice confirm the critical role of TFAP2B in 
DA development and limb patterning.14,15  
Two previous studies on transcriptional profiles of the DA and aorta in fetal rats 
revealed characteristic differences between both vessels16,17 although these 
studies are hardly comparable in the analysis and finality because of the 
differences in perspective and reference.18  Upregulation of sarcomeric genes, 
characteristic for the fetal DA in the study of Costa et al.16 was found in the aorta by 
Jin et al.17 Growth hormone receptor (Ghr) exhibited the most significant 
upregulation in the DA among all DA-specific genes in the study of Jin et al.17 but 
was not differentially expressed in the dataset of Costa et al.16 Both studies used 
pooled whole vessel preparations of DA and aorta for the microarray analysis.  
In microarray analyses of whole vessel extracts the specific role of different cell 
populations, i.e. ECs and SMCs of the DA and descending aorta, cannot be 
determined. We have chosen for a selective technique. Gene expression profiling 
of laser-captured microdissected cells offers the opportunity to study gene 
expression profiles in cells of different embryonic origin, with different reactions on 
the same environmental conditions and different functions during development. By 
analyzing the profiles from late fetal (day 18) and near term (day 21) rats we were 
able to study the change in ECs and SMCs during the DA remodeling process at 
late gestation. We hypothesized that both cell-types of the DA and aorta bear a 
distinct transcriptional profile characterizing the artery that will close after birth and 
the neighboring vessel that will remain open for the duration of life. We postulate 
that transcriptional profiles in ECs and SMCs from DA and aorta reflect either a 
different origin or function of these cells, which might be detected in the perinatal 
period accompanying the radical changes of environment and phenotype. 
Failure of DA closure leads to one of the most common cardiovascular anomalies 
in children causing morbidity and mortality especially in premature infants.19,20 
Inhibition of DA closure on the other hand is critical for the immediate postnatal 
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survival of infants with various types of severe structural heart disease.21 The 
present study aims to increase the knowledge of the molecular mechanisms 
governing physiological DA closure and to improve the available pharmacological 
strategies to treat both groups of patients. 
Animals and Methods 
Animals 
Pups from 6 timed–pregnant Wistar rats were delivered after respectively 18 and 
21 days of gestation (spontaneous birth occurs at 22 days of gestation) by 
hysterotomy through a median abdominal incision. For the time of delivery the 
dams were anesthesized with sevofluorane 2.5% room air subsequently the dams 
were euthanized. Care was taken to keep the time between the delivery of the first 
and the last pup within 5 minutes. The litter size was approximately 12 pups per 
dam. Out of these 12 the first 3 pups were used for the microarray experiment. 
Isolation of the fetal thorax was carefully performed in RNase free conditions, 
frozen in tissue tek (Sakura Finetek USA, Torrance, CA, USA), and stored at -80 C. 
One half of the remaining pups were processed in the same way in order to provide 
spare material for additional microarray experiments. The other half of the pups 
were fixed for 24 hours in 4% buffered paraformaldehyde and embedded in 
paraffin for conventional and immunohistochemical evaluation. The feasibility of the 
experiments was tested in a separate pilot experiment using 4 Wistar rat embryos 
after 21 days gestation. Data from the pilot experiment are presented in the 
supplemental figures 3 and 5. 
Both experiments were approved by an independent Institutional Animal Care and 
Use committee at the LUMC in accordance with the Helsiniki convention for the 
use and care of laboratory animals.  
Laser-capture microdissection  
Cryostat sections (8 µm) were attached to RNase free (Superfrost™) microscopic 
slides and immediately placed on dry ice. The slides were preserved in -80°C 
conditions. Processing of separate batches of tissue sections of a specified embryo 
was performed at random. Three slides of each embryo were immuno-
histochemically stained in one batch. RNase free PBS was used for the appropriate 
dilution of antibodies and washing steps. Furthermore, Superase (AM2696, 
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Ambion, Austin, TX, USA) was added to the diluted antibody solution (1U/µl). After 
fixation in cold acetone (4°C) during 2 minutes, cold (4°C) conditions were 
maintained during further immunohistochemical staining. The three slides could 
easily be air-dried after acetone fixation. 30 µl of cold PBS was applied to each 
tissue section and drained off. In subsequent order, 30 µl of Biotin-conjugated 
mouse anti-rat CD31 (BD 555026) (5 ug/100ul), Cy3 Streptavidin (1:100) and alpha 
smooth muscle Actin antibody (1A4) FITC (Abcam ab8211) (1 µg/30 µl) were 
applied. In order to further limit Rnase activity, each antibody solution was only 
applied for 2 minutes. Subsequently, the antibody was gently drained off with 200 
µl of cold PBS. The slides were dehydrated at room temperature in 75% EtOH 
(30 sec), 95% EtOH (30 sec), 100% EtOH (30 sec), 100% EtOH (120 sec), xylene 
(180 sec). Dehydration was immediately followed by laser capture microdissection 
(LCM) (Veritas Microdissection Instrument. Arcturus Bioscience Inc., Mountain 
View, CA, USA). 100 to 200 cells from three tissue sections were dissected from 
the DA and descending aorta of each embryo. ECs were defined as cells lining the 
lumen and staining positive for anti-rat CD31. Alpha-smooth muscle actin positive 
cells were identified as SMCs. The microdissected cells were transferred to a Gene 
Amp tube (Applied Biosystems, Foster City CA, USA) containing 75 µl of RNeasy 
lysis buffer (RLT; Qiagen, Hilden, Germany) containing 0.14 M beta-
mercaptoethanol and 200 ng Polyinosinic Acid (Sigma Aldrich, USA). The samples 
were incubated at 42°C during 20 minutes and stored at -80°C.  
RNA isolation, amplification, labeling, and microarray 
hybridization 
The samples were processed further in one batch after thawing. RNA was isolated, 
cleaned up and eluted in 14 µl of RNase-free water according to the RNeasy 
Minelute protocol (Qiagen, Hilden, Germany). Two rounds of linear mRNA 
amplification were performed (modified Eberwine protocol): two-cycle cDNA 
synthesis and synthesis of biotin-labeled aRNA was performed according to the 
GeneChip Eukaryotic Sample and Array Processing Manual (Affymetrix, Santa 
Clara, CA, USA). MEGAscript T7 kit (Ambion, Austin, TX, USA) was used for in 
vitro transcription of the second cDNA strand in the first round of amplification. The 
second round of amplification, starting from 100 ng of first round aRNA, was 
finalised during the GeneChip in vitro transcription (IVT) labelling. Despite 
immunohistochemic double-staining and laser-capture dissection sufficient 
amounts of RNA could be isolated from these cells and amplified for the microarray 
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experiment. (see supplement (Table S5.1, S5.2) for cRNA yields). Labeled RNA 
was hybridized to GeneChip Rat Genome 230 2.0 Array. Hybridization was 
performed using 12.5 µg of biotin-labeled RNA at 45°C for 16 hours under 
continuous rotation. Arrays were stained in Affymetrix Fluidics stations using 
streptavidin-phycoerythrin (SAPE), followed by staining with anti-streptavidin 
antibody and a second SAPE staining. Subsequently, arrays were scanned with an 
Affymetrix Gene Chip 3000 Laserscanner (Affymetrix, Santa Clara, CA, USA). 
Real time quantitative PCR analysis 
First-strand cDNA synthesis was performed on the cRNA from the microdissected 
cells using random hexamer primers and Superscript III RT (Invitrogen, Grand 
Island, NY, USA). 50 ng of first-strand cDNA was used for subsequent reactions. 
Quantitative PCR (qPCR) was performed on an ABI Prism 7900 cycler (Applied 
Biosystems, Foster City, CA, USA) using a Taqman PCR kit (Applied Biosystems, 
Foster City, CA, USA). Serial dilutions of cDNA were used to generate standard 
curves of threshold cycles versus the logarithms of concentration for PGK1/PPIB 
and the genes of interest. See supplemental Table S5.3 for sequences and 
TaqMan® gene expression assays. 
Statistical analysis  
The Affymetrix probe level data were summarized using FARMS (Factor Analysis 
for Robust Microarray Summarization). Raw intensities were log2 transformed to 
get data normally distributed. First, an unsupervised multivariate projection method, 
Spectral Map Analysis, was applied to reduce the complexity of highly dimensional 
data (n genes versus p samples). Spectral Map Analysis provides an unbiased 
identification of the predominant clusters of genes and subjects that are present in 
the data set. Second, we modeled the expression data in LIMMA (Linear Models 
for Microarray Data)21,22, a method that is designed to get stable analyses even for 
experiments with small number of arrays. In LIMMA, we used a model that includes 
the three dichotomous factors of cellular origin (anti-CD31cells versus anti-alpha 
smooth muscle actin cells), tissue origin (aorta versus DA), and time (day 18 
versus day 21), as well as all two-way interactions between these factors. In this 
model, we performed tests for differential gene expression between the two cellular 
origins. Third, differences between DA and aorta in expression profiles over 
embryonic age were investigated by testing for the presence of a two-way 
interaction of tissue origin and time, using the same model in LIMMA. Models like 
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LIMMA assume that all the samples have been randomly and independently 
collected. This was the case in our separate experiments. In all our LIMMA 
analyses, we tested for the differences corresponding to each factor both globally 
over all samples to obtain increased power, but also separately for subsets of the 
samples corresponding to specific values of the other factors, to be able to detect 
whether effects are consistent for different values of the other factors. We 
corrected each of the analyses separately for multiple testing, using the false 
discovery rate (FDR) and corrected all p-values for multiplicity. Multiplicity-adjusted 
p-values below 0.05 were considered significant. The complete set of data is 
available in the GEO database. 
Immunohistochemistry  
Immunohistochemistry was used as a qualitative technique to confirm protein 
expression in tissue sections. By rigorously standardizing the methodology 
(ensemble staining of sections using the same aliquots, timing, temperature we 
were able to validate differences in staining intensity between sections, albeit not 
the degree of difference.  
The experiments were performed on sections from 4% paraformaldehyde fixed 
tissue routinely processed for paraffin immunohistochemical investigation. Primary 
Antibodies against RGS5 (Santa Cruz Biotechnology, CA, USA, SC-28492) 1:200 
-1:400, PCP4 (Santa Cruz Biotechnology,CA, USA, SC—98549) 1:200-1:400, 
DLX-1 (Aviva Systems Biology, San Diego, CA, ARP32866) 1:1000, TCFAP2beta 
(Abcam, Cambridge, MA, USA ab18113) 1:200 were used. The primary antibodies 
were dissolved in phosphate buffered saline (PBS)-Tween-20 with 1% Bovine 
Serum Albumin (BSA, Sigma Aldrich, USA). Slides were incubated overnight. 
Between subsequent incubation steps all slides were rinsed in PBS 2x and PBS 
Tween-20 1x. The slides were incubated with secondary antibodies for 45 min: for 
RGS 5 with Biotinylated Horse anti Goat (H+L) (Vector laboratories, USA 
BA-9500), 1:200 and 1:66 normal horse serum (Brunschwig Chemie, Switzerland, 
S-2000), for PCP4 and DLX1 with Biotinylated Goat anti Rabbit (H+L) (Vector 
laboratories, USA, BA-1000), 1:200, for TCFAP2B with Biotinylated Horse anti 
Mouse (H+L) (Vector laboratories, USA, BA-2000), 1:200 and 1:66 normal horse 
serum (Brunschwig Chemie, Switzerland, S-2000). The slides were incubated with 
ABC-reagent (Vector laboratories, USA, PK-6100) for 45 min. For visualization the 
slides were incubated with 400µg/ml 3-3’di-aminobenzidin tetrahydrochloride (DAB, 
Sigma-Aldrich Chemie, USA, D5637) dissolved in Tris-maleate buffer pH 7.6 to 
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which 20 µl H2O2 was added for 8 minutes. Counterstaining was performed with 
0,1% haematoxylin (Merck, Darmstadt, Germany) for 5 sec., followed by rinsing 
with tap water for 10 min. All slides were dehydrated and mounted with Entellan 
(Merck, Darmstadt, Germany) 
Results  
First we explored the microarray data of all 48 samples by the unsupervised 
spectral map analysis (SPM). This analysis revealed evident differences between 
the 24 samples from day 18 and the 24 samples from day 21(Figure 5.1A). The 
SPM bioplot illustrates the results of this unsupervised analysis. The first 
component of the principal component analysis explained 29% of the total variance 
in the dataset of the 11484 genes that were reliably detected, and separated the 
samples from day 18 from those from day 21. The second component explained 
8% of the total variance and separated ECs from SMCs. Next we analyzed the 
dataset with a supervised test. With the linear model for microarray data analysis 
(LIMMA) (P-values <0,05 adjusted for multiple testing using the False Discovery 
Rate (FDR)) we compared all samples by gestational age (ie. day 18 versus day 
21), by cell-type (i.e. ECs versus SMCs) and by vascular origin (i.e. DA versus 
aorta). LIMMA confirmed the strong age-dependency of the gene expression 
detected by the unsupervised test. In the gene-by–gene analysis 3239 genes were 
differentially expressed between the 24 samples from day 18 and the 24 samples 
from day 21. Compared to the other factors as cell-type and vascular origin 
gestational age had the largest effect on the distribution of the data.  
Comparing ECs and SMCs we found differential expression of 858 genes in the 
gene-by-gene analysis. Examples of these differences were found among well-
known endothelial-specific genes such as tyrosine kinase with immunoglobulin-like 
and EGF-like domains 1 (Tie1), endothelial tyrosine kinase, (Tek), 
platelet/endothelial cell adhesion molecule 1 (Pecam1) and von Willebrand factor 
(vWf). The latter was found to be the highest upregulated gene (5.1 logfold) in ECs 
(adjusted P-value 1.8e-06) in the LIMMA analysis. The upregulation of vWf was 
also validated by rtqPCR confirming that the LCM procedure was successful for the 
enrichment of EC.  
The comparison between the DA and the aorta revealed 16 genes that were 
differentially expressed between both vessels (Figure 5.1B). Five out of these 16 
genes were significantly upregulated in the aorta. Among these genes Pcp4 
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showed the highest (3.2 log-fold, adj. P<0.001) and the most significant 
upregulation. Out of the nine ductus-dominant genes Rgs5 (3.1 log-fold, adj. 
p=0.045) had the highest expression level. Table 5.1 lists the 16 genes together 
with their functional categories. Apart from the two genes involved in intracellular 
signaling Pcp4 and Rgs5 none of the other genes had earlier been detected in 
connection with DA remodeling.  
 
Table 5.1  The 16 most significant differentially expressed genes between DA and aorta. Functional 
categories, probe set identification numbers (ID Affymetrix) of the GeneChip Rat Genome 230 2.0. 
Array, gene name according to UniGene, gene symbols, logfold changes (LogFC) between DA en aorta 
and the adjusted p-value are shown. 
Probe set ID  
Affymetrix 
Gene Name (UniGene) Symbol LogFC 
DA:Ao 
P-value 
 Structural System    
Membrane protein     
 Lipidphosphate phosphatase-related 
protein type 4 (LPPR4)  
Prg1 -0.753 <0.050 
DNA, RNA protein 
processing 
    
294864_at Chaperonin containing TCP1  Cct5 -0.509 <0.045 
295284_at RNA binding motif protein 8A  Rbm8_predicted -0.388 <0.050 
Cytoskeleton and 
matrix components 
    
316758_at Laminin alpha 1  Lama1 -1.42 <0.050 
304021_at Collagen type 8 alpha Col8a1_predicted -2.081 <0.001 
1383708_at Integrin, beta-like protein 1 (Itgbl1) LOC498564 -2.216 <0.050 
 Intracellular Signaling    
Transcription 
factors 
    
296500_at Distal-less homeobox1  Dlx1 -1.741 <0.050 
Intracellular 
signaling 
    
25510_at 
 
Purkinje cell protein 4 (also known as 
neuron specific protein PEP-19) 
Pcp4 -3.185 <0.001 
54294_at Regulator of G-protein signaling 5 Rgs5 -3.075 <0.050 
1378988_at mab-21-like 2 LOC680102 -0.947 <0.050 
     
 Tissue Modeling    
Regulators of cell 
cycle and apoptosis
    
25203_at Cyclin B1 Ccnb1 -0.587 <0.050 
296883_at Replication protein A3  Rpa3_predicted -0.642 <0.045 
85246_at Growth arrest specific protein 7  Gas7 -0.676 <0.021 
     
 Metabolic system    
293652_at NADH dehydrogenase (ubiquinone)  
Fe-S protein 8 
Ndufs8_predicted -0.573 <0.045 
     
 Immune response    
29199_at Hemochromatosis gene  Hfe -0.426 <0.050 
 Others    
1372066_at 
 
Family with sequence similarity 103, 
member A1  
RGD1310022 -0.709 <0.045 























Figure 5.1  A: Spectral map bioplot. The first principal components (PC) of the weighted spectral map 
analysis (SPM) of normalized microarray data are plotted. Colored squares with numbers depict 
different samples, while circles depict genes. Distances between the squares are a measure for 
similarity between samples. Genes that do not contribute to the differences between the samples are 
indicated as dots in the cloud around the centroid (represented by the cross). The ten most significantly 
contributing genes to the differences between samples are positioned in the largest distance from the 
centroid and annotated by their gene symbol. The first PC represented on the x-axis explains 29% of 
the variance in the dataset and discriminates samples from day 18 (n = 24) from those of day 21 (n=24). 
The second PC represented on the Y-axis explains 8% of the variance and discriminates between ECs 
and SMCs. Among the genes that contribute to the differences are the muscle proteins myosin heavy 
chain 3 (Myh3), myosin light chain, phosphorylatable (Mylpf), myosin heavy chain 8 (Myh8) and 
tenascin N (Tnn2). B: Histogram showing the 16 most significant differentially expressed genes 
between DA and aorta. The annotation of the genes is on the x-axis. The adjusted P-values are shown 
on the y-axis. Red bars represent genes that are upregulated in the aorta. Green bars represent genes 
that are upregulated in the DA. C: Volcano plot. The volcano plot constructed with LIMMA analysis 
summarizes the fold changes between the two types of samples (i.e. DA versus aorta) and the log 10 
transformed p-values. The negative log 10 transformed p-values (y-axis) are plotted against the log 
ratios between the samples (log2 fold change). For our study we selected 4 genes. The position of these 
genes in the upper left (Rgs5, Tfap2B, Dlx1) or upper right (Pcp4) is the result of a high ratio of 
differential expression in combination with a high significance level. This suggests biological relevance 








































 Laser-capture microdissection and comparative microarray identified Rgs5 and Dlx1 
95 
Figure 5.2  Gene expression of Rgs5, Dlx1, Tfap2B, and Pcp4 by microarray and quantitative RT-PCR. 
Expression levels are expressed as fluorescent signal intensity measured on the array after 
normalization (a,c,e,g). Expression levels are shown for individual samples. The colors correspond to 
the colors used in Figure 5.1. The colored horizontal lines represent the means. The graphs on the right 
side show the relative quantification of mRNA of (b) Rgs5, (d) Dlx1, (f) Tfap2B, (h) Pcp4 by quantitative 
RT-PCR (qRT-PCR) normalized against Ppib. The red symbols represent ECs, the green SMCs. All 
individual samples are presented. The horizontal lines indicate the means. The same mRNA 
preparations were used for microarray and the qRT-PCR. (a,b) Rgs5 was detected by microarray and 
qRT-PCR as a DA-dominant gene. The microarray revealed the highest Rgs5 expression in the ECs of 
the DA at 21 days. (b) qRT-PCR detected the largest relative expression in the SMCs of the DA at 21 
days. (c) Dlx1 was identified as DA-dominant gene with high levels of expression in EC of the DA at day 
18 and day 21 by the microarray. (d) Quantitative RT-PCR confirmed the dominance in all cell-types of 
the DA. In the aorta Dlx1 was virtually absent. (e) Tfap2B expression levels by microarray were higher 
in EC than in SMC with the highest levels in the DA at day 18 and 21. (f) qRT-PCR demonstrated 
Tfap2B expression almost exclusively in the DA. There was no significant difference between the two 
time-points (18 versus 21 days) and cell-types (ECs versus SMCs) of the DA. (g,h) Pcp4 was identified 
as aorta- dominant with both techniques. (g) By microarray higher expression levels of Pcp4 were found 
in SMCs than in ECs. (h) By qRT-PCR the highest relative Pcp4 expression was detected in the ECs at 
day 21. At day 18 the expression levels were comparable in ECs and SMCs of the aorta. 
 
 
Volcano plots, displaying the magnitude of the gene expression ratio on the x-axis 
and the significance of the difference on the y-axis are provided (Figure 5.1C and 
supplemental Figure S5.2). The volcano plot (Figure 5.1C) shows the comparison 
between DA and aorta in all 48 samples. From this plot we selected four genes 
(Rgs5, Dlx1 and Tfap2B in the DA and Pcp4 in the aorta) for further study. These 
four genes were found in the left (Pcp4) or right (Rgs5, Dlx1, Tfap2B) upper part of 
the plot. The high ratio of differential expression combined with a high significance 
level is responsible for the position of the genes in the plot and suggests biological 
relevance of these genes. In volcano-plots showing the comparison between DA 
and aorta separately for each cell-type and gestational age (supplemental Figure 
S5.2) the four selected genes were found among the highest and most significantly 
differentially expressed genes.  
Rgs5 
Rgs5 was identified as a DA-dominant gene by the microarray. LIMMA revealed a 
significant up-regulation of Rgs5 in all four cell-types of the DA at both time-points 
(Figure 5.2a) showing higher expression levels at day 21 as compared to day 18. 
In order to confirm the findings we performed rtqPCR analyses (Figure 5.2b). Using 
validated fluorogenic TaqMan® gene expression array normalized against the Ppib 
we confirmed the upregulation of Rgs5 in the DA in comparison to the aorta. The 
highest relative expression of Rgs5 was found in the SMCs of the DA at day 21. At 
day 18 RGS5 was significantly lower expressed in the SMC of the DA confirming 
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also the strong age-dependency of this gene in the DA. ECs of the DA expressed 
comparably low levels of Rgs5 at day 18 and 21.In the aorta Rgs5 was below the 
detection level in both cell-types at day 18 and remained at a very low level at 
day 21. 
Dlx1 
Dlx1 was detected as a DA-dominant gene in the microarray. Globally Dlx1 
exhibited a 1.75 log-fold upregulation in the cells of the DA when compared to the 
cells from the aorta (Figure 5.1b). Expression levels of DLX1 were higher in all 
samples of ECs than in those of SMCs (Figure 5.2c). The DA-dominance was 
significant in ECs and SMCs at day 18 and in SMC at day 21. In ECs at day 21 the 
differential expression of Dlx1 did not reach statistical significance. RtqPCR 
analysis normalized against Ppib confirmed the DA-dominant Dlx1 expression 
(Figure 5.2d). The clear expression difference was present in all cell-types. Dlx1 
was virtually absent in aortic ECs of both gestational ages and in aortic SMCs of 
day 21 (0.3-0.4 fold-difference). In the DA at day 18 and day 21 both ECs and 
SMCs had a high magnitude of Dlx1 expression (ranging between 24 and 84 fold-
difference). An increase of the expression levels with gestational age was present 
in the SMCs but not detected in ECs.  
Tfap2B 
Tfap2B was selected because of its differential expression between DA and aorta 
shown in the volcano-plot (Figure 5.1C). An upregulation of Tfap2B was 
documented in both cell-types of the DA at both time-points (Figure 5.2e) showing 
higher expression levels at day 21 as compared to day 18. Using validated 
fluorogenic TaqMan® gene expression array normalized against the Ppib we 
confirmed the ductus-specific expression in ECs en SMCs at day 18 and day 21 
(Figure 5.2f). Differences between the expression levels in the SMC and the EC of 
the DA were not significant. In cells from the aorta Tfap2B expression was below or 
just slightly above detection level.  
Pcp4 
Pcp4 was recognized as an aorta-dominant gene with the highest and most 
significant level of differential expression between aorta and DA by LIMMA in ECs 
and SMCs at both time-points (Figure 5.2g). Furthermore, the expression level of 
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Pcp4 was higher in all samples from day 21 as compared to day 18. LIMMA 
analysis also revealed the significant up-regulation in the aorta (log-fold 3.2, adj. 
P<0.001) globally and also separately for gestational age and cell-type. Because of 
its high and significant up-regulation in the aorta, we selected Pcp4 for confirmatory 
rtqPCR. The validated fluorogenic TaqMan® gene expression array normalized 
against the Ppib gene also showed an up-regulation of this gene in the aorta 
compared to the DA (Figure 5.2h). The highest and most significant up-regulation 
(10 fold-difference) was found in the ECs of the aorta at day 21 while the 
magnitude of expression was only 2 fold increased in aortic ECs at day 18. SMCs 
of the aorta did not show an increase of Pcp4 expression with gestational age. In 
all samples of DA cells relative Pcp4 expression was detected at very low levels 
(0.3-0.7 fold difference) confirming the microarray data.   
Immunohistochemistry 
The expression of RGS5, PCP4, and DLX1 protein was visualized by 
immunohistochemistry in tissue samples of the DA and aorta (Figure 5.3). As the 
highest levels of mRNA expression of these genes were observed at day 21 we 
used this stage for the analysis of protein expression. Immunohistochemical 
staining revealed expression of RGS5, PCP4, and DLX1 in all samples. Although 
immunohistochemistry is an essentially qualitative technique, we could confirm 
quantitative differences. The differential protein expression in DA and aorta 
confirmed the results of the microarray and rtqPCR. RGS5 was expressed in the 
cytoplasm of EC and SMC. The highest intensity of staining was detected in SMC 
of the DA localized in the subendothelial part of the intima (Figure 5.3a). ECs and 
SMCs in other parts of the DA wall were also more intensely stained than the aortic 
ECs and SMCs in the descending aorta (Figure 5.3b). DLX1 staining resulted in 
cytoplasmatic positivity in mostof DA and aorta (Figure 5.3c, d). The highest 
intensity of DLX1 staining was found in the EC of the DA and as a whole the DA 
(Figure 5.3c) was more intensely stained than the descending aorta (Figure 5.3d). 
The expression of TFAP2B protein was not identified by immunohistochemistry in 
the DA or aorta by absence of available selective antibodies. Sections stained 
against PCP4 exhibited a strong nuclear positivity and a weaker cytoplasmatic 
staining (Figure 5.3e, f). The strong nuclear staining was most prominent in the EC 




























Figure 5.3 Protein expression of RGS5, DLX1 and PCP4 by immunohistochemistry. Photomicrographs 
of representative transverse sections show (a,b) RGS5 (c,d) DLX1 and (e,f) PCP4 expression in DA and 
aorta. The DA (a) shows a more intense cytoplasmatic staining against RGS5 in ECs and SMCs than 
the aorta (b). This is most clearly seen in the EC and the subendothelial layer of SMCs which were also 
studied in the microarray experiment. Dlx1 is predominantly expressed in the DA (c) where EC and the 
innermost layers of SMC show the most intense staining. The EC in the aorta (d) are almost negative 
for DLX1. PCP4 is predominantly expressed in the aorta (f). The staining is most intense in the nuclei of 
the EC of the aorta. In comparison with the aorta (f) the DA (e) shows less stained nuclei and 
cytoplasma of ECs and SMCs.  Scale bars: 100 µm. 
Discussion 
DA maturation and closure is regulated by the interaction of many genes in 
different cell-types. We performed a genome-wide microarray analysis searching 
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for genes that are differentially expressed between DA and aorta of fetal rats at day 
18 and day 21. Laser-capture microdissection was used to isolate ECs and SMCs 
as an efficient and precise method for the sampling of single cells or subgroups of 
cells in heterogeneous tissues.23 This selective approach minimizes the noise of 
the microarray introduced by the variation in tissue composition.24 We selectively 
amplified mRNA from ECs and SMCs from DA and aorta and intentionally did not 
pool the various samples. Analysis of the microarray data revealed for the most 
part DA- and aorta- dominant genes that were not detected by former studies16,17 in 
which microarrays of the complete wall of the aorta were performed. Among 16 
differentially expressed genes between DA and aorta detected by LIMMA, this 
study for the first time identified Rgs5 and Dlx1 as DA-dominant molecular markers 
in the fetus. Together with Pcp4, the most significant aorta-dominant gene in our 
analysis, and Tfap2B these genes were studied more extensively with other 
techniques.  In all analyses a significant time-dependency for Rgs5, Dlx1 and Pcp4 
was observed. This strengthens the initial observation that gestational age had the 
largest influence on the differential gene expression between all samples.  
The small overlap in detected genes between the current study and former studies 
is not surprising as differences are unavoidable when comparing transcriptional 
profiles by the microarray technique as Coceani et al.18emphasized commenting on 
the large variance between two former studies.16,17 Therefore it was suggested that 
any such comparison should consider cohorts of genes for distinct functions rather 
than single genes.18 Cell populations were rigorously separated in the current study 
enabling us to discuss single genes that were most significantly differentially 
expressed between ECs and SMCs in DA and aorta in a selective microarray 
study.  
Rgs5 is a DA-dominant gene in ECs and SMCs at the end of gestation. 
Furthermore we document the maturation–state dependent upregulation of the 
Rgs5 expression from day 18 to day 21 in the DA. Rgs5 is coding for a protein 
regulating the function of vasoactive G-protein coupled receptors (GPCRs).25 Many 
GPCRs are active during fetal maturation and postnatal closure of the DA such as 
EP2, 3, 426, angiotensin16 and ET-1 receptors.27 Rgs5 is the most highly and 
differently expressed Rgs-R4 subfamily member in arterial smooth muscle, 
suggesting that Rgs5 is a candidate for regulating arterial contractility,28 probably 
under control of platelet-derived growth factor (PDGF) that represses RGS5.25 
Rgs5 is downregulated in pericytes and vascular smooth muscle cells of Pdgf null 
mice.29 The maturation–dependent upregulation of this DA-dominant-gene in the 
newborn was not categorized in the fetal cohort.16 Recently it was shown, that the 
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homogeneous RGS5 expression in the aorta of neonatal mice changed into a 
mosaic pattern in adult animals.30 The lowest expression levels were found in the 
ascending aorta and carotid arteries. Interestingly a localized high Rgs5 expression 
was documented at the site of the former DA insertion30 suggesting that an origin-
specific epigenetic program resulting in differential RGS5 promoter methylation is 
involved in the regulation of Rgs5 expression. A likely explanation for differences in 
Rgs5 expression levels between DA and descending aorta relates to the origin of 
the SMCs as we selected cells derived from different embryonic sources. The DA 
SMCs derive from neural crest cells populating the 6th pharyngeal arch, while the 
SMCs from the descending aorta are derived from the adjacent somites. We did 
not study the role of epigenetic factors causing differential Rgs5 promoter 
methylation as shown in mice.30 
Microarray analysis also revealed Dlx1 as a DA-dominant gene. It discriminates the 
DA from the aorta at day 18 and day 21 and is highly enriched in both ECs and 
SMCs of the DA as documented by quantitative rtPCR. This is a novel finding, 
Costa et al.16 and Jin et al.17 did not identify DA dominance of this gene. Dlx1 is 
part of a subfamily of vertebrate homeobox-containing genes that are structurally 
similar to the Drosophila distal-less gene. Six members in this family have been 
identified in three bigene clusters in mammals (Dlx1, Dlx2, Dlx3, Dlx5, Dlx6, and 
Dlx7). Dlx1 plays a role in the development of pharyngeal arch elements including 
jaws and teeth, and during neurogenesis in the forebrain.31 Dlx genes have been 
detected in several cancer cell lines32 where deregulation of Dlx genes was related 
with tumor progression.32 Dlx1 and 2 are expressed in the embryonic caudal 
pharyngeal arch complex including the sixth, in which the ductus arteriosus 
develops.33 This is also the case for Msx and Prx genes that interact with Drx.34 
Interestingly, DA-specific expression of Prx2 in developing chicken DA contrasts 
with Prx1 in the adjoining vessel parts35 whereas the Prx1/2 double null results in 
DA malformations.36 The interactions between Msx, Prx2 and Dlx1 genes in DA 
development have yet to be elucidated. In addition to its role in embryogenesis 
DLX1 has been reported in hematopoetic cells37 as a regulator of multiple signals 
from TGF-beta superfamily members.38 DLX2 the counterpart of DLX1 in the 
bigene cluster is expressed depending on reactive oxygen species (ROS) in 
response to glucose deprivation.39 Based on our data and the information from 
other biological contexts we propose that Dlx1 is involved in late gestational 
vascular remodeling of the DA.  
The differential expression of Tfap2B shown in volcano-plots let us select this gene 
for further validation by rtqPCR.  We confirmed its DA-dominance as we reported 
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high levels of Tfap2B in both cell-types of the DA at day 18 and 21 with a 
predominance of this gene in the SMC. The AP-2B transcription factor is involved 
in the regulation of SMC development in the DA in a transcriptional network with 
ET-1 and HIF2a.14 Tfap2B was shown to be necessary for proper ET-1 signaling in 
the DA.14 Therefore it has been suggested that patent DA in Tfap2B deleted 
animals could partly be attributed to the lack of ET-1 signaling. Recently Zhao et 
al15 described the phenotype of Tfap2B knockout mice and documented Bmp2 and 
Bmp4 as downstream targets of Tfap2B. These mice are characterized by a PDA, 
postaxial accessory digits and enhanced apoptotic cell death of renal epithelial 
cells.15, 40 Interestingly, DLX1 directs the expression of BMP4 in various biological 
contexts.38 The DA–dominant expression of both transcriptionfactor genes Dlx1 
and Tfap2 B suggests a vessel-specific regulation of Bmp4 signaling during fetal 
DA remodeling. 
Pcp4 was identified as the most significant aorta-dominant gene. From day 18 to 
day 21 a increase in Pcp4 levels was observed. The late gestational up-regulation 
of Pcp4 provides evidence for a biological function of Pcp4 in the aorta during this 
period. However, the role of Pcp4 and its protein has not been characterized 
sufficiently in the vascular system. Pcp4 has mainly been studied in neuronal 
tissues where it regulates calcium/calmodulin interactions41 and inhibits calcium 
induced neuronal cell-death by apoptosis.42 By analogy to the neuronal tissues we 
postulate that up-regulation of Pcp4 in the aorta might protect the aorta around 
birth against apoptosis. Accordingly, the relatively lower expression of Pcp4 in the 
DA might render the EC and SMC in the DA more susceptible for apoptosis, which 
plays an important role in postnatal DA closure.5 Interestingly, a study on the 
parturition of mice linked another apoptosis driven process – the softening of the 
cervix at the end of gestation with a relative decline in Pcp4 expression in cervix 
tissue.43 This supports a role for Pcp4 as anti-apoptotic regulator. The results of Jin 
et al17are in concordance with our results and categorized Pcp4 as aorta-dominant 
gene in the fetus. Costa et al16 detected a postnatal up-regulation of the same 
gene in the DA in comparison to the aorta.  Additionally a cluster of other calcium-
linked genes was identified in the neonatal DA, while its postnatal up-regulation 
was related to a modified calcium homeostasis and increased drive of the DA to 
contraction. 16 Our analysis of mRNA from ECs and SMCs from fetal DA did neither 
identify Pcp4 nor one of the other members of the cluster of calcium-linked genes 
described in the neonatal DA.  
In conclusion, our study confirms a DA-specific transcriptional profile in ECs and 
SMCs and thereby offers a basis to unravel the molecular regulation of fetal DA 
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maturation. For the first time we recognized Rgs5 and Dlx1 as DA-dominant genes. 
These genes represent novel molecular targets for the regulation of fetal DA 
maturation and postnatal DA closure. 
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Non-standard abbreviations and acronyms 
ABC-reagent avidin-biotin complex reagent 
anti-rat-CD 31 antibody against CD 31 also known as PECAM-1 (platelet 
endothelial cell adhesion molecule) 
aRNA antisense RNA), which is mRNAderived 
BMP bone morphogenetic protein  
cDNA complementary DNA synthesized from mRNA 
DA ductus arteriosus 
DLX1-7 distal-less homeobox1-7, homeobox transcription factor similar 
to the drosophila distal-less 1-7 
DRX retinal homeobox gene 
ECs endothelial cells 
ET-1 Endothelin-1 
FARMS factor analysis for robust microarray summarization 
FDR false discovery rate 
TaqMan  real-time PCR assay using hydrolysis probes relying on the 
activity of taq polymerase 
GHR growth hormone receptor 
GPCRs G protein-coupled receptors 
Kv-channel voltage-gated potassium channel 
LCM laser-capture microdissection    
LIMMA linear models of microarray  
LMNA lamin A/C 
MSX  muscle segment homeobox, homeobox transcription factor 
similar to the Drosophila muscle segment homeobox  
MYH3 myosin heavy chain 3 
MYH8 myosin heavy chain 8 
MYLPF myosin light chain, phosphorylatable 
PCP4 purkinje cell protein 4 
PPIB peptidylprolyl isomerase B (cyclophilin B)  
PDGF platelet-derived growth factor 
PECAM1 platelet endothelial cell adhesion molecule 
PRX1/2 paired-related homeobox transcription factor 1/2 
qPCR quantitative polymerase chain reaction  
RGS5 regulator of G-protein signaling 5 
RGS-R4 regulator of G-protein signaling 5-receptor 4 
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RLT-buffer lysis buffer supplied with RNeasy kit® 
ROCK Rho-associated, coiled-coil containing protein kinase 1 
ROS reactive oxygen species 
RT reverse transcriptase  
SMCs (vascular) smooth muscle cells 
SPM spectral map analysis 
TEK tyrosine kinase, endothelial    
TFAP2B transcription factor AP-2 beta (activating enhancer binding 
protein 2 beta) 
TGF-beta transforming growth factor beta 
TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains1 
TNN2 tenascin N 
VWF von Willebrand factor 
 
Human: Gene symbols generally are italicised, with all letters in uppercase. 
Protein designations are the same as the gene symbol, but are not italicised; all 
letters are in uppercase. Genomics 2002;79:464-470 
Mouse and rat: Gene symbols generally are italicised, with only the first letter in 
uppercase and the remaining letters in lowercase. Italics are not required on web 
pages. Protein designations are the same as the gene symbol, but are not 
italicised and all are upper case. According to the 2011 Guidelines of the International 
Committee on Standardized Genetic Nomenclature for Mice and Rat Genome and Nomenclature 
Committee 
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Figure S5.1  Sections used for laser-capture microdissection after immunohistochemic double- staining.  
The arrows represent the sites of laser dissection in the aorta (AO) of a fetal rat at 18 days (18d) 
gestation and the ductus (DA) of a fetal rat at 21 days (21d) gestation. Smooth muscle cells are labelled 













Figure S5.2  Gene expression of von Willebrand Factor (vWf) by microarray and RT-PCR. Expression 
levels are expressed as fluorescent signal intensity measured on the array after normalization (a). 
Expression levels are shown for individual samples. The colors correspond to the colors used in Figure 
5.1. The colored horizontal lines represent the means. Black dots represent samples that are not 
reliably detected. Note the high expression level of vWf in all EC samples. The graph (b) shows the 
relative quantification of mRNA of vWf by quantitative RT-PCR (qRT-PCR) normalized against PGK1.  
The red symbols represent EC, the green SMC. All individual samples are presented. The horizontal 
lines indicate the means. The same mRNA preparations were used for microarray and the qRT-PCR. 
The PCR results confirm the microarray results by showing a high relative expression of vWf in EC 
while its mRNA is just above detection level in SMC of the aorta. 





























Figure S5.3  A: Spectral map bioplot of samples of day 21 in the independent pilot experiment. The first 
principal components (PC) of the weighted spectral map analysis (SPM) of normalized microarray data 
are plotted. Colored squares with numbers depict different samples, while circles depict genes. 
Distances between the squares are a measure for similarity between samples. Genes that do not 
contribute to the differences between the samples are indicated as dots in the cloud around the centroid 
(represented by the cross). The ten most significantly contributing genes to the differences between 
samples are positioned in the largest distance from the centroid and annotated by their gene symbol. 
The first PC represented on the x-axis explains 28% of the variance of the dataset and discriminates 
between DA and aorta. The second PC represents 13% of the variance and discriminates between ECs 
and SMCs. Note vWf among the genes that contribute to this difference. B: Volcano plot of the pilot 
experiment. Differential expression between samples of SMC of the DA and the aorta at day 21. The 
volcano plot constructed with LIMMA analysis summarizes the fold changes between the two types of 
samples (i.e. DA versus aorta) and the log 10 transformed p-values. The negative log 10 transformed p-
values (y-axis) are plotted against the log ratios between the samples (log2 fold change). From the four 
selected genes of our study Dlx1 and Rgs5 are found in the upper left of the plot. C: Volcano plot of the 
pilot experiment. Differential expression between EC of the DA and aorta. Dlx1 (upper left) and Pcp4 
(upper right) both show a high ratio of differential expression in combination with a high significance 





























Figure S5.4  Volcano plots constructed with LIMMA analysis plotted separately for (a) EC at day 18, (b) 
SMC at day 18, (c) EC at day 21 and (d) SMC at day 21.  The four selected genes Rgs5, Dlx1, Tcfap2B 
and Pcp4 are all identified with high ratios of differential expression in combination with a high 
significance level in (a) and partly in (b,c,d). 
 


































Figure S5.5  Gene expression of Rgs5 (a), Dlx1 (b), Pcp4 (c), and Tcfap2B (d) at day 21 by microarray 
in the independent pilot experiment using 4 DA and 4 aorta samples. One DA sample was excluded 
because of mRNA degradation. Expression levels are expressed as fluorescent signal intensity 
measured on the array after normalization. Expression levels are shown for individual samples. The 
colors correspond to the colors used in Figure 5.3. The colored horizontal lines represent the means. 
This experiment identifies Rgs5 as a DA-dominant gene with the highest expression in SMC of the DA. 
DLX1, also DA-dominant, shows the highest expression in the SMC of the DA. Pcp4 is found to be aorta 
dominant. The highest expression levels were documented in EC of the aorta. Tcfap2B is predominantly 
found in the DA with a little higher expression level in SMC than in EC. All findings from the pilot 
experiment concerning predominant expression of Rgs5, Dlx1, Pcp4, and Tcfap2B are confirmed in the 

























7101 1 8399 E Aorta SMC 18d 24,69 493,8 2007,89 120,47 2,01 
7102 2 8469 B Aorta SMC 18d 11,01 220,2 2347,47 93,90 2,35 
7103 3 8469 B DA SMC 18d 13,44 268,8 1950,83 78,03 1,95 
7104 4 8462 M Aorta EC 21d 21,74 434,8 1601,12 64,04 1,60 
7105 5 8462 M Aorta SMC 21d 23,9 478 2558,39 102,34 2,56 
7106 6 8469 F DA EC 18d 19,87 397,4 1989,22 79,57 1,99 
7107 7 8412 I DA EC 21d 15,64 312,8 2462,99 98,52 2,46 
7108 8 8412 I DA SMC 21d 15,09 301,8 2633,82 105,35 2,63 
7109 9 8462 A DA SMC 21d 22,19 443,8 1677,63 67,11 1,68 
7110 10 8462 C DA SMC 18d 20,47 409,4 1149,93 46,00 1,15 
7111 11 8462 A DA EC 21d 26,47 529,4 1842,4 110,54 1,84 
7112 12 8469 D DA EC 18d 18,07 361,4 1480,23 59,21 1,48 
7113 13 8412 I Aorta EC 21d 24,9 498 802,44 32,10 0,80 
7114 14 8412 I Aorta SMC 21d 39,51 790,2 756,09 30,24 0,76 
7115 15 8462 M DA EC 21d 21,72 434,4 851,29 34,05 0,85 
7116 16 8469 B DA EC 18d 13,94 278,8 2894,31 115,77 2,89 
7117 17 8399 H Aorta EC 18d 25,61 512,2 2060,53 82,42 2,06 
7118 18 8399 F Aorta EC 18d 23,97 479,4 2323,01 92,92 2,32 
7119 19 8412 D DA EC 21d 21,7 434 1118,98 44,76 1,12 
7120 20 8469 B Aorta EC 18d 35,78 715,6 2078,61 83,14 2,08 
7121 21 8399 E Aorta EC 18d 15,19 303,8 1422,11 56,88 1,42 
7122 22 8399 F Aorta SMC 18d 18,95 379 1376,75 55,07 1,38 
7123 23 8462 C Aorta EC 21d 19,41 388,2 2273,48 90,94 2,27 
7124 24 8469 D Aorta SMC 18d 9,62 192,4 2184,54 87,38 2,18 
7125 25 8469 F Aorta EC 18d 32,07 641,4 1919,89 115,19 1,92 
7126 26 8469 F DA SMC 18d 25,8 516 1370,44 54,82 1,37 
7127 27 8469 D Aorta EC 18d 22,88 457,6 2054,34 82,17 2,05 
7128 28 8412 A Aorta SMC 21d 21,71 434,2 578,04 23,12 0,58 
7129 29 8412 A Aorta EC 21d 26,51 530,2 690,37 27,61 0,69 
7130 30 8469 F Aorta SMC 18d 17,82 356,4 1998,24 79,93 2,00 
7131 31 8412 D Aorta EC 21d 15,42 308,4 694,46 27,78 0,69 
7132 32 8399 F DA SMC 18d 27,22 544,4 1912,01 76,48 1,91 
7133 33 8412 D DA SMC 21d 19,43 388,6 769,08 30,76 0,77 
7134 34 8462 M DA SMC 21d 12,37 247,4 1649,3 65,97 1,65 
7135 35 8412 A DA SMC 21d 27,78 555,6 1688,72 67,55 1,69 
7136 36 8412 D Aorta SMC 21d 11,91 238,2 733,54 29,34 0,73 
7137 37 8412 A DA EC 21d 23,3 466 1181,48 47,26 1,18 
7138 38 8399 F DA EC 18d 28,29 565,8 1977,44 79,10 1,98 
7139 39 8462 C DA EC 21d 15,28 305,6 1607,9 64,32 1,61 
7140 40 8399 H DA SMC 18d 23,61 472,2 1787,44 107,25 1,79 
7141 41 8469 B DA SMC 18d 51,29 1025,8 1668,08 66,72 1,67 
7142 42 8399 E DA EC 18d 27,55 551 1998,44 119,91 2,00 
7143 43 8399 H DA EC 18d 39,05 781 2076,34 124,58 2,08 
7144 44 8462 A Aorta SMC 21d 23 460 2112,28 84,49 2,11 
7145 45 8462 A Aorta EC 21d 30,43 608,6 1278,07 51,12 1,28 
7146 46 8399 H Aorta SMC 18d 20,26 405,2 1528,84 61,15 1,53 
7147 47 8462 C Aorta SMC 21d 21,94 438,8 1654,4 66,18 1,65 
7148 48 8399 E DA SMC 18d 20,8 416 2694,16 107,77 2,69 
Table S5.1  RNA yields of amplified RNA (aRNA) and biotin-labeled antisense mRNA (cRNA). Chip 
ID = Chip identification number, Individual samples are described by a four-digit number followed by a 
capital letter, sample site, cell type and gestational age. Aorta = descending aorta, DA= ductus 
arteriosus, EC = endothelial cells, SMC = smooth muscle cells, 18d =18 days, 21d = 21d. 
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Assay ID Gene Symbol 
Rn00564515_m1 Purkinje cell protein 4,Gene rCG52610 Celera Annotation 
Rn01443930_m1 Purkinje cell protein 4,Gene rCG52610 Celera Annotation 
Rn01511929_m1 transcription factor AP-2 betaGene rCG43555 Celera Annotation 
Rn01492194_s1 Von Willebrand factor homologGene rCG29743 Celera Annotation 
Table S5.2  Showing a list of the pre-designed assays (Applied Biosystems) that were used for 
quantitative rt-PCR. As the validated Applied Biosystems assays for Dlx1 will all detect sequences 5’ 
upstream of the 3’ sequence detected by the Affymetrix microarray probes. Therefore, primers/ probes 
designed against this 3’ sequence were used. Forward 5’-AGG TCG CTT GAA AGT CAG AC-3’. 
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Aims: Persistent ductus arteriosus (PDA) and familial thoracic aneurysm and 
dissection (TAAD) are genetically heterogeneous. Data on the prevalence of aortic 
disease including TAAD, the familial recurrence of PDA, and other congenital heart 
disease (CHD) provide essential information for the investigation of genetic factors 
of these diseases.  
 
Methods and results: Retrospective patient-based study using a questionnaire 
assessing the prevalence of cardiovascular disease in family members of children 
with PDA. A thorough family history provided information on three generations. The 
data were analyzed by a binominal test. The prevalence in the general population 
was derived from a Dutch population-based study. 
Over the last 30 years 320 patients older than 3 months with isolated PDA have 
been treated in our institution. Data on175 patients and their 2336 family members 
were available. The prevalence of aortic disease was higher in the study group 
compared to the general Dutch population. Aortic disease was reported in 4/590 = 
0.7% of first grade relatives and 29/1339 = 2% of second grade relatives. In 
second grade relatives the prevalence of TAAD was increased to 0.7% (9/1339) 
compared to 0.016% in the general population (p<0.001). The recurrence rate of 
CHD was higher (2.7%) in first-degree relatives than in second-degree relatives 
(0.79%). 
 
Conclusion: These data provide evidence for a genetic association of PDA and 
aortic disease. The prevalence of PDA and other CHD is increased in first grade 
relatives of the index patient, suggestive of common genetic factors in the 
determination of CHD and aortic disease. 
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Introduction 
Isolated persistent ductus arteriosus (PDA) is a common minor congenital cardiac 
anomaly. The prevalence varies between about 0.8 and 10.2 per 1000 live births.1,2 
Symptoms and therapeutic consequences of the persisting fetal connection 
between aorta and pulmonary artery vary with patient’s age and the size of the 
PDA. The large variability of available data is explained by the difficulty to 
differentiate clinically between the delayed closing ductus arteriosus (DA) and the 
structurally abnormal PDA in young infants, mild or absent symptoms in patients 
with small PDA, and the increasing survival of premature babies. The present study 
focuses on the families of patients treated for an isolated PDA above the age of 
3 months, in whom we considered PDA as a primary congenital malformation. 
Nowadays, it is possible to treat most of the affected patients by catheter 
techniques.3 Surgery, considered the golden standard for PDA treatment in the 
past, is restricted to patients who are not suitable for catheter interventional 
therapy. Clinical problems, caused by the left-to-right shunt between aorta and the 
pulmonary system, disappear after closure. Therefore, patients with isolated PDA 
are in general not followed after successful treatment has been performed and 
documented.4 
Isolated PDA beyond the neonatal age is considered a sporadic and multifactorial 
disease. Examples for environmental factors include maternal exposure to the 
rubella virus5, and several drugs that increase the incidence of PDA.6-8 Bokenkamp 
et al.9 reviewed a correlation of PDA with some monogenic defects, such as Char 
syndrome and specific genetic defects including trisomy 21, 18 and CHARGE 
syndrome. In addition, populations with increased parental consanguinity have 
been reported with autosomal recessive inheritance with variable penetrance.10 
Although familial cases of PDA are rare the recurrence rate of 5% in sibs11 
suggests a genetic component also in less consanguineous populations. 
The association of thoracic aorta aneurysm and dissection (TAAD) with PDA has 
been documented in two families carrying mutations in genes encoding smooth 
muscle cell (SMC)- specific beta-myosin (MYH11)12 or aortic smooth muscle alpha-
actin (ACTA2)13. This suggests that unimpaired SMC contractility is a prerequisite 
for proper DA remodeling in addition to its critical role in maintaining the structural 
integrity of the aorta.14 Recently it has been documented that ACTA2 mutations 
predispose patients to a variety of diffuse and diverse vascular diseases, including 
TAAD, premature coronary artery disease, ischemic strokes, and Moyamoya 
disease.15 Whether other cases of familial TAAD and PDA,16 can be attributed to 
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anomalies in contractile proteins is unclear. Considering the embryonic processes 
responsible for the formation of vessel walls in general and the DA in particular, all 
mutations impairing endothelial (EC) and SMC function as well as elastogenesis 
might be responsible for PDA and TAAD. DA closure and normal aortic 
distensibility both depend on proper interaction between EC and SMC and involve 
turnover and repair of extra cellular matrix substances.17  
Different from earlier studies on the familial segregation of vascular diseases in 
families with TAAD mutations12,13 we investigated whether aortic pathology, 
specifically TAAD, occurs more frequently in families of children with isolated PDA 
of unknown origin. In addition to the determination of the prevalence of aortic 
disease in these families we aimed to study the familial recurrence of PDA and 
other types of CHD in first and second-degree relatives of patients with PDA. 
Methods 
Study population 
For this study 322 patients treated for PDA after 3 months of age have been 
identified from the patient databases of the Centre of Anomalies of the Heart 
Amsterdam/Leiden (CAHAL) covering a time-span of 30 years.  
The 322 patients, or in case of patients younger than 16 years, their parents or 
guardians, were sent a questionnaire appropriate to the patient’s age and familial 
situation. (Supplement questionnaire) 175 questionnaires were returned resulting 
in a response rate 54%. These index patients provided information spanning 2336 
family members with a mean of 14.3 family members per patient. Data from 634 
first-degree relatives (parent, sibling or offspring) and 1390 second degree relatives 
(grandparent, uncle, aunt, nephew, niece, half-sibling) were included in our study.  
 
Recorded data included age, sex, cardiovascular morbidity and mortality and 
general mortality in the families. All cardiovascular interventions and a positive 
family history for connective tissue disorders were noted. Aortic disease was 
concluded from answers that were suggestive for any type of aortic disease 
including aortic aneurysms, acute or chronic dissections, aortic root or valve 
disease. A more detailed description of the aortic disease including “ruptured aorta” 
or “dilated aorta” was necessary to conclude that a relative had TAAD. The 
recurrence rate of PDA and CHD in general was analyzed in the cohort of first-
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degree relatives. The recurrence rate was defined as percentage of patients 
affected related to the number of index cases. The family history was part of a 
more extended study on the elastic properties of the aorta in PDA patients and had 
been approved by the medical ethical board of the LUMC. 
Statistics 
SPSS 19.0 was used for analysis of the family history data. The prevalence of TAA 
was based on data describing a prevalence of 0.0016 in the Dutch population.18,19 
A Wald test was used to compare the proportions of patients and family members 
with aortic disease to the prevalence in the Dutch population. To take into account 
a possible dependence within families, robust standard errors were computed by 
using the generalized estimating equations module in SPSS and assuming an 
independence working correlation. A p-value <0.05 was considered as statistically 
significant. Cardiovascular morbidity and mortality data were compared to data 
published for the Dutch population in the same study period.20 
Results  
Baseline characteristics of the patients are summarized in (Table 6.1). Our study 
cohort consisting of 175 patients who responded to the questionnaire showed a 
male preponderance (male to female ratio of 1.76). The majority of the patients 
(142, 81.1%) were treated by catheter techniques. Treatment for PDA took place at 
a mean age of 2.8 (0.3-46.5) years.  
 
Table 6.1  Baseline characteristic of the study population. 
Characteristics Total population PDA patients 
Number of patients 2511 175 
Male, n (%) 1020 (40.6) 111 (63.1) 
Female, n (%) 1052 (41.9) 63 (35.8) 
Unknown, n (%) 439 (17.5) 1 (1.1) 
mean age at inclusion (in years) 42.8 (0-110) 12.0 (1-50 
mean age at PDA treatment (in years) n.a. 2.8 (0.3-46.5) 
PDA surgery, n (%) n.a. 29 (16.6) 
PDA catheter treatment, n (%) n.a. 142 (81.1) 
PDA treatment unknown,n (%) n.a. 4 (2.3) 
n.a. = not applicable 
 
The distribution of aortic disease among the PDA patients and relatives is depicted 
in Table 6.2A and 6.2B. Thirty-six relatives of PDA patients fulfilled our definition of 
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aortic disease (Table 6.2A). In 11 out of these 36 relatives we concluded that the 
aortic disease was TAAD. According to the binominal test for proportions TAAD 
was significantly more frequent in second- degree relatives of PDA patients than in 
the Dutch general population. Results are provided in Table 6.2B.  
 
Table 6.2  Distribution of aortic disease in the PDA patient group and their relatives.  
A      
Degree of relationship Aortic disease n Observed Prop. Test Prop. p 
PDA patients no   113  0.974 0.998   0.002 
  yes       3  0.026   
  total   116  1.0   
First-degree relatives no   586  0.993 0.998   0.045 
  yes       4  0.007   
  total   590  1.0   
Second-degree relatives no 1309  0.978 0.998 <0.001 
  yes     30  0.002   
  total 1339  1.0   
B      
Degree of relationship TAAD n Observed Prop. Test Prop. p 
PDA patients no   116  1.0 0.998   0.793 
  yes       0  0   
  total   116  1.0   
First-degree relatives no   588  0.997 0.998   0.454 
  yes       2  0.003   
  total   590  1.0   
Second-degree relatives no 1330  0.993 0.998 <0.001 
  yes       9  0.007   
  total 1339  1.0   
Observed Prop. = observed proportion of absence (no) or presence (yes) of aortic pathology or of TAAD 
in the study group, Test Prop. = test proportion absence of aortic pathology or absence of TAAD in the 
Dutch population, p = p-value of the binominal test 
 
 
We observed an increased prevalence of CHD in first and second-degree relatives 
of patients with PDA (2.73% resp. 0.79%) as compared to the Dutch population 
exhibiting 0. 43% CHD (confidence interval 0. 35 and 0.54). The frequency and the 
type of congenital heart disease (CHD) among relatives of PDA patients are 
summarized (Table 6.3). CHD was present in 17 (2.73%) first-degree relatives, 
including isolated PDA in 9 and the combination of PDA with atrial septal defect 
(ASD), ventricular septal defect (VSD) or arrhythmia in 5. In addition, 3 other first-
degree relatives had non-specified valve anomalies (2) and non-specified septal 
defect (1). Eleven (0.79%) second-degree relatives were diagnosed with CHD, 
among those were VSD in 2, valve anomalies in 7 and transposition of the great 
arteries in 2 cases.  
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Table 6.3  Frequency and the type of congenital heart disease (CHD) among relatives of PDA patients.  
Degree of relationship Diagnosis n Percentage (%) 
First-degree relatives PDA, isolated   9 1.4 
  PDA + ASD   2 0.3 
  PDA + VSD   2 0.3 
  ASD of VSD   1 0.2 
  PDA + arrhythmia   1 0.2 
  valve anomaly   2 0.3 
  PDA total 14 2.2 
      
  all anomalies 17 2.7 
Second-degree relatives VSD   1 0.1 
  TGA   2 0.1 
  valve anomaly   7 0.5 
      
  all anomalies 10 0.7 
ASD = atrial septal defect, VSD = ventricular septal defect, TGA = transposition of the great arteries 
 
 
The familial recurrence of CHD was further analyzed in the cohort of first-degree 
relatives. The recurrence rate of CHD in general was 9.7%. Isolated PDA recurred 
in 9/17 first-degree relatives conform to a recurrence rate of 5%. As all 14 cases 
with PDA, regardless whether the PDA was isolated or associated with other 
lesions, the recurrence rate of PDA was 8%. Compared to the general population 
exhibiting a frequency of PDA of 0.05%.21 PDA was more frequent in first degree-
relatives of PDA patients (1.4% isolated PDA and 2.2% all types of PDA) as 
extrapolated from our data.  
Even higher than the direct concordance of 52% (9/17) (i.e. another family member 
with an isolated PDA) is the partial concordance for CHD (i.e. another family 
member with a CHD) of 82% (14/17) in first degree-relatives. In the group of 
second-degree relatives no PDA was reported. 2/10 individuals with various CHD 
were born with a transposition of the great arteries, which is more than the 
expected birth prevalence of 0.2/1000.22 One index patient was exposed to 
maternal rubella infection. Apart from one case of trisomy 21 no other genetic 
syndromes were diagnosed in index patients. Out of the 18 deaths in the group of 
626 first-degree relatives 2 were reported as a consequence of CHD in infancy. 
Among the 283 deaths of second-degree relatives just one was related to CHD in 
an infant.  
We analyzed the data on the frequency of and mortality due to CVDs to get insight 
in the total prevalence of cardiovascular diseases (CVDs) according to the 
definition of the WHO. This includes coronary, cerebrovascular, peripherial arterial, 
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rheumatic, congenital disease and deep vein thrombosis and pulmonary embolism 
in families of PDA patients. Among the first degree-relatives 42/553 (6.6%) had 
CVDs. The mortality due to CVDs was 0.2%. As expected among second-degree 
relatives the prevalence 172/1174 (12.4%) and the mortality due to CVDs (2%) was 
higher, most probably due to the increased age of these individuals at inclusion. 
With respect to coronary disease, we did not find a higher prevalence in relatives of 
PDA patients than in the general Dutch population. Table 6.4 provides an overview 
of the distribution of coronary disease in comparison to the prevalence in the 
population as provided by the Netherlands Heart Foundation.20 
 
Table 6.4  Overview over the frequency of coronary disease in the study population compared to the 
prevalence in the Dutch population.  
Relation to the indexpt. Mean age (y) Coronary disease (n) Coronary disease (%) Prevalence 
Maternal grandmother 67.0 10    5.7  86.97/1000 
Maternal grandfather 66.4 24  13.7  192.06/1000 
Paternal grandmother 69.9   4    2.3  126.06/1000 
Paternal grandfather 69.4 16    9.1  192.6/1000 
Mother 41.5   0    0  4.45/1000 
Father 44.9   2    1.1  27.29/1000 
Sister 16.0   0    0  0/1000 
Brother 13.7   0    0  0.3/1000 
Maternal aunt 39.9   0    0  4.54/1000 
Maternal uncle 37.9   2    1.2  3.97/1000 
Paternal aunt 40.7   0    0  4.54/1000 
Paternal uncle 42.8   0    0  8.1/1000 
Child   5.3   0    0  0/1000 
Indexpt. = indexpatient, y=years, prevalence = prevalence in the Dutch population after.20 
Discussion 
The most important result of our study is that aortic disease and especially TAAD 
occurs more frequently in relatives of patients with PDA. As expected from data on 
familial patterns of TAAD23 significantly more cases than in the general population 
were found in the cohort of second-degree relatives, which included the generation 
of the grandparents whose mean age ranged between 66.4 and 69.9 years. The 
asoociation of PDA and TAAD indicates a common molecular mechanism that 
might be responsible for both diseases. This might put PDA patients, usually 
treated in childhood, and their families at a higher risk to develop aortic disease 
later in life. 
As DA closure and normal aortic distensibility both depend on proper interaction 
between EC and SMC involving turnover and repair of extra cellular matrix 
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substances17, all mutations impairing EC and SMC function and elastogenesis are 
candidate culprits. Only a small number of mutations affecting contractile proteins 
have been documented in studies on the familial segregation of vascular diseases 
in families with TAAD mutations.13,24 To our knowledge studies taking the PDA-
patient as starting-point to study the incidence of aortic disease and the underlying 
genetic background have not been published yet. 
Various mutations under which MYH 11 and ACTA 2 mutations might link PDA with 
TAAD or aortic disease in our study. Defects in the transcription factor myocardin 
diminish the contractile function of vascular SMC and associate PDA with aortic 
aneurysms in animal models.25,26 Mutations in TFAP2B impair the differentiation of 
SMC during fetal development27 and are responsible for PDA in Char syndrome,28 
although aortic aneurysms have not been described. The lack of aortic disease in 
Char syndrome could be explained by a specific spatial overexpression of Tfap2B 
in the DA as documented in rats (data submitted).  
Aortic aneurysms and dissections are the leading clinical problem in genetic 
syndromes impairing elastogenesis such as Marfan and Loeys-Dietz syndrome 
(LDS). As the loss of intimate spatial association between elastin deposits and 
vascular smooth muscle cells is the histological hallmark of LDS it is plausible that 
patients with LDS show an increased incidence of PDA.29 In the Brown-Norway rat 
small PDA and aortic fragility including aneurysms is related to an abnormal 
distribution of elastic fibers and diminished elastin content.30-32 In our study 
population only one family member, but no index patient, was diagnosed with 
Marfan syndrome and Char syndrome has not been reported. In view of the 
increased incidence of aortic disease and TAAD in families with PDA we advocate 
a thorough family history in all PDA patients. In selected cases genetic testing will 
be needed to define the underlying genetic abnormality in a family.  
The high prevalence of CHD (2.7% among first-degree relatives of patients with 
PDA) corroborates larger population–based studies33-35 and is comparable to the 
recurrence rate of other CHD in first degree-relatives detected by detailed fetal 
echocardiography.36 In 5% of our index patients a first-degree relative was 
diagnosed with an isolated PDA. This recurrence rate is in agreement with other 
studies11,37 and supports the idea of a genetic component in the pathogenesis of 
isolated non-syndromic PDA.10 Our study documents a relatively high complete 
(52%) and partial (82%) concordance for recurrent PDA in first-degree relatives. 
The degree of concordance for various types of CHD varies between the different 
studies. So is the concordance for PDA higher than for other CHD based on fetal 
echoscreening38 or at the same level as described by others.36,39 Despite the 
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relatively high concordance for recurrent PDA in our study, a familial association of 
PDA with more complex CHD was also present. In this point our data support the 
international guidelines that recommend a fetal echocardiographic study in all first 
degree-relatives of patients with PDA. When counseling relatives about prenatal 
diagnostic tests it must be realized that the DA is a normal fetal structure. An 
isolated PDA cannot be detected on a fetal echocardiogram. The recurrence rate of 
5% and the relatively high complete and partial concordance compared to other 
lesions justifies a postnatal clinical and echocardiographic investigation in addition 
to the fetal examination. In second-degree relatives we found an increased 
frequency of valve anomalies. This observation was made in the older cohort of 
second –degree relatives and has two potentially interconnected reasons. In the 
first place the higher frequency might reflect the usually late clinical manifestation 
and diagnosis of minor structural aortic valve anomalies such as bicuspid aortic 
valves. Secondly, the valve anomaly might be related to the dilatation of the 
ascending aorta in patients with aortic disease, which is also more frequent at an 
older age. We are aware of the limitations inherent to survey research i.e. low 
response rate and the lack of details in the diagnosis data.40 The response rate in 
our study was 54%, which is more than expected from a mailed questionnaire.40 
According to the answers we categorized the diseases into CHD and other CVDs. 
While aortic disease, PDA and CHD were overrepresented in our sample, coronary 
disease was not more frequent and did not show an earlier onset in our study 
population as compared to the general population. As assessed by the frequency 
of coronary disease the study population was a representative sample of the 
general Dutch population. The premature onset of coronary disease, which might 
occur with ACTA2 mutations,15 was not observed.  
In conclusion our data provide evidence for an association of isolated PDA and 
aortic disease in members of the same family. This links a minor cardiac anomaly 
usually treated in childhood to serious aortic disease that will manifest later in life. 
In addition we showed that the prevalence of PDA and other more complex CHD is 
increased in first-grade relatives of the index patient. This suggests common 
genetic factors in the determination of CHD and aortic disease in these families. 
Moreover, searching specifically for mutations in these families could help to 
identify new genes that may contribute to PDA, other CHD and cause aortic 
disease. 
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Questionnaire for patients of 16 years and older: 
1. Are your grandparents alive? 
2. What is the age of your grandparents? / At what age have your grandparents 
died? 
3. Has or had one or more of your grandparents a heart or vessel disease? 
4. If yes, who has/had what kind of heart or vessel disease? 
5. Has or had one or more of your parents been operated on his/her heart or 
vessels? 
6. If yes, who had which kind of operation? 
7. Has or had one or more of your grandparents a disease of the aorta? 
8. Is your father alive? 
9. How old is your father or how old was your father when he died? 
10. Has or had your father heart or vessel disease? 
11. If yes, which kind of heart or vessel disease? 
12. Has your father been operated on his heart or vessels? 
13. Has or had your father a disease of the aorta? 
14. Is your mother alive? 
15. How old is your mother or how old was your mother when she died? 
16. Has or had your mother heart or vessel disease? 
17. If yes, which kind of heart or vessel disease? 
18. Has your mother been operated on her heart or vessels? 
19. Has or had your mother a disease of the aorta? 
20. Do you have brothers or sisters? 
21. How many brothers and sisters? 
22. How old are your brothers and sisters? 
23. Are all your brothers and sisters alive? 
24. What was the cause of death? 
25. At what age have they died? 
26. Has of had one of your brothers or sisters a heart or vessel disease? 
27. What kind of heart or vessel disease? 
28. Has one of your brothers or sisters been operated on his/her heart or vessels? 
29. Has one of your brothers or sisters a disease of the aorta? 
30. Do you have children? 
31. If yes, how many children do you have? (How many boys how many girls?) 
32. How old are your children? 
33. Are all of them alive? 
34. If not, what was the cause of death? 
35. At what age have they died? 
36. Has or had one of your children a heart or vessel disease? 
37. If yes, which kind of heart and vessel disease? 
38. Has or had one of your children a disease of the aorta? 
39. Has or had one of your family members a connective tissue disease such as 
Marfan, Ehlers Danlos syndrome or does one have the syndrome of Char? 
40. Does one of your family members sleepwalk? 
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Supplement 2 
1. Questionnaire for mother/father of an index-patient: 
2. Are your parents alive? 
3. What is the age of your parents? / At what age have your parents died? 
4. Has of had one of your parents a heart or vessel disease? 
5. If yes, what kind of heart or vessel disease? 
6. Has one of your parents been operated on his/her heart or vessels? 
7. Has one of your parents a disease of the aorta? 
8. Do you have brothers or sisters? 
9. How many brothers and sisters? 
10. How old are your brothers and sisters? 
11. Are all your brothers and sisters alive? 
12. What was the cause of death? 
13. At what age have they died? 
14. Has of had one of your brothers or sisters a heart or vessel disease? 
15. What kind of heart or vessel disease? 
16. Has one of your brothers or sisters been operated on his/her heart or vessels? 
17. Has one of your brothers or sisters a disease of the aorta? 
18. Do you have a heart or vessel disease? 
19. What kind of heart or vessel disease? 
20. How old are you? 
21. Have you been operated on your heart or vessels? 
22. If yes, what kind of operation? 
23. Do you have a disease of the aorta? 
24. How many children do you have? How many boys? How many girls? 
25. What is the age of your children? 
26. Are all your children alive? 
27. If not, what was the cause of death? 
28. How old was the child that has died? 
29. Has one or have more of your children a heart of vessel disease? 
30. If yes, what kind of heart or vessel disease? 
31. Has one or have more of your children a disease of the aorta? 
32. Has or had one of your family members a connective tissue disease such as 
Marfan, Ehlers Danlos syndrome or does one have the syndrome of Char? 





























Why do we need a thesis on the ductus arteriosus (DA) after more than eleven 
thousand papers containing the term “ductus arteriosus”, which are accessible via 
the service PubMed in the U.S. National Library of Medicine's® (NLM) bibliographic 
database “Medline” and other NLM® databases? The amount of 323 papers 
dealing with the DA in 2011 proves that the topic is still of interest for the medical 
and biomedical scientific community. Most of these papers (n=273) cover the 
“patent” or “persistent” DA, a term that is not defined unanimously in literature. The 
combination of “patent ductus arteriosus treatment” accounts for more than half of 
these papers (n=145). A small selection of titles of the studies sheds light on the 
ongoing problems with the definition “How do we define congenital heart defects 
for scientific studies?”1, the indication for treatment “Patent ductus arteriosus: to 
treat or not to treat”2 and search for genetic background in animal models “A heart-
hand syndrome gene: TFAP2B plays a critical role in the development and 
remodeling of mouse ductus arteriosus and limb patterning”.3 Mainly in clinical 
papers the expressions “patent” and “persistent” DA, both abbreviated as “PDA”, 
are used synonymously. As described in the introduction of this thesis we use 
“patent DA” as an umbrella term for all situations in which the DA is open either 
physiologically or pathologically. We define a patent DA beyond the age of three 
months after full gestation as a persistent DA. This type of DA is in general 
characterized by a structural anomaly of the vessel wall.4 
Careful study of the literature revealed many examples of vascular-bed specific 
differences in the expression of genes and proteins in smooth muscle cells (SMC) 
during development.5 The characterization of the differences among mural cells 
may lead to understanding tissue- and vascular-bed specific responses to 
pathophysiological stressors.6 The intriguing fact, that the DA reacts completely 
different to the postnatal changes of the environmental conditions than the 
adjacent vessels triggered us to search for vessel-specific differences between DA 
and adjacent aorta at transcriptional and protein level. Our studies are based on 
the morphological features that differentiate the normal as well as the abnormal DA 
from the aorta. Studying two successive fetal stages we documented how vessel-
specific gene expression patterns develop during normal fetal development and 
maturation. In the normal closing DA of human neonates we investigated a 
molecular mechanism underlying the DA-specific cellular process of cytolytic 
necrosis. The morphological features of the persistent DA and the aorta in the 
animal model of the BN-rat suggested a link between a structurally abnormal 
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persistent DA. This observation was the basis for our study on the association 
between persistent DA, aortic disease and other congenital cardiovascular defects 
among families. In our experimental work on human and rat tissue samples we 
used multiple techniques from conventional histology and immunohistochemistry to 
PCR and DNA sequencing, microarray and quantitative rt-PCR. To study the 
differential gene expression in the DA and aorta of fetal rats we applied a new 
technique.  We isolated mRNA selectively from the two most important cell-types 
from the DA and aorta (i.e. ECs and SMCs), which we harvested by laser-capture 
microdissection after immunofluorescence labeling. In the last part of the thesis we 
used a survey to investigate recurrent persistent DA and other congenital cardiac 
and vascular anomalies in first and second-degree relatives of the patients treated 
for isolated persistent DA. 
From the process of normal ductal closure to 
treatment options 
Therapeutic interventions on the neonatal ductus arteriosus became feasible after 
some of the physiological and anatomical peculiarities of the fetal muscular artery 
were elucidated. In that regard the constrictive effect of oxygen on the DA of the 
neonate,7 the relaxing effect of prostaglandin (PG) E28,9 and the acknowledgement 
of the pronounced intima thickening in human DA at term10 were hallmarks. 
Ductal closure procedures in neonates 
The PG-pathway is the basis for the current pharmacotherapy to promote closure 
of patent DA in the premature infant as well as for the term neonate with a DA-
dependent cardiovascular anomaly. In prematures who clinically need DA closure 
the unselective cyclooxygenase (COX) inhibitors indomethacin and ibuprofen are 
equally efficacious.11  
 
Ibuprofen has less renal side effects probably due to its lower affinity to the (renal) 
COX1 and is therefore increasingly used.12,13 Most side effects of both drugs are a 
direct consequence of the reduced level of endogenous prostaglandins. This leads 
to decreased cerebral, gastrointestinal, and renal blood flow with the most common 
clinical problems of gastrointestinal perforation, hemorrhage and temporary renal 
failure. In addition COX-inhibition alters the platelet function, which further 
increases the risk of bleeding.12 Based on the risk of potential serious side effects 
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pharmacologic DA closure is contraindicated in infants with pre-existent renal 
insufficiency, bleeding, thrombocytopenia and gastrointestinal complications. 
Symptomatic premature infants in whom COX inhibitors are contraindicated are 
offered surgical DA closure. Although surgical DA closure is not considered a high-
risk surgical procedure it carries the risk of transient hypotension, bleeding and 
pneumothorax and musculoskeletal deformities as a possible deleterious long-term 
effect of the thoracotomy14,15 As a whole the surgical procedure poses a risk for 
further compromise of cerebral oxygenation in the sick preterm infants,16 that is 
associated with adverse neurodevelopmental outcome after surgical DA closure as 
documented in long-term studies. Despite the large amount of data published in 
studies on the indications and the best way of treatment of the patent DA in the 
premature infant, there is still space for refinement of the current practice. The 
most recent studies advocate a less aggressive approach that takes the variation 
of the physiological process of DA closure into account.17-19 Furthermore, the use 
of paracetamol or acetaminophen seems a promising option for medical DA 
closure in premature infants in whom the standard COX inibitors are 
contraindicated or have failed.20 This is an example how a slight modification of the 
approach to the pharmacologic target (e.g. prostaglandinsynthase) can broaden 
the therapeutic options and potentially decrease side effects. Concurrently it shows 
that comprehensive knowledge of the physiological process of DA closure is 
necessary for a rational new drug design and use. 
Prevention of ductal closure in neonates 
Concerning the efforts to reopen or keep the DA patent in infants with duct-
dependent congenital heart disease the physiological process of DA closure has 
other challenges. In general, the DA in the term neonate with congenital heart 
disease (CHD) will close functionally within days after birth21 and subsequently 
remodel exhibiting cytolytic necrosis and apoptosis.22 Since it has been established 
that the application of systemic PGs can counteract the functional part of the 
closure process the drug has been live-saving for many critical-ill neonates. 
However, the application of systemic PG has diverse risks and drawbacks that 
need to be acknowledged.  The most relevant risks when initiating the therapy are 
apnea and hypotension. About 10% of the patients will experience apnea.23 
Systemic vasodilation is inherent to PG treatment and will cause some extent of 
arterial hypotension. After initiating therapy the children need to be closely 
monitored. There must be immediate access to ventilation facilities, fluid and 
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inotropes should be accessible to treat hypotension. If transfer to a specialized 
cardic unit is necessary it is in general safer to intubate the child prior to transport. 
At least when it is decided after 15-30 min of observation after the therapy has 
started not to intubate the child one should be prepared to do so, en route. Few 
studies focused on the dosage of PG during transport.24,25 Theoretically the optimal 
PG dose that is needed varies with gestational and postnatal age, maturation of 
the DA, type, number, and sensitivity of PG receptors. Data on these topics are 
sparse in humans.26,27 In pigs it has been described that newborns have less PGE2 
receptors than fetuses.28 In rabbits a maturational difference in the number and 
distribution of PGE2 receptor subtypes has been shown.29 From morphologic 
studies in premature infants it is known that maturation does not strictly correlate 
with gestational age,30 in animal studies PG receptors diminish or become less 
reactive. In addition, disease specific (DA perfused with blood with high or low 
oxygen content) and patient specific characteristics (TFAP2B polymorphisms in 
prematures) might play a role. These theoretical considerations lead to the 
following practical approach to PG therapy in the newborn with duct-dependent 
heart disease: neonates immediately after birth who were diagnosed prenatally or 
those who are proven to have an open DA by echocardiography should receive a 
low dose of 10 nanograms/kg/min with increments to 50 nanograms/kg/min if 
needed. Higher start doses (100 nanograms/ kg/min) are indicated in children in 
whom a closed DA needs to be reopened. The initial dose should be lowered to a 
maintenance dose (5-10 nanograms/kg/min) as soon as successful reopening op 
the DA has been established in order to avoid dose-dependent side effects. This 
will lower the risk of major and minor side effects (fever, flushing, jitteriness, 
hyponatriemia, gastric outlet obstruction, convulsions) that might be associated 
with systemic PG application.31 It has not been reported that a DA that does not 
respond to the high dose of 100 - 400 nanogram/kg/min will reopen with a further 
increase of the dosage.32 In addition to the systemic side effects of PG there are 
also vascular side effects. Lacerations of the vessel wall with intramural bleeding33 
indicate PG-related vascular fragility in the DA that also might occur in other 
arteries. After long-term PG therapy reversible cortical hyperostosis can occur34 
due to PG induced osteoblast proliferation and mineralization. However, there are 
clinical situations that may justify long-tem use of PG as part of a hybrid treatment 
strategy for PA/IVS or HLHS.35,36 Long-term oral PG therapy has been described in 
the 1980ies but is no longer used in clinical practice. It had been shown to be less 
effective than the intravenous (iv) application.37 In addition the pharmacokinetic 
properties of the drug necessitate hourly doses, which make its use inconvenient 
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and impractical. Thus, approaches including sustained PG application are 
hampered by the need for intravenous application of the drug and the wide range 
of serious side effects associated with the systemic use of synthetic PG. 
Furthermore, ongoing intima thickening in the DA is a concern of long-term PG-
treatment. The development of a circular obstruction at the aortic end of the DA 
has been reported after 33-58 days of low-dose PG application.38 The potential 
obstruction of the DA endangers the life of patients with a DA-dependent 
circulation and is therefore the major drawback of prolonged PG therapy. 
Searching for an alternative, DA-stenting has been introduced as a new clinical tool 
for manipulation of the DA in the 1990ties. It is used as a substitute for a modified 
Blalock-Taussig-shunt in patients with restricted or fully DA-dependent pulmonary 
flow39,40 and is part of the hybrid strategy for the treatment of HLHS where it 
guarantees systemic perfusion.40 In pulmonary atresia the tortuous course of the 
DA makes percutaneous stenting technically challenging but could be overcome in 
most cases with the use of low-profile and easy deliverable coronary stents.41  
Ductal closure procedures in older children and adults 
In older children treatment options for the DA include transcatheter closure with 
various devices and surgical procedures. As PDAs vary in size and morphology42 a 
uniform approach is not possible. Transcatheter implantation of a closure device 
either from the venous or from the arterial side is the treatment of choice for most 
PDAs in children and adults.43 The variety of devices on the market allows proper 
device selection according to the specific morphology in almost all children 
>6 months. Nowadays, surgery is reserved for very large and short PDAs that 
might even need patch closure with the use of cardiopulmonary bypass instead of 
simple ligation. A clear indication for DA closure in children and adults is 
symptomatic left-to-right-shunt. Left sided cardiac enlargement is considered a 
prophylactic indication for DA closure in asymptomatic patients, as it prevents 
future complications.43 The indication for closure of the tiny or “silent” PDA in 
asymptomatic children and adults remains a matter of debate. Supporters of PDA 
closure use the risk of clinical endarteritis as an argument to advocate 
transcatheter closure43,44 while the opponents see a greater risk for complications 
in the procedure itself. In patients with increased pulmonary resistance due to a 
large PDA meticulous haemodynamic assessment is necessary to determine if the 
patient will profit from closure of the PDA. Problematic are adult patients with 
Eisenmenger’s syndrome caused by a large PDA having a pulmonary resistance 
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above 8 Wood units. Despite the procedural risks and the uncertainty to predict 
long-term reversibility of the pulmonary vascular disease, some authors advocate a 
lung biopsy to aid the decision for or against DA closure.45 
The “ideal” drug for manipulation of the DA 
As described manipulation of the DA with drugs and /or devices is used on a 
routine basis in three different groups of patients: i.e. premature babies, neonates 
with DA-dependent cardiac defects, and children and adults with PDA. Each group 
has its special needs in accordance with the underlying pathology. 
Ductal closure in neonates 
Current therapeutic modalities are associated with many adverse effects as 
discussed. Premature babies exhibit a DA with less intima cushion formation30 and 
reduced sensitivity for oxygen but increased sensitivity to PGE2, nitric oxide (NO), 
and perhaps endothelin-1.46 As functional and anatomical DA closure both depend 
on gestational maturity the “ideal” drug for DA closure would be a drug that 
matures all closing mechanisms of the DA without systemic side effects, safe and 
effectively. The application should be feasible in small infants with gastrointestinal 
and venous access problems. There is evidence that administration of cortisol to 
fetal lambs improves the response of the fetal DA to oxygen and PG-inhibition.47 
The decreased rate of patent DA in premature babies born after antenatal 
corticosteroid treatment, (current guidelines advocate antenatal corticosteroids to 
all women at high risk to preterm delivery between 24 and 34 weeks of gestation)48 
suggests that this might also be the case in humans.  Maternal and (long-term) 
offspring side effects of this approach are still under investigation. In chapter 5 we 
demonstrated the increased expression of Rgs5 in the fetal DA compared to the 
aorta. RGS5 is a negative regulator of G-protein–coupled signaling in the heart and 
vessels.49 As PGE2 acts through G-protein–coupled receptors (GPCRs) to relax the 
vascular smooth muscle layers.50 RGS5 is a candidate target for the development 
of alternative drugs to promote DA constriction without the adverse effects of 
unselective COX inhibition. However, before this concept can be used all 
regulatory pathways in which RGS5 is involved need to be elucidated.  
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Prevention of ductal closure in neonates 
In neonates with DA-dependent cardiac defects reliable patency of the DA is 
desired until a shunt or another surgical procedure has been performed. Systemic 
PG therapy and, if long-term patency is necessary, stents are the therapeutic 
options for these patients. The broad range of local and systemic side effects of 
PGs and the potential complications associated with the implantation of stents50,51 
motivate the search for an alternative concept. Some years ago a prenatal gene-
transfer experiment showed that it is possible to engineer a patent DA in lambs by 
transferring PGE synthase.52 The variety of unsolved issues of gene therapy such 
as the short-lived nature of the therapy, immunogenicity and problems with viral 
vectors led to strict governmental regulations and prevented further development of 
this concept for human use. Avoiding the physiological remodeling process 
completely instead of solely inhibiting postnatal DA contraction would be 
advantageous and possibly the most efficient way to guarantee prolonged patency 
of the DA. However, a new strategy targeting on remodeling needs thorough 
understanding of the underlying process. In chapter 5 we studied the postnatal 
anatomical remodeling of the DA and detected selective progerin expression in 
association with remodeling of the DA. Two different classes of drugs are shown to 
work against the toxic cellular effects of progerin. Farnesyl-transferase inhibitors 
(FTIs) belong to the first class of drugs that were discovered. FTIs inhibit the 
farnesylation of progerin and thereby avoiding the toxic effects of progerin on the 
nucleus.53,54 Recent publications show that rapamycin abolishes the characteristic 
nuclear effects, prolongs the life span, and enhances the turnover of the cultured 
fibroblasts of HGPS patients.55 This is a promising finding not only for HGPS 
patients as we showed in chapter 4 that DA remodeling is associated with progerin 
expression and suggested that activation of Lamin A LMNA alternative splicing is 
involved in neonatal DA closure. In addition to a clinical trial with rapamycin or its 
analogues, which is under consideration for HGPS patients, this family of drugs 
seems worthwhile to be evaluated for its potential to inhibit DA remodeling. Based 
on our data both drugs could potentially be useful in the inhibition of anatomical DA 
remodeling. It is obvious that potential adverse effects of these drugs need to be 
carefully studied and weighed against existing therapies before its use in neonates 
can be advocated. With the increasing accessibility and accuracy of fetal 
echocardiography for the diagnosis of cardiac defects a prenatal approach to 
prevent the formation of intimal cushions in the DA might also be useful.  Although 
not proven in humans, the chronic activation of the EP4 receptor that is needed to 
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induce hyaluronic acid mediated cushion formation in rodent fetus56 is interesting. 
Hyaluronic acid synthase (HAS) could be a new target for DA manipulation that 
might even be accessible in the fetus. Data on the increased incidence of patent 
DA in infants exposed to antenatal indomethacin57 suggest, that chronic activation 
of the EP4 receptor mediated HAS induction is also needed for proper intima 
cushion formation in humans. 
Future developments in DA stenting 
In-stent stenosis due to neointima formation and stenoses caused by DA-tissue 
that has not been covered by the stent are the main reasons for complications after 
DA stenting. In-stent stenosis is inherent to vessel stenting and resembles the 
normal remodeling process of the DA.58 In order to attenuate neointima formation 
rapamycin-impregnated stents have been evaluated, as this drug induces cell-cycle 
arrest, ultimately resulting in inhibition of SMC proliferation.59 In a pig model these 
stents were efficiently counteracting the initial contraction and the secondary 
intimal thickening of the DA over a period of 6 weeks. These data were, however, 
not sufficient to introduce rapamycin-impregnated stents for clinical use in 
neonates.60  
There is no stent specifically designed for the use in the neonatal DA on the 
market. Stents that are used are developed for coronary lesions, peripheral arterial 
lesions and the use in bile ducts of adults. A ductal stent should be adapted for the 
tortuous course and length of the DA, easy to manipulate in a vessel with a much 
weaker and looser wall structure than arteriosclerotic coronary or systemic arteries. 
One should bear in mind that the prior use of PG will weaken the wall even more.33 
Furthermore the delivery system either a balloon catheter or a catheter carrying a 
self-expanding stent should be as small and as flexible as possible to avoid 
additional vascular damage when delivering the stent via the transvenous or 
transarterial route in a neonate. A stent in a reopened previously stenotic DA 
needs a higher radial strength than a stent in a widely patent DA. Various stent 
materials are used in the DA such as cobalt chromium, stainless steel or nickel 
titanium (nitinol). Stent designs include closed or open cells, wire based or laser cut 
devices. If the patency of the adjacent potentially stenotic aortic isthmus is a 
concern, as in hybrid Norwood procedures,61 an open cell stent is preferable. A 
stenosis coverd by an open cell stent can be reopened by a stent that is implanted 
retrogradely in the aorta.62 Although being potentially superior to bare metal stents 
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in the DA, local and systemic drug effects need to be further evaluated. Finally, 
biodegradable stents providing scaffolding for a short period of about 6 months are 
an interesting option. The ideal characteristics of a biodegradable stent have been 
defined as (1) sufficient radial strength to prevent vascular recoil, (2) minimal 
thrombotic and inflammatory response, (3) avoidance of intimal proliferation, (4) 
reabsorption of stent components within months, (5) no release of toxic products or 
embolic material during breakdown and (6) easy processing and sterilization. 
Based on these considerations, two different concepts have evolved: absorbable 
polymer stents and absorbable metal stents including magnesium and iron stents.63 
Besides incidental use of magnesium stents in infants39 none of these stents has 
been used systematically in children.  
A link between PDA and aortic disease 
Brown Norway rats differ from other rat strains in vascular elastin content and are 
prone to develop ruptures in the elastin lamellae of the thoracic and abdominal 
aorta.64,65 We detected that a high proportion (10/12) of adolescent BN rats also 
showed an inherited PDA.66The small PDA in these rats had an abnormal 
distribution of elastin lamellae. Therefore we proposed that impaired elastin 
metabolism is related to the persistence of the DA. In addition this model implicates 
a genetically determined factor linking PDA with aortic fragility.  A study on the 
genetic basis of the specific arterial phenotype of the BN rat revealed significant 
quantitative trait loci (QTLs) for PDA on chromosomes 8 and 9 and for aortic 
fragility a region on chromosome 5 and a locus on chromosome 10, which is 
syntenic to one linked to a syndrome of thoracic aortic aneurysms (TAAD) with 
PDA in humans.67 Among genes present in these QTLs were large numbers of 
myosin genes, which is of interest in view of the recently reported involvement of 
MYH11 in the human syndrome with aortic aneurysm and PDA.68 Mutations in 
another component of the contractile apparatus, the aortic alpha-smooth muscle 
actin (ACTA 2) gene, are responsible for 14% of familial TAAD.69 Interestingly 
associated findings in families with ACTA 2 mutations may include livedo 
reticularis, a bicuspid aortic valve, iris flocculi and PDA.69 These associated 
findings let us set out a study on the familial association of PDA and aortic disease, 
especially TAAD, presented in chapter 6. The key finding of our survey among 
patients treated for PDA was a significantly increased prevalence of aortic disease 
and TAAD in first and second-degree relatives as compared to the general 
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population. These data provide evidence for a genetic association of PDA and 
aortic disease and give essential information for the investigation of the genetic 
background of both lesions.   
Three different types of PDA 
The first differentiation between types of PDA dates back in the 1980ies.4 By the 
means of histology it was identified, that the PDA in children >3 months differed in 
structure from the delayed closing DA in the premature infant, in the clinical 
practice also called a PDA. An aberrant distribution of elastin with a subendothelial 
elastic lamina was characteristic for the primary congenital malformation of the DA 
wall in older children with PDA.4 Children with isolated PDA and in those with 
associated CHD showed the same histology. In chapter 4 we documented the lack 
of progerin expression in the wall of the PDA. Recent genetic data showed that 
mutations in the neural-crest related transcription factor gene TFAP2B are the 
underlying cause of PDA in Char syndrome70 and explain some cases of isolated 
PDA.71,72 Histological data on the PDA in humans harbouring mutations in TFAP2B 
are lacking. However, data from a knock-out mouse model for this disease show an 
abnormal distribution of elastin lamellae in the DA.73 The increased rate of delayed 
closing DA in prematures with a specific polymorphism of TFAP2B underscores its 
relevance also for normal DA closure.74,75 In chapter 5 we documented the DA-
specific expression of the analogue of the TFAP2B gene in fetal rats.   
In view of the current data presented in this thesis we are inclined to distinguish a 
third type of PDA from the former two.  This third type is a PDA as part of a general 
vasculopathy. The vasculopathy might be genetically determined and linked to 
aortic disease. This is the case in families with mutations impairing contractile 
proteins, or elastogenesis discussed in chapters 2 and 6. PDA and pulmonary 
artery branch stenoses in cases of congenital rubella represent a virus-induced 
vasculopathy, characterized by differential retardation of tissue growth in the DA 
and pulmonary arteries.76,77  
As a conclusion of the current thesis we propose to differentiate between three 
types of PDA, i.e. (1) the immature, (2) the primary congenital malformation and 
the (3) general vasculopathic type.  Each type of PDA needs a different approach 
to diagnostics, treatment and follow-up depending on gestational age and 
associated pathology. A vasculopathic type of PDA should be considered in 
premature babies whose PDA’s are refractory to drug treatment, any patient with 
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PDA and additional vascular anomalies or a positive family history for aortic 
disease. In these patients a thorough family history, detailed imaging of all 
cardiovascular structures and in selected cases genetic diagnostic might help to 
define an underlying general vascular anomaly that might be present in the family 
and affect adult individuals later in life. 
 
The data presented in this thesis show that the DA is coming of age in several 
aspects. Starting from the description of the fetal vessel and the understanding of 
its function in the circulation, basic research has developed its extensions into the 
fields of molecular and cell biology and genetics. Among others, the use of high-
throughput molecular profiling techniques offers the opportunity to study the 
molecular basis for the DA-specific morphology and function. Progerin, responsible 
for premature ageing in Hutchinson-Gilford Progeria syndrome and related to 
vascular ageing in the elderly, has also been identified in the neonatal DA and 
linked to the maturation and regression of this vessel. The DA is not only of interest 
in the fetal and neonatal period as in some patients with PDA medical attention 
should be extended into adult life and to their family members. 
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Summary 
The aim of the research described in this thesis was to investigate the genetic 
background and molecular mechanisms underlying the specific remodeling 
processes leading to postnatal closure of the ductus arterisosus (DA). To achieve 
this goal both the normal closing and the persistent ductus arteriosus (PDA) in rats 
and humans were studied.  
 
In chapter 2 the literature on the pathogenesis and genetic background of patency 
of the ductus arteriosus is studied. By describing the animal models used in DA 
research an overview is given on the regulatory pathways that are involved in 
physiological DA closure. Studying human genetic syndromes associated with PDA 
it becomes evident that in virtually all of these anomalies genes are affected, which 
interfere with the remodeling of the smooth muscle cells (SMC). Therefore the 
pivotal regulatory role of SMCs in ductal closure is emphasized. 
 
Chapter 3 presents a new animal model of a PDA. The inbred strain of Brown- 
Norway (BN) rats is characterized by abnormally distributed elastin lamellae in the 
PDA.  The elastin lamellae in the aorta were deficient. Anatomical and histological 
features of the PDA in the BN rat are documented and compared to the Wistar rat 
with a normal closing DA. The discussion focuses on the role of elastin in ductal 
closure and the possible relationship between PDA and aortic aneurysm formation.  
 
In chapter 4 we investigated the expression of lamin A/C and the defective 
truncated lamin A form, progerin, in the human neonatal DA. Abnormally expressed 
progerin destabilize the nuclear membrane and causes the abnormalities that are 
responsible for the premature ageing in Hutchinson Gilford progeria syndrome. 
Recently progerin has also been discovered in the skin and vessels of normal 
ageing individuals. By documenting progerin expression predominantly in the areas 
of the DA where anatomical remodeling commences we relate progerin with this 
physiological process in the neonate. As a consequence we propose alternative 
splicing of the pre-mRNA of the lamin A/C as a molecular mechanism of 
anatomical remodeling of the DA. 
 
Chapter 5 focuses on genes that are differentially expressed between fetal DA and 
aorta. By microarray analysis of laser-captured ECs and SMCs we identified for the 
first time the regulator of the G-protein coupled receptor RGS5 and the homeobox 
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gene transcription factor Dlx1 as DA-specific genes in rats at the end of gestation. 
In the aorta of the same animals the gene encoding Purkinje-cell protein 4 PCP4 
was preferentially expressed. Expression patterns of these genes also validated 
with quantitative RT-PCR confirmed that DA and aorta-specific transcriptional 
profiles are present in ECs and SMCs. RGS5 and DLX1 represent new molecular 
targets for the regulation of fetal DA maturation and postnatal closure. 
 
In chapter 6 we assessed in a patient-based study the prevalence of PDA, aortic 
disease and other cardiovascular anomalies in first-and second-degree family 
members of patients treated for PDA. Data of 177 families with 2511 members 
were available. In second-degree relatives of PDA patients the prevalence of aortic 
disease was significantly higher than in the general Dutch population. The 
recurrence rate of CHD was higher (2.7%) in first-degree relatives than in second-
degree relatives (0.7%). Our data provide evidence for a genetic association of 
PDA and aortic disease. In addition the increased prevalence of PDA and other 
CHD in the studied families is suggestive of common genetic factors determining 
PDA, CHD and aortic disease.  
 
In the concluding considerations presented in chapter 7 the topics covered by the 
chapters 2 to 6 from a clinical perspective are reviewed. The current therapeutic 
modalities to manipulate the DA and problems associated with medical and 
catheter-based therapy are discussed. All patient groups including premature 
infants with delayed closing of the DA, neonates with DA-dependent congenital 
heart disease, older children or adults with PDA and their families might profit from 
a better understanding of the mechanisms underlying DA remodeling. The findings 
presented in this thesis could be seen as a starting-point for the development of 
new diagnostic and therapeutic strategies for the DA in these patients. 
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Samenvatting 
Het doel van het onderzoek, dat tot dit proefschrift leidde, was het bestuderen van 
de genetische basis en de moleculaire mechanismen, die het vaatspecifieke 
sluitingsproces van de ductus arteriosus (DA) na de geboorte sturen. Om dit doel 
te bereiken werden zowel de normaal sluitende als de persisterende DA (PDA) bij 
de rat en bij de mens bestudeerd.  
 
In hoofdstuk 2 wordt de literatuur over de pathogenese en de genetische 
achtergrond van het openblijven van de DA na de geboorte onderzocht. Aan de 
hand van de beschrijving van de diermodellen, die tot nu toe in het onderzoek naar 
de ductussluiting gebruikt werden, wordt een overzicht van de regulatie-
mechanismen gegeven, die betrokken zijn bij de fysiologische ductussluiting. De 
analyse van de genetische syndromen, die bij de mens met een PDA geassocieerd 
zijn, maakt duidelijk dat nagenoeg bij al deze syndromen afwijkingen in de genen 
voorkomen, die de “remodeling” van gladde spiercellen beïnvloeden. Daarom 
wordt die cruciale rol van gladde spiercellen in de regulatie van de ductussluiting in 
het bijzonder benadrukt. 
 
In hoofdstuk 3 wordt een nieuw diermodel voor een PDA gepresenteerd. De 
inteelt-stam van de Brown-Norway (BN) rat wordt gekenmerkt door abnormaal 
verdeelde elastinelamellen in de PDA die deficiënt zijn en een vermindering van 
het aantal elastinelamellen in de aortawand. De anatomische en histologische 
bijzonderheden van de PDA bij de BN rat worden beschreven en met de 
bevindingen bij de Wistar-rat vergeleken, bij welke de DA normaal sluit. De 
discussie concentreert zich op de rol van elastine bij de ductussluiting en de 
mogelijke relatie tussen een PDA en de ontwikkeling van aneurysmata van de 
aorta.  
 
In hoofdstuk 4 onderzochten wij de expressie van lamin A/C en de verkorte en 
afwijkende vorm ervan, progerin, in de DA van pasgeboren kinderen. Het 
afwijkende eiwit progerin destabiliseert de kernmembraan en is daardoor 
verantwoordelijk voor de vervroegde veroudering bij het Hutchinson-Gilford 
Progeria syndroom. Kortgeleden werd progerin ook in de huid en de vaten van 
genetisch normale oudere personen aangetoond. Wij documenteerden progerin in 
de DA van neonaten vooral in die gebieden waar het anatomische 
remodelleringsproces van het bloedvat begint. Het specifieke expressiepatroon van 
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progerin duidt onzes inziens op een verband tussen de fysiologische ductussluiting 
en progerinexpressie. Daarom menen wij te kunnen concluderen, dat de 
alternatieve splitsing van het pre-mRNA van het lamin A/C één van de moleculaire 
mechanismen is, die tot de anatomische “remodeling” van de DA leiden. 
 
Hoofdstuk 5 richt zich op genen, die gedifferentieerd in werking komen in de 
foetale DA en de aorta. Met behulp van een microarray analyse van door “laser-
capture” geisoleerde endotheel- en gladde spiercellen van de DA konden wij voor 
het eerst de regulerende werking van de G-protein coupled receptor RGS5 en van 
de homeobox transcriptiefactor DLX1 als DA-specifieke genen bij de rat aan het 
einde van de zwangerschap identificeren. In de aorta van dezelfde dieren zagen 
wij de preferentiële expressie van het gen dat voor het Purkinje-cell protein 4 
(PCP4) codeert. Expressiepatronen van deze genen werden ook met een 
kwantitatieve rt-PCR gevalideerd. Met PCR werd bevestigd, dat er zowel DA als 
aorta- specifieke genexpressiepatronen in de endotheel- en gladde spiercellen 
bestaan. Voor de DA zijn RGS5 en DLX1 als nieuwe moleculaire targets te 
beschouwen, die een rol spelen bij de transcriptionele regulatie van de DA.  
 
In hoofdstuk 6 analyseerden wij in een patiëntgericht onderzoek de prevalentie 
van PDA, aortaziekten en andere cardiovasculaire anomalieën bij eerstegraads en 
tweedegraads familieleden van patiënten, die voor een PDA behandeld werden. Er 
konden gegevens van 177 families met 2511 leden verzameld worden. Bij 
tweedegraads familieleden van PDA patiënten was de prevalentie van aortaziektes 
significant hoger dan bij de Nederlandse bevolking in het algemeen. De 
herhalingskans voor aangeboren hartafwijkingen was met 2,7% hoger bij 
eerstegraads familieleden dan bij tweedegraads familieleden (0,7%). Onze data 
leveren enig bewijs voor een genetische associatie van een PDA met aortaziektes. 
Bovendien duidt de verhoogde prevalentie van PDA en andere aangeboren 
hartafwijkingen in de onderzochte families op een gemeenschappelijke genetische 
factor, die PDA, aangeboren hartafwijkingen en aortaziektes bepaalt. 
 
In de concluderende beschouwing, die in hoofdstuk 7 gepresenteerd wordt, 
worden de onderwerpen vanuit een klinisch perspectief bekeken. De huidige 
therapeutische mogelijkheden om de DA open te houden of te sluiten worden 
besproken. Mogelijke problemen die bij de medicamenteuze en katheter-
interventionele behandelingen kunnen optreden worden bediscussieerd. Alle 
patiënten, van de prematuur geborenen met een onrijpe vertraagd sluitende DA, 
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en de neonaten met ductusafhankelijke aangeboren hartafwijkingen tot de oudere 
kinderen en volwassenen met een PDA en hun families zouden van een grotere 
kennis van de basale mechanismen van de fysiologische ductussluiting kunnen 
profiteren. In deze zin zijn de in dit proefschrift gepresenteerde bevindingen te zien 
als een uitgangspunt voor de ontwikkeling van nieuwe diagnostische en 
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Zusammenfassung 
Das Ziel der hier vorgelegten Arbeit war es die den genetischen Hintergrund und 
die molekulären Mechanismen zu untersuchen, die dem einzigartigen 
physiologischen Prozess zugrunde liegen, der zum postnatalen Duktusverschluß 
mit anschließender anatomischer Remodellierung führt. Um dieses Ziel zu 
erreichen haben wir sowohl den normal schließenden Duktus als auch den 
persitierenden Duktus bei der Ratte und beim Menschen untersucht.  
 
In Kapitel 2 geben wir eine Übersicht über die Literatur, die sich mit der 
Pathogenese und dem genetischen Hintergrund des Offenbleibens des Duktus 
befasst. Durch die Beschreibung der für die Erforschung des Duktus verfügbaren 
Tiermodelle geben wir eine Zusammenfassung der Regulationsprozesse, die beim 
physiologischen Duktusverschluß bekannt sind. Die Analyse der humanen 
genetischen Syndrome, die mit persitierendem Duktus (PDA) assoziiert sind, liefert 
weitere Anhaltspunkte für Gene, die eine Rolle beim Duktusverschluß spielen 
können. Durch die Syndrome richtet sich unser Augenmerk vor allem auf Gene mit 
einer Funktion bei der Remodellierung von glatten Gefäßmuskelzellen.  
 
In Kapitel 3 präsentieren wir ein neues Tiermodell für einen kleinen PDA. Der 
beschriebene Inzuchtstamm der Brown-Norway-Ratte wird charakterisiert durch die 
abnormale Verteilung von Elastin im Duktus und ein Defizit an Elastinlamellen in 
der Aorta. Die anatomischen und histologischen Besonderheiten des PDA der 
Brown-Norway-Ratte werden mit den Befunden bei der Wistar-Ratte verglichen. In 
der Diskussion dieses Kapitels wird vor allem auf die Rolle von Elastin bei der 
duktusspezifischen Remodellierung der glatten Gefäßmuskelzellen (SMCs) 
eingegangen.  
 
Für Kapitel 4 untersuchten wir die Expression von Lamin A/C und seiner 
Spleißvariante Progerin im humanen neonatalen Duktus. Progerin verursacht die 
Anomalien der Kernmembran, die verantwortlich sind für den frühzeitigen 
Alterungsprozeß der zum klinischen Bild des Hutchinson-Gilford-Progeriesyndrom 
führt. Kürzlich wurde Progerin auch in der Haut und den Blutgefäßen genetisch 
normaler älterer Individuen entdeckt. Unsere Untersuchungen zeigen Progerin 
erstmals im Duktus des Neugeborenen. Durch die besondere Verteilung des 
Progerinproteins, das vor allem in den Arealen des Duktus angetroffen wurde, in 
denen die anatomische Remodellierung des Duktus beginnt, ließen uns auf eine 
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Bedeutung diese Proteins für den physiologischen Duktusverschluß schließen. 
Schlussfolgernd gehen wir davon aus, dass alternative Spleißung einer der 
molekulären Mechanismen ist, der zur anatomischen Remodellierung des Duktus 
beitragen.  
 
In Kapitel 5 konzentrieren wir uns auf Gene, deren Expression sich zwischen 
fötalem Duktus und fötaler Aorta unterscheidet. Mit Hilfe von DNA-Microarrays von 
durch Laser Capture Mikrodissektion gewonnenen Endothelzellen (ECs) und 
SMCs identifizierten wir erstmals den Regulator des G-Protein gekoppelten 
Rezeptor Rgs5 und den Homeoboxtranscriptionsfaktor Dlx1 als duktusspezifische 
Gene bei der Ratte am Ende der Gestationsperiode. In der Aorta derselben Tiere 
fanden wir die bevorzugte Expression des Genes für das Purkinje-Zellen Protein 4 
(Pcp4). Die Expressionsmuster der differentiell exprimierten Gene, die auch mit 
quantitativer RT-PCR Technik verifiziert wurden, bestätigen das Vorliegen von 
spezifischen Transkriptionsprofilen in ECs und SMCs  von sowohl Duktus als auch 
Aorta. RGS5 and DLX1 stellen Ansatzpunkte für eine neue gezielte Behandlung 
dar, die in die fötale Duktusreifung und den postnatalen Duktusverschluß eingreift. 
 
In Kapitel 6 untersuchten wir in einer patientengebundenen klinischen Studie die 
Prävalenz von PDA, Aortenerkrankungen und anderen kardiovaskulären 
Anomalien bei Familienmitgliedern ersten- und zweiten Grades  von Patienten, die 
wegen eines isolierten PDA behandelt wurden. Daten von 177 Familien mit 
insgesamt 2511 Mitgliedern standen uns zur Verfügung.  Bei den Verwandten 
zweiten Grades der PDA-Patienten bestand eine signifikant erhöhte Prävalenz von 
Aortenerkrankungen im Vergleich zur niederländischen Allgemeinbevölkerung.  Die 
Wiederholungrate angeborener Herz- und Gefäßfehler war deutlich höher bei 
Familienmitgliedern ersten Grades (2.7%) als bei denen zweiten Grades (0.7%). 
Unsere Daten weisen auf eine genetische Assoziation zwischen PDA und 
Aortenerkrankungen. Die ebenfalls erhöhte Prävalenz von anderen angeboren 
Herz- und Gefäßfehlern in den untersuchten Familien deutet außerdem auf einen 
gemeinsamen genetischen Faktor für angeborene Herz- und Gefäßfehler und 
Aortenerkrankungen. 
 
In der schlussfolgernden Betrachtung in Kapitel 7 beurteilen wir die in den Kapiteln 
2 bis 4 beschriebenen Untersuchungen aus einer klinischen Perspektive. Die 
aktuellen Behandlungsmöglichkeiten zur Manipulation des Duktus und deren 
Probleme werden dargestellt. Alle Zielgruppen der Duktusbehandlung: 
   
166 
Frühgeborene mit verzögert schließendem Duktus, Neugeborene mit 
duktusabhängigen Herzfehlern, ältere Kinder und Erwachsene mit PDA und deren 
Familien könnten von einem besseren Verständnis der Mechanismen, die der 
Remodellierung des Duktus zugrunde liegen profitieren. Die Befunde, die in der 
vorliegenden Arbeit präsentiert werden, sind als Ausgangspunkt für die 
Entwicklung neuer diagnostischer und therapeutischer Möglichkeiten für die 
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“Leider läßt sich eine wahrhafte Dankbarkeit mit Worten nicht ausdrücken.“ 
J.W. von Goethe 
 
In deze woorden van Goethe kan ik mij helemaal vinden. Desalniettemin, wil ik hier 
iedereen bedanken die mij heeft ondersteund bij het schrijven van dit proefschrift: 
 
ondersteund door het creatief verder helpen ontwikkelen van mijn eerste 
ideeën of juist door een origineel idee te hebben,  
ondersteund bij het verzamelen van onderzoeksmateriaal, bij het uitvoeren 
van experimenten en hun analyse,  
ondersteund door alles te lezen van het eerste concept tot de drukproeven 
en de nodige correcties aan te brengen, 
ondersteund door foto’s en illustraties te maken, 
ondersteund door een goede collega te zijn  
en vooral 
ondersteund door mijn vriendin of vriend te zijn.  
 
Het zijn er meer dan ik hier kan noemen – dat weet ik zeker. 
 
Aan de wieg van elk proefschrift staat naast de promovendus een promotor. Ik heb 
er zelfs drie, die zoals gebruikelijk op de daarvoor bestemde pagina genoemd zijn. 
Bedankt Adri, Nico en Marco. In mijn beleving is er nog een vierde. Mijn eerste 
klinische baas in Nederland Jaap Ottenkamp. Dank voor je steun en hulp in alle 
fasen van dit proefschrift. Mijn eerste wetenschappelijke baas in Nederland 
(1991/1992) was Adri, die met haar enthousiasme voor het vak mijn interesse voor 
de ductus arteriosus en het werken op een laboratorium wist te wekken. 
Terugkijkend naar het jaar 1991 mag Hans–Carlo Kallfelz, mijn eerste klinische 
baas in Duitsland, niet vergeten worden. Tenslotte was hij het, die ervan overtuigd 
was, dat een tijd in het lab van Adri in Leiden goed voor mijn toekomstige 
ontwikkeling zou zijn. Dat ik als kindercardioloog 10 jaar later naar Leiden terug 
zou gaan, was zover ik weet, niet van het begin af aan gepland. 
 
Daniel en mijn ouders weten al lang, dat ik bijzonder dankbaar ben dat zij mijn 
familie zijn. Van mijn ouders heb ik altijd de liefde en steun ervaren, die ik nodig 
heb om ook moeilijke projecten tot een goed einde te brengen. Vielen, vielen Dank 
Ihr Lieben. 
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